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Summary
This study investigated the determinants of yellow fever (YF) virus 
pathogenesis at the molecular level by generating nucleotide and deduced amino acid 
sequences for the structural protein genes of attenuated variants of YF virus. In total, 
approximately 75 kilobases of nucleotide sequence were generated.
The membrane (M) or envelope (E) protein gene sequences of four 17D-204 
vaccine viruses and three French neurotropic vaccine viruses were determined and 
compared with published sequence data. Despite completely different routes of 
attenuation, the two vaccine strains shared a substitution at amino acid 35 in the M 
protein (M-35), and exhibited a cluster of substitutions in the E protein. Sequence 
analysis of a YF virus attenuated by limited passage in HeLa cells revealed that this 
virus consisted of a mixed population of variants. The structural proteins and two 
non-structural proteins were sequenced for several clones and the E protein was 
shown to have the highest rate of mutation. Comparison with the YF vaccine viruses 
suggested that M-67 and E-27 amino acid substitutions were important for the 
attenuated phenotype.
A number of YF variant viruses were studied in which the E proteins had 
previously been demonstrated to have unusual antigenic profiles. Several of the 
variant viruses were shown to have altered virulence phenotypes in mice, including 
avirulence, intermediate virulence, persistence and complete lethality. The 
pathogenesis of these viruses in the murine brain was investigated further by 
determining the levels of infectious virus or viral RNA. Sequence analyses of the E 
protein genes of these viruses implicated E-153, E-240, E-305 and E-325 in the 
altered phenotypes.
Overall, the results indicate that the M and E proteins are major molecular 
determinants of YF virus pathogenesis.
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CHAPTER 1 
General Introduction
1.1 General introduction to yellow  fever virus
The study of yellow fever (YF) virus has made many important 
contributions to the history of virology. Early in this century, Walter Reed and his 
coworkers demonstrated that YF virus was transmitted to man by mosquitoes 
(Reed & Carroll, 1902). This represented a major breakthrough both for medicine 
and in the potential control of disease. More importantly, though, it provided the 
first example of an arthropod-borne virus (Strode, 1951; Monath, 1990). 
Knowledge gained during epidemiological and pathogenic studies of YF formed 
the basis for understanding other viral diseases and the importance of vector 
control. YF virus was isolated in 1927 and cultivated in vitro in 1932. During the 
next several years, work by Max Theiler ultimately led to the development of a 
live-attenuated YF vaccine (Theiler & Smith, 1937a, b). Techniques for isolating 
and cultivating many other viruses in the laboratory, as well as the methods 
required for vaccine preparation, were also developed from this work. The 
importance of Theiler's work was rewarded with the Nobel Prize in 1951.
In recent years, YF has once again been brought to our attention with the 
threat of future explosive epidemics in urban areas of the Americas, continuing 
epidemics in Africa and concerns about the introduction of YF into Asia. The 
incidence of YF has increased dramatically over the last few years, effective 
control of the mosquito vectors has collapsed and vaccination is conducted only 
on an emergency basis (Monath, 1994).
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1.2 History of yellow  fever virus
1.2.1 History of the disease
YF was first described as a disease entity in Mexico in 1648. The origins 
of the disease are in doubt, but the susceptibility of New World - but not African - 
monkey species to lethal infection (suggesting contact with the virus in relatively 
recent times) indicates an African origin of the virus (Monath, 1994). In relatively 
recent times, the slave trade led to the introduction from Africa of the domestic 
mosquito vector, Aeofes aegypti, and the emergence of urban epidemic YF in the 
Americas.
Throughout the 18th and 19th centuries, and for several decades of this 
century, YF was one of the great plagues of the world with major centres in 
tropical and sub-tropical areas of West Africa, Central and South America 
(Monath, 1987). With the opening up of the American continent by European 
colonisation there were devastating epidemics of mosquito-borne YF in the 
growing cities of Latin America, the West Indies and the southern states of the 
USA (Strode, 1951; Blake, 1968; Porterfield, 1989b). Galveston Island suffered 
annual epidemics of YF, beginning in 1839, which were capable of killing up to 
10% of the population in one summer (Cartwright, 1991). In the 19th century, 
outbreaks spread as far north as Boston and even to Europe via carriage of 
mosquitoes in ships. An outbreak of YF was recorded in Swansea, with 17 deaths 
following the arrival of a Cuban vessel (Smith & Gibson, 1986).
1.2.2 History of the virus
The etiology and mode of transmission of YF were the subject of intense 
interest and speculation during the 250 years which followed its recognition. 
W ithout specific tests and clear case definitions, YF was clinically confused with 
other infections, including malaria, typhoid, typhus, leptospirosis and other 
"bilious fevers". Until the early 19th century, the disease was widely thought to 
be the result of airborne miasmas.
Suggestions that YF was transmitted by mosquito bite were advanced by 
Nott (1848), Beauperthuy (1854) and Finlay (1881). Finlay's theory later spurred 
Major Walter Reed to undertake his landmark studies in Cuba on mosquito 
transmission of YF. In 1900, Reed and his colleagues demonstrated transmission 
of YF to volunteers by the bite of mosquitoes (Ae. aegypti) which had previously 
fed on clinically ill patients (Reed et a/., 1900). Subsequent studies proved vector 
transmission, demonstrated by direct human-human passage that the etiologic 
agent was present in blood, defined the period of extrinsic incubation in the 
mosquito and showed that a filterable agent (virus) was responsible for the disease 
(Reed & Carroll, 1902; Reed, 1902). The virus however, was not to be 
propagated, established or characterised for a further three decades.
There were many false leads in the search for the agent of YF. In 1897, a 
bacillus (Bacillus icteroides) was claimed to be the causative organism (Sanerelli, 
1897). In 1918, a Japanese scientist suggested that the causative agent of YF was
«
a leptospire, later named Leptospira icteroides (Noguchi, 1919). This 
misapprehension gained some support and exacted a very real price in terms of 
human lives, as the mosquito abatement campaigns in Africa and the Americas, 
instigated by the Yellow Fever Commission, suffered as a result (Porterfield, 
1989b).
Finally, in May 1927, workers at the Rockefeller Foundation's West African 
Yellow Fever Commission initiated attempts to isolate the agent by inoculation 
of blood from patients into rhesus monkeys. Within a few months Drs. Mahaffy, 
Bauer, Beewkes, Stokes and Hudson had succeeded in isolating the virus and 
passaging it in the first laboratory host, the rhesus macaque (Stokes et al., 1928). 
The virus, recovered from the blood of a Ghanaian man named Asibi and named 
after him, later served as the parent of the 17D live-attenuated vaccine virus. 
Shortly afterwards, Mathis et a i  (1928) working in Dakar had similar success, 
establishing the French viscerotropic virus (FW) strain, parent of the live- 
attenuated French neurotropic vaccine (FNV) virus. In 1930, Theiler discovered 
that the common albino mouse was susceptible to intracerebral inoculation of the 
virus, opening the door to progress in serological epidemiology, quantitative 
virology and vaccine development.
1.3 Classification of yellow fever virus
YF virus has been classified by various different criteria. The ecological
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classification of YF virus is as an arbovirus, the pathological classification as a 
haemorrhagic fever virus and the taxonomie classification as a member of the 
family Flaviviridae, genus Flavivirus. Each of these groups is discussed in more 
detail in the following sections.
1.3.1 Arboviruses
The term arbovirus (derived from arthropod-borne and introduced in 1942) 
is an umbrella classification to describe animal viruses that are maintained in a 
transmission cycle between haematophagous arthropod vectors and susceptible 
vertebrate hosts. An essential property for classification as an arbovirus is that the 
arthropod does not merely provide mechanical transport for the virus between 
hosts, but is a true biological host in which the virus replicates before 
transmission. A number of different arthropods have been implicated in the 
transmission of arbovirus diseases, including mosquitoes, ticks, Culicoides midge 
species and Phlebotomus sandfly species (World Health Organisation (WHO) 
Technical Report Series, 1967).
The first recognised arboviruses were associated with large epidemics in 
man and animals, including YF, Rift Valley Fever (RVF), Japanese encephalitis (JE), 
St. Louis encephalitis (SLE) and Murray Valley encephalitis (MVE) viruses. The 
number of viruses classified as arboviruses has increased dramatically over the 
past few years. In 1953, there were 35 catalogued arboviruses, but by 1978 this 
figure had risen to 389 viruses (Berge, 1975), largely as a result of field
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investigations connected with major epidemics of diseases, like YF, that occurred 
in various parts of the world (Theiler & Downs, 1973). The 1985 edition of The 
International Catalogue of Arboviruses refers to 504 registered viruses, 32 of 
which are in doubt (Karabatsos, 1985). Members of five major taxonomic groups 
are currently classified as arboviruses: (1) family Togaviridae, genus Alphavirus; 
(2) family Flaviviridae, genus Flavivirus; (3) family Bunyaviridae; (4) family 
Rhabdoviridae and; (5) family Reoviridae. The registered arboviruses are currently 
separated into 63 serogroups (Karabatsos, 1985).
1.3.2 Haemorrhagic fever viruses
More recently, classification of viruses causing haemorrhagic fevers in man 
has also been adopted (Andrei & De Clercq, 1993). Viruses causing haemorrhagic 
fevers in man belong to the following virus families: Flaviviridae, genus Flavivirus 
(YF, dengue (DEN), Kyasanur Forest disease (KFD), Omsk haemorrhagic fever 
(OHF)), Togaviridae, genus Togavirus (Chikungunya), Arenaviridae, genus
Arenavirus (Argentinian haemorrhagic fever, Bolivian haemorrhagic fever, Lassa
\
fever), Filoviridae, genus Filovirus (Ebola, Marburg), Bunyaviridae, genera 
Phlebovirus (RVF), Nairovirus (Crimian-Congo haemorrhagic fever) and Fiantavirus 
(Korean haemorrhagic fever). The routes of transmission of these haemorrhagic 
fever viruses vary considerably: by mosquito bites in the case of YF, DEN and 
RVF viruses, by tick bite in KFD and OHF, and by contact with rodents and their 
excreta in the case of Arenavirus and Fiantavirus infections.
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Although relatively rare, the high mortality rates associated with viral 
haemorrhagic fevers, together with the potential ease of air transport from remote 
areas to large population centres make them a cause for concern. The viral agents 
of many of these diseases, including YF, DEN and JE viruses, are termed 
"emergent viruses", due to the increasing numbers of outbreaks. These viruses 
have diverse replication strategies, but it is interesting to note that they all possess 
an RNA genome.
1.3.3 Flaviviridae
In 1984, the International Committee on Taxonomy of Viruses (ICTV) 
approved a recommendation of the ICTV Togavirus Study Group that the 
Flavivirus genus be transferred from the family Togaviridae to form a new taxon, 
the family Flaviviridae (Westaway et al., 1985a, b). This recommendation was 
made as a result of the distinct differences seen between the two genera at the 
levels of virion and genome structure, and intracellular development. In the 
virion, the alphavirus nucleocapsid was shown to have cubical symmetry 
(Horzinek & Mussgay, 1969), whereas the nucleocapsid of the flaviviruses is 
icosahedral (Murphy, 1980). At the molecular level, the alphavirus transcribes a 
subgenomic 26S messenger RNA (mRNA) encoding the structural proteins 
(Kââriâinen & Sôderlund, 1978). However, no subgenomic RNA was 
demonstrated in fIavivirus-infected cells (Westaway, 1973; Westaway & Shew, 
1977).
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The family Flaviviridae contains three genera: Flavivirus, Pestivirus and the 
newly characterised hepatitis C virus, which was placed in a separate as-yet- 
unnamed genus. The Flavivirus genus, of which YF virus is the prototype member, 
is discussed further in Section 1.4. The pestiviruses are collectively known as the 
mucosal disease viruses and include bovine viral diarrhoea (BVD) virus, hog 
cholera virus and border disease virus. They remain comparatively little studied 
as compared to the flaviviruses, but they are agents of important veterinary 
diseases (Porterfield, 1986).
The existence of HCV was only recognised in 1975 (Bukh et a/., 1993). 
There are currently at least six major and more than 12 minor genotypes of HCV, 
based on genomic sequence heterogeneity. This third type of human viral 
hepatitis has a worldwide distribution, with the prevalence of anti-HCV immunity 
ranging from 1 % in developed countries to almost 10% in developing countries 
(Purcell, 1994). Unlike other members of the Flaviviridae, HCV does not appear 
to have an arthropod vector transmission cycle (Alter et al., 1989).
Cell fusing agent (CFA), a virus originally isolated from Ae. albopictus 
mosquito cell culture (Igarashi et al., 1976), and simian haemorrhagic fever virus 
(Leon et al., 1982) also remain relatively unstudied, but have been suggested as 
possible members of the family Flaviviridae (Porterfield, 1986). Recent 
determination of the entire genomic sequence of CFA supports this tentative 
classification (Camissa-Parkes e ta /., 1992).
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Controversial recent evidence has suggested that, based on the sequence 
homology of the RNA-dependent RNA polymerase, the current assignments of the 
Flavivirus, Pestivirus and the unnamed genus of HCV to one family may be 
wrong, and that they should in fact form three distinct families designated 
Flaviviridae, Pestiviridae and Hepciviridae (Ward, 1993).
1.4 The Flavivirus genus
1.4.1 Antigenic classification
Flaviviruses have been classified together as a genus due to their antigenic 
related ness as determined by serological assays. These assays focus on the surface 
protein antigens possessed by flaviviruses. The original grouping of flaviviruses 
was established by their cross-reactivities in haemagglutination inhibition tests 
performed using polyclonal antisera (Casals & Brown, 1954). Cross-neutralisation 
tests, using polyclonal hyper-immune antisera, refined these initial studies. 
DeMadrid and Porterfield (1974) classified flaviviruses into seven antigenic 
complexes comprising 36 viruses, six of which did not fall within any of these 
groups.
More recently, 68 members of the Flaviviridae were classified into eight 
antigenic complexes on the basis of cross-neutralisation tests using polyclonal 
antisera (Calisher et a i,  1989). Table 1.1 shows this classification structure, and
Table 1.1: Relationship between Flavivirus subgroup and mode o f transmission
Tick-borneviruses 
Virus  Subgroup
Non vector borne 
Virus Subgroup
Mosquito-borneviruses 
Virus Subgroup
Central European 
tick-borne enc.
Karashi 
Kyasnur Forest 
Langat 
LoupingE 
Negishi 
Omsk 
Powassan 
Royal Farm 
Russian spr/summ
Carey Island 1
Phnomh Penh bat 1
Apoi
Bukulasabat 
Dakar bat 
Entebbe bat 
Rio Bravo 
Saboya
2A
2A
2A
2A
2A
2A
Alfuy
Japanese enc.
Kedougou
Kokobera
Koutango
Kunjin
Murray Valley 
St. Louis enc. 
Stratford 
Usutu 
West Nile 
Yaounde
3
3
3
3(5?)
3
3
3
3
3
3
3
(3)*
Sponweni
Zika
Meaban 1A Cowbone Ridge 2B
SaumarezRidge 1A Jutiapa 2B
Tyuleniy LA Modoc 2B
SalVieja 2B
SanPerlita 2B
Gadgets Gully 
Kadam
U
u
Aroa
BatuCave
Cacipacore
Montana M.L.
Sokuluk
TamanaBat
U
(U)*
U
U
U
U
Bagaza 
Israel Turkey 
Ntaya 
Tembusu 
Yokose
Banzi 
Bouboui 
Edge Hill 
Podskum 
Uganda S
Dengue 1
Dengue 2 
Dengue 3 
Dengue 4
Busuquara
Bheus
Jugra
Naranjal
Rocio
Sepik
Wesselsbron 
Yellow fever
6
6
6
(6)*
6
7
7
7
7
U
U
U
U
U
U
U
U
Adapted from Calisher etal. , 1989. U = unrelated to any other virus
* Batu Cave, Potiskum and Yaounde viruses were not examined in the study, but are included 
forcompleteness 11
also the vector with which the subgroups are associated. This antigenic 
classification conforms to the major biological and epidemiological 
characterisations of flaviviruses. Of the 68 currently registered members, 48% are 
mosquito-borne and are responsible for epidemics of diseases such as YF, DEN 
and JE. The remainder are either tick-borne (27%) or have no known arthropod 
vector (25%) (Calisher et a/., 1989).
1.4.2 Flaviviruses of medical significance
From a medical standpoint, the flaviviruses represent a very important 
group of viruses. Almost half of the 68 currently registered flaviviruses have been 
associated with human disease (Karabatsos, 1985). Indeed, many members have 
been isolated from humans during either sporadic or epidemic outbreaks of 
disease. In addition to YF virus, DEN and JE viruses also cause epidemics in man 
which are of panregional and global concern (Monath, 1986). All three of these 
viruses are mosquito-borne.
Yellow fever:- As mentioned previously, YF has been recorded as a 
scourge of mankind for at least two centuries, and major epidemics still occur 
despite the introduction of live-attenuated vaccines in the 1930's (Theiler & Smith, 
1937). The "17D" vaccine in use today is arguably the finest example of a live- 
attenuated virus vaccine. Unfortunately, in an epidemic the effectiveness of 
vaccination may be limited by vaccine availability, the remoteness of some 
affected regions and failure to recognise early cases before an epidemic occurs.
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YF is discussed further in the following sections.
Dengue:- There are four DEN serotypes (DEN 1-4), and all give rise to 
classical DEN fever, a self-limiting febrile illness associated with a rash. As with 
YF, the virus is transmitted by the bite of an infected mosquito, and DEN viruses 
cause the highest morbidity of any flavivirus (Halstead, 1988). In the last 20 years 
the incidence of DEN fever epidemics has increased and hyperendemic 
transmission has been established over a geographically expanding area (Monath, 
1994). Furthermore, the disease is reappearing in regions from which it had been 
eradicated. For example, prior to an outbreak in Rio de Janiero in 1986 
(Shatzmayer et a/., 1986), DEN fever had been absent from Brazil for over 50 
years. A severe form, DEN haemorrhagic fever (DHF)/DEN shock syndrome (DSS), 
is an immunopathologic disease appearing in persons who experience sequential 
DEN virus infections by different DEN virus serotypes (Halstead, 1980; 1988). All 
four serotypes have been associated with DHF/DSS. However, infection with 
DEN-1 virus followed by infection with DEN-2 virus carries the greatest risk of 
developing DHF/DSS (Sangkawibha et a/., 1984; Burke et a/., 1988).
Japanese encephalitis:- JE virus is associated with endemics and epidemics 
throughout much of Asia and causes the highest mortality of any flavivirus. 
Mortality rates are usually 10-20% in most epidemic outbreaks, but figures greater 
than 30% have been recorded (Bu'Lock, 1986; Umenai et a/., 1985). In a 
significant proportion of the survivors, permanent neurological impairment can 
occur as a sequelae. Extensive vaccination programmes against JE virus have been
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undertaken in Asian countries, yet large populations remain at risk. It is possible 
that vaccination strategies are undermined by the high degree of antigenic 
variation.exhibited by different subtypes of JE virus (Susilowati et al., 1981).
In addition to the three major diseases described above, there are a 
number of other mosquito-borne flaviviruses of medical significance. SLE was first 
reported as a serious public health problem in the United States in the 1960's, 
and sporadic outbreaks continue (Kokernot et a/., 1969). MVE virus causes 
intermittent epidemics in Australia in regions experiencing high rainfall levels 
(Forbes, 1975). Epidemics usually coincide with high population levels of the 
mosquito vector, and occur mainly between January and March (Shope, 1980). 
West Nile (WN) virus, unlike the serologically related JE, SLE and MVE viruses, 
is not usually associated with encephalitis, but causes a generalised fever, rash 
and lymphadenopathy (Sprigland et a/., 1958). WN virus is found in Africa, the 
Middle East, Europe and Asia. In hyperendemic areas, the high numbers of sero­
positive adolescents and adults suggest that infection usually occurs during 
childhood (McIntosh et a/., 1976).
Several tick-borne flaviviruses are also known to cause encephalitic disease 
in humans. Tick-borne encephalitis (TBE) has long been recognised as a public 
health problem in Eastern Europe, and the virus caused high mortality in Russia 
in the 1930's, prompting great efforts to isolate the causative agent and produce 
a vaccine (Silber and Soloviev, 1946). The TBE virus complex encompasses a 
number of different viral subtypes found in different geographical areas. Far
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eastern subtypes include Sofyn virus/ the causative agent of Russian spring- 
summer encephalitis (RSSE) (Silber & Soloviev, 1946). Neudorfl (Ackerman et a/.,
1986) and Hypr (Blaskovic et al., 1967) viruses are examples of western subtypes.
Two additional tick-borne flaviviruses cause diseases which are largely 
haemorrhagic in nature. Hundreds of cases of KFD occur annually in India, 
characterised by fever, mild meningoencephalitis and haemorrhagic fever. The 
mortality rate varies between 1 and 10% (Work 1958; Sreenivasen et al., 1979). 
OH F caused large outbreaks in 1944 and 1946 in the Omsk region of the former 
Soviet Union. As the name suggests, the disease causes fever with associated 
haemorrhage, but the case fatality rate is low (1-2%) (Shope, 1980).
1.4.3 Flaviviruses of veterinary importance
Eight flaviviruses have so far been reported to cause disease in 
domesticated and wild animals. In the former group, these diseases can have 
major economic importance. The mosquito-borne JE virus has high economic 
impact in many parts of Asia, causing epizootic encephalitis in horses, and still­
birth/abortion in pigs (Umenai et al., 1985) as well as both wild and domesticated 
boars (Habu et a/., 1977). Pigs and birds have been established as the principal 
viraemic amplifying hosts of JE virus, with Culex species of mosquito responsible 
for the transmission of the virus to man (Beuscher & Scherer, 1959).
Louping ill (LI) virus is a member of the TBE complex which causes
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neurological disease in sheep, mainly in Scotland (Monath, 1989). It has also 
been responsible for economic losses due to infection of pigs, red grouse and 
deer (Reid et a/., 1982; Bannatyne et ai., 1980). Serologically related viruses have 
been isolated in other European countries including Spain, Norway, Bulgaria, 
Portugal and Turkey.
Wesselsbron (WSL) virus, which is not classified within any antigenic 
complex (see Table 1.1), is found in South Africa, where it causes abortion and 
death of newborn lambs and pregnant ewes (Henderson et al., 1970). It was also 
isolated from a cow which died during an epizootic RVF attack in Zimbabwe in 
1978 (Blackburn & Swanpoel, 1980). It has since been proposed that WSL virus 
infection occurs on a much greater scale than the number of recorded cases 
imply. Serological evidence suggests that detailed epidemiological study of 
livestock is required where virus infection is implicated (Swanpoel, 1988).
Between 1958 and 1959, turkey populations in Israel were dramatically 
affected by a flavivirus causing morbidity approaching 50% and case-fatality rates 
between 10 and 12% (Komarov & Kalmar, 1960). The causative agent was Israel 
Turkey Meningo-encephalitis (ITME) virus. The only other recorded outbreak of 
this disease occurred in South Africa (Barnard et al., 1980). A reservoir for the 
virus has not yet been found.
Several other flaviviruses cause diseases of veterinary importance to varying 
degrees. Horses have been infected by WN virus (Guillon et a/., 1968), and by
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Kunjin virus, which was isolated from the spinal cord of a horse with severe 
encephalomyelitis in Australia (Badman et a i,  1984).
1.4.4 Epidemiology of flaviviruses
In general, flaviviruses are transmitted to man via the bite of an arthropod 
vector. Despite the presence of virus in the blood and bodily secretions during 
acute infection, flavivirus infections are not contagious. Accordingly, an available 
reservoir of infectious virus and high levels of vector populations are prerequisite 
for the outbreak of epidemics.
The natural epidemiology of YF is a cycling of the virus through 
transmission by forest mosquitoes to wild primates. However, there is evidence 
that transovarial transmission of YF virus can occur in mosquitoes (Beatty et a/., 
1980). Transovarial transmission of virus in mosquitoes is important in the 
maintenance of YF virus, and has also been shown to be important in the natural 
history of other flaviviruses (e.g. JE and SLE viruses) (Rosen, 1986; 1987). The role 
of vertebrates other than forest primates in maintenance of the virus in nature 
remains uncertain (Porterfield, 1989b).
1.4.5 Vaccines against flaviviruses
To date commercially produced vaccines prevent only three flavivirus 
diseases: YF, JE and TBE. The first is prevented by a live-attenuated vaccine
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(discussed further in Section 1.7) and the latter two by inactivated vaccines. No 
vaccines prevent DEN. A number of experimental vaccines exist: live-attenuated 
DEN, live-attenuated JE, and both inactivated and live-attenuated TBE.
The greatest success with DEN research has come from the development 
of experimental live-attenuated vaccines. Any potential DEN vaccine must be 
tetravalent, protecting against all four serotypes of DEN virus. Recently, a group 
in Thailand used primary dog kidney (RDK) cells to attenuate strains of all four 
serotypes of DEN virus (Bhamarapravati et a/., 1987). Encouraging preliminary 
results were reported following the immunisation of a small number of individuals 
with live-attenuated DEN 1, DEN 2 or DEN 4 PDK-passaged virus 
(Bhamarapravati et al., 1987; Marchette et al., 1990; Hoke et al., 1990; Edelman 
et al., 1994).
Vaccine against JE consists of formalin-inactivated virus, purified by 
density-gradient ultracentrifugation. Multiple inoculations confer substantial 
protection (90%) of uncertain duration (Hoke et al., 1988). Despite relative purity, 
its derivation in mouse brain is undesirable and the costly production methods 
dter broad use of the vaccine in less-developed countries where the need is 
greatest. To date the most promising live-attenuated JE virus vaccine is the 
Chinese SA14-14-2 virus, produced by passage in primary hamster kidney (RHK) 
cells (Yu et al., 1973). The safety and efficacy of this vaccine have been 
confirmed in over five million human vaccinees in China (Yu e ta l., 1981, 1988; 
Ao et al., 1983), but its use is prohibited by the WHO due to its derivation in
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RHK cells. A PDK-passaged SA14-14-2 vaccine has now been prepared (Eckels et
a /./  1988), but was not as successful as the original vaccine in clinical trials
'
(Barrett, personal communication).
Far eastern and central European TBE vaccines are propagated in primary 
chick embryo fibroblast culture, pruified by density-gradient centrifugation, and 
formalin-inactivated (Klockman eta/., 1989; Elbert et a/., 1989). Only preparations 
against the less widespread and less virulent central European subtype of TBE 
demonstrate constant efficiency. There has also been development of live- 
attenuated TBE vaccines in Russia. Unfortunately, this work has not yet been 
published.
1.5 Epidemiology of yellow fever virus
1.5.1 Transmission cycles of yellow fever virus
YF virus infects humans and other vertebrates, principally monkeys, in 
tropical areas of Africa and America. Mosquitoes are the known vectors, although 
isolation of virus from ticks has been documented (Germain et al., 1982). There
are two principal cycles of infection: sylvatic (or jungle) and urban (Figures 1.1
and 1.2). The urban cycle, in which humans are the primary host and the urban 
mosquito species Ae. aegypti is the vector, was the first to be identified. Urban 
YF is principally a "house disease" and occurs indiscriminately among non-
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Figure 1.1: YF virus transmission cycles in Africa.
Adapted from Taylor (1951).
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Figure 1.2: YF virus transmission cycles in the Americas.
Adapted from Taylor (1951).
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immunes living in or visiting infected houses (Soper, 1936). It is spread either by 
the movement of the human host during the period of infection or by the 
accidental transportation of the infected mosquito from place to place. However, 
this progress revealed the existence of the sylvatic cycle occurring in the tropical 
jungles and forests, where the virus is endemic in several species of monkeys and 
transmission is by the mosquitoes of the forest canopy. Humans become involved 
in this cycle secondarily by entering jungle areas. Clearly, on the edge of jungle 
areas these two cycles intermingle, and infected workers returning from jungle 
areas often form the focus of an urban outbreak. The WHO classifies all outbreaks 
in which Ae. aegypti is the vector as urban YF regardless of the area and all 
outbreaks involving other mosquito species as jungle VF (Brès, 1986).
Africa:- Outbreaks of YF probably occurred in Africa much earlier than in 
the Americas, but the first well-documented epidemic was in 1778 (Freestone,
1988). The epidemiology of YF in Africa is much more complex than in the New 
World (Figure 1.1). The virus is present in a vast area of tropical Africa: in 1971, 
the WHO suggested that YF virus was either endemic or epidemic in 29 countries 
between the latitudes of 15°N and 10°S (WHO Technical Report Series, 1971). 
The disease is endemic in many species of monkey, resulting in a subclinical 
infection and a balanced host-parasite relationship. According to the restricted 
definition applied here, it is probable that very little jungle YF occurs in Africa. 
The mosquito, Ae. africanus, involved in the sylvatic cycle rarely bites man 
because it prefers monkey blood and is a night feeder. The infection of man with 
the forest virus takes place through the intermediary of a semi-domesticated
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mosquito species, Ae. simpsonii. Although this appears to be a minor distinction, 
it has important epidemiological manifestations. Exposure to infection results from 
the proximity of man's habitation to the forest, not from "personal contact" with 
the forests, and consequently all members of the household are more or less 
equally exposed.
Unlike South America, tree-hole breeding Aedes spp. are also involved in 
epidemic transmission. Amplification of the virus transmission cycle occurs in 
moist savannah and forest-savannah transition zones, terms "zones of emergence" 
(Germain et a/., 1982) where the density of tree-hole breeding Aedes spp. reach 
high levels during the rainy season. In these circumstances, humans are frequently 
infected and the vectors associated with this are Ae. furcifer, Ae. africanus and 
Ae. luteocephalus. In urban areas or areas of low rainfall, where water storage 
practices favour breeding of domestic Ae. aegypti, this vector may be involved in 
explosive epidemic spread, with humans serving as the vireamic host. 
Transovarial transmission of YF virus occurs in mosquitoes at low frequencies 
(Aitkin et a i,  1977; Beaty et a i,  1980) and is now believed to be significant in 
the maintenance of infection, given the limited infectivity of monkeys (and 
humans) and the relatively short lives of mosquitoes.
Americas:- In the last 50 years, YF outbreaks have occurred exclusively 
in South America and jungle YF has accounted for all these cases. Consequently, 
in the Americas YF strikes mainly young adult males engaged in timbering and 
agricultural pursuits in the Amazon and Orinoco river basins. The howler monkey
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(Alouatta spp.), spider monkey {Ateles spp.) and several other primates are 
effective viraemic hosts and some species succumb to fatal disease (Figure 1.2). 
The die-offs of these animals often provide a clue to local YF activity (Monath, 
1994). The principal mosquito vectors are species of the genus Haemagogus 
(Monath, 1989). Transovarial transmission in a Haemagogus sp. has been 
demonstrated for YF (Duraty & LeDuc, 1981), but the mechanism of virus 
maintenance during the dry season remains unclear.
1.5.2 Control of mosquito vectors
Attempts to eradicate the transmission vector of YF virus began in Cuba as 
early as 1901 (Smith, 1951). The results of the anti mosquito campaign were 
suprising and impressive; in 1909, the whole island was declared free of YF and 
has remained so ever since. In 1905, the last known outbreak of YF in the United 
States occurred New Orleans, during which some 3,402 cases and 452 deaths 
were recorded. This freedom came however, not from efforts by the cities to 
protect themselves, but from the removal of endemic centres from the Carribean. 
The eventual disappearance in the early 1940's of urban YF, once a major 
endemic and epidemic disease in South and Central American towns and cities, 
was attributed to successful programs to control the domestic vector, Ae. aegypti.
The discovery of the sylvatic cycle and "YF without Ae. aegypti" (now 
called jungle YF) was a major disappointment to all those who firmly believed 
that the urban cycle represented the only significant mechanism in the
24
maintenance of YF. It became clear in the early 1930's that it was impossible to 
eradicate the jungle vectors and host reservoirs and YF remains endemic in Africa, 
the Carribean, South and Central America (Figure 1.3).
Low levels of insecticide in the water supplies can reduce vector levels to 
such an extent that the risk of outbreaks of YF can be considered low. A more 
environmentally friendly and effective method of vector control is to place 
Gambusia minnows into the water, which prey on mosquito larvae (Monath,
1989). However, larviciding and environmental measures provide only delayed 
control of adult populations. Therefore, in the event of a YF outbreak, the 
application of ultra-low volume insecticide (ULV) is employed. ULV can be 
distributed by aerial, ground, vehicle-mounted and hand-held equipment. Trials 
using the insecticide "Fenitrothion" in Asia, South America and Africa have 
produced satisfactory results (Gratz, 1991). ULV is used for rapid and effective 
emergency control of vectors when outbreaks of YF occur in urban or semi-urban 
regions, but are not suitable as routine control measures (Gratz, 1991).
1.5.3 The threat of future urban yellow fever epidemics
YF and DEN have recently been classified among the emergent diseases, 
based on the increasing incidence of endemic and epidemic cases in the last few 
years and the threat of future large-scale urban outbreaks. These concerns stem 
in part from the reinvasion of South America by the principal vector of urban YF, 
Ae. aegypti. Perhaps most disturbing is the reappearance of Ae. aegypti and
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Figure 1.3 : Epidemiological patterns of yellow fever in ecological zones of the Americas 
(left) and Africa (right). Adapted from P.LJ. Bres, 1986.
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epidemic DEN in Central and South American cities, which historically were key 
centres of urban YF and which harbour large non-immune populations. However, 
despite the occurence of jungle YF outbreaks in areas affected by DEN and 
infested with Ae. aegypti, urban transmission of YF virus has not occurred in the 
Americas since 1942.
The introduction of Ae. albopictus from Southeast Asia into the New 
World and now Africa (Morbidity and Mortality Weekly Record, 1991; Savage et 
al., 1992) in used tyres also gives cause for concern. This Aedes species has 
particularly aggressive biting habits, is competent as a vector (Whitman, 1951) 
and is able to use both natural and domestic larval habitats, thereby acting as a 
potential bridging vector between jungle and urban situations, as Ae. simpsonii 
does in Africa (Miller et al., 1989). Moreover, Ae. albopticus is an aggressive 
colonizer, as demonstrated by it's rapid spread and establishment in North 
America and Brazil (Hawley, 1988). So far, however, YF virus has not been 
isolated from Ae. albopictus mosquitoes in the wild.
Recent speculations on the influence of global climate changes on 
infectious diseases have also included YF (Shope, 1991). In the past, outbreaks of 
urban YF were annual summer events because Ae. aegypti is killed rapidly at 
freezing temperatures (Kniping & Sullivan, 1957; Smith & Love, 1958). The 
northernmost winter survival of Ae. aegypti is now 35°N latitude, (the latitude of 
Memphis, Tennessee). This distribution is predicted with global warming to move 
northward and encompass additional large population centres. Ae. albopictus has
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established itself in scattered foci as far north as 4 2 ° N latitude. With global 
climate change, predictably this vector will also become more prevalent and 
extend its range even further north, thus compounding the risk of YF transmission 
(Shope, 1991).
Finally, for unknown reasons, YF has historically been absent from the 
continents of Asia and Australia. It seems probable that there would have been 
multiple opprtunities for the introduction and transmission of YF into this vast 
region inhabited by Ae. aegypti and a large non-immune population, and that 
these opportunities would have expanded with air-travel. The barrier to YF 
invasion may be effected by cross-protective immunity following DEN infection, 
reduced competence of Asian Ae. aegypti strains or a geographic or demographic 
obstacle.
It appears, therefore, that multiple factors relating to host, vector and virus 
combine to limit the risk of YF to Asia as well as to unaffected areas more 
intimately associated with enzootic maintenance cycles in Africa and South 
America. Since the human factors relating to behaviour, demography and 
geography are subject to change, as are the distribution and genetic characteristics 
of Aedes spp. and of YF virus strains, vigilance is necessary. It has been predicted, 
for example, that in the event of a YF outbreak in New Orleans 100,000 people 
would become ill and 10,000 would likely die within 90 days (US Institute of 
Medicine, 1992). Vaccination of the 500,000 or more people at risk from 
infection would likely prove impossible due to the shortage of vaccine. As Dr.
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Monath said in his address to the Fifth Arbovirus Research Symposium in 
Australia, "the spectre of urban YF should inspire surveillance and research" 
(Monath, 1991).
1.6 Pathology of yellow fever virus
1.6.1 Clinical symptoms of human yellow fever infection
YF in man varies from an invariably fatal, fulminating disease with 
symptoms following a biphasic course, to an almost inapparent, abortive infection 
in which symptoms abate rapidly after the first phase (Monath, 1989). This 
complicates diagnosis in the field. YF is a haemorrhagic disease in humans with 
the added complications, in severe cases, of hepatitis and nephritis due to 
excessive viral multiplication in the liver and kidneys, as well as in the bone 
marrow (Taussig, 1987). YF shares clinical features with other viral haemorrhagic 
fevers such as DEN haemorrhagic fever, Lassa fever and Congo-Crimean 
haemorrhagic fever, but hepatic involvement is usually more prominent (Monath,
1987). The clinical symptoms of YF infection have been reviewed both classically 
(Kerr, 1951) and more recently (Monath, 1987; Freestone, 1988).
The symptoms of abortive YF infection are typically non-specific, 
manifested as fever, headache and constitutional problems. In such cases, patients 
recover in a few days with no ensuing sequelae. Severe YF is much better
29
delineated, with abrupt onset of disease. As mentioned above, the course of the 
disease is biphasic. YF virus is introduced into the primate host by injection of the 
saliva of an infected mosquito. Virus replicates in the vascular epithelium and 
reticulo-endothelial cells in lymph nodes. A brief vireamia results, which is 
sustained at levels sufficient to infect arthropod vectors. The "period of infection" 
lasts about three days with symptoms including headache, generalised malaise, 
fever, nausea, lumbosacral pain, myalgia and Fagets signs (increasing temperature 
with decreasing pulse rate).
After a brief "period of remission" lasting up to 24 hours, during which the 
fever falls rapidly and the patient feels better, the major manifestations of disease 
occur in the second phase or "period of intoxication". Fever recurs with frequent 
vomiting, epigastric pain, prostration and dehydration. Liver damage leads to 
jaundice (hence YF) and kidney damage to extreme albuminuria and acute renal 
failure, while gastrointestinal haemorrhage is responsible for the characteristic 
black vomit (haematemesis). Antibodies can be detected at this stage, whilst 
viraemia is usually absent. Finally, delirium, convulsions and coma (caused by 
metabolic encephalopathy and cerebral oedema) presage death, which occurs in 
20 and 50% of severe cases. Patients usually die between the seventh and tenth 
days of illness, but in atypical fulminant cases death may occur as early as three 
days after onset, sometimes without prominent hepatic or renal signs (Sérié et al., 
1968). In non-fatal cases, recovery is generally complete, although jaundice can 
sometimes persist for several months (Monath, 1984) and rarely late deaths occur 
during convalescence due to cardiac damage (Kirk, 1941).
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1.6.2 Pathology of human yellow fever infection
Gross pathology of human fatal YF reveals that the kidneys are generally 
grossly enlarged, congested and oedematous. The heart is also often enlarged. The 
liver, the characteristic organ of YF infection, is normal or slightly enlarged in 
size, reddish or yellow in colour, and the lobular markings are obliterated (Klotz 
& Belt, 1930).
Microscopic pathologic changes in the liver include swelling and necrosis 
of hepatocytes in the midzone of the liver lobule, with sparing of cells in the 
portal area and surrounding the central veins. The presence of Councilman 
bodies, together with disarray of the midzonal heptocyte plate and microvesicular 
accumulation of fat, are considered to be the hallmarks of fatal human YF 
infection (Monath et al., 1989; Brito et al., 1992). Viral antigen and RNA are 
demonstrable by immunocytochemistry and nucleic acid hybridisation in cells 
undergoing these pathologic changes, and cytopathology appears to be mediated 
by direct viral injury (Monath et a i,  1989; Brito et al., 1992). Inflammatory 
changes are absent or minimal, and patients with hepatitis who recover do not 
develop residual scarring or cirrhosis.
The kidneys show acute tubular necrosis, probably the result of reduced 
perfusion of blood rather than direct viral injury. Focal degeneration of muscle 
cells may be present in the heart (Brito et al., 1992). Spleen and lymph nodes 
show necrosis of B cell areas (Klotz & Belt, 1930). The brain shows oedema and
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petechial haemorrhages, but viral invasion and encephalitis are very rare events. 
Haemorrhage results principally from decreased synthesis of clotting factors by the 
liver. The mediators of hypotension and shock remain to be elucidated.
It should be noted that the disease caused by wild-type YF virus infection 
is largely viscerotropic in nature, with any neurological symptoms appearing 
rarely, and late in the infection process. However, it has been observed that when 
vaccine strains of YF virus revert to virulence, they tend to cause neurotropic 
disease, as opposed to viscerotropic (Anonymous, 1966).
1.6.3 Diagnosis of human yellow fever infection
The clinical diagnosis of YF remains difficult because of case-to-case 
differences in severity and clusters of symptoms. Although classical cases should 
be recognised, jaundice is more often absent than present, and YF may not be 
included in the differential diagnosis of patients presenting symptoms of 
headache, nausea, backache and fever. Laboratory diagnosis of YF is therefore 
important and rests on three criteria: (1) isolation of virus from the blood of a 
patient or from postmortem samples, (2) demonstration of the development of 
specific antibody in the serum of a patient during illness and, (3) demonstration 
of the classical histological lesions of YF in liver from fatal cases obtained by 
viscerotomy or at post-mortem (WHO Technical Report Series, 1971). However, 
these lesions resemble those of other haemorrhagic fevers and are no longer 
considered to be pathognomonic. Detection of YF viral RNA by nucleic acid
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hybridisation and viral antigen by immunocytochemistry have been proposed for 
rapid specific diagnosis of YF (Brito et al., 1992).
1.6.4 Treatment of human yellow fever infection
Treatment for YF is mostly supportive, although most patients with YF are 
unable to benefit from the modern intensive care units. As the occasion arises in 
the future, it will be essential to document and publish observations on intensive 
care of YF patients (Monath, 1987). A number of compounds with antiviral 
activity in vitro  have been described, including ribavirin. However, trials with 
ribavirin in experimentally-infected monkeys have yielded conflicting results 
(Huggins et a/., 1984). Interferon treatment of monkeys resulted in delayed onset 
of viraemia and illness, but had no effect on survival (Arroyo et a/., 1990).
1.6.5 Experimental yellow fever infections in animal models
The pathogenesis of YF has been studied in sub-human primates, mice, 
guinea-pigs and hedgehogs, but our level of understanding is at the descriptive 
rather than the mechanistic level.
Monkeys:- The Indian Macaca rhesus monkey was the first primate to be 
successfully infected with YF virus (Stokes et a i,  1928). The virus has since been 
shown to infect other species (Burgher, 1951). Susceptible monkeys, inoculated I y 
peripherally, develop a viscerotropic illness similar to humans. However, the
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course of disease is more rapid than in humans, with death occurring five to six 
days post-infection. Initial sites of viral replication have not yet been clearly 
defined, but probably include lymphatic tissue draining the site of viral 
inoculation. Viraemia follows with increasing titres between the second and fifth 
days post-infection, and the liver becomes infected. Early virus replication occurs 
in fixed macrophages (Kupffer cells) in the liver, which undergo necrosis. The 
virus then invades hepatocytes, which develop accelerated cytopathologic 
changes during the 24 hours before death (Monath et al., 1981). Central nervous 
system (CNS) involvement is seen in the terminal phase, as in human infection.
In primates, as in humans, viscerotropic infection is the rule; monkeys 
inoculated intracerebrally with wild-type YF virus replicate virus in brain tissue 
and develop histopathologic evidence of encephalitis, but die of hepatitis (Monath 
et al., 1981; Monath, 1994). Unlike the human situation, however, anti-YF 
antibodies are not detectable during monkey YF infection.
Mice:- In contrast to monkey, in mice YF virus is neurotropic. 
Nevertheless, the white mouse is the customary laboratory host used in YF virus 
studies because of the expenditure necessary for monkey studies. In mice, the 
brain and ganglia are the major sites of replication and there is no evidence of 
hepatitis. In 1930, Theiler discovered that adult white mice succumbed to YF 
virus when inoculated intracerebral ly. By comparison, mice become resistant to 
peripheral inoculation of YF virus with increasing age: newborn mice (24-48 
hours old) are invariably susceptible, but 20 day old mice are resistant to any YF
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virus (Fitzgeorge & Bradish, 1980). Considerable variation in mouse 
neuroinvasiveness and neurovirulence is seen between strains of YF virus 
(Fitzgeorge & Bradish, 1980; Barrett & Gould, 1986; Gibson et a/., 1990).
In addition, guinea pigs have been shown to be susceptible to intracerebral 
challenge with YF virus (Theiler, 1933). The European hedgehog (Erinaceus 
europaeus) is the only non-primate animal which manifests a viscerotropic 
response to YF infection with histopathologic features similar to those in humans. 
YF is observed (Findlay & Clarke, 1934). However, no investigations of this 
interseting model have been conducted for more than 40 years.
1.7 Yellow fever vaccines
Two live-attenuated virus vaccines for YF were independently and 
simultaneously developed, namely 17D and FNV. These vaccines were, with 
smallpox and rabies vaccines, the first vaccines to be developed against human 
disease and, thus, represent a major advance in virus vaccine development 
(Barrett, 1990). Epidemic YF has been effectively controlled by the use of these 
two vaccines.
1.7.1 The 17D vaccines
The original 17D variant of wild-type YF virus, from which the modern
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live-attenuated 17D vaccine substrains derive, was attenuated by Max Theiler and 
colleagues (Theiler & Smith, 1937a & b). Today, the 17D vaccine is considered 
to be among the safest and most efficacious viral vaccines available. It has 
currently been administered to more than 260 million people with a 
seroconversion rate of 96%, and immunity has been demonstrated in some cases 
to last more than 45 years (Poland et a i,  1981).
In 1927, a wild-type strain of YF virus was isolated by monkey-to-monkey 
passage from a mild case of YF in a Ghanian named Asibi (Stokes et al., 1928). 
Theiler (1930) reported a marked variation in the "Asibi" virus strain following 18 
serial passages in mouse brain. Inoculated peripherally in monkeys, this mouse 
brain virus possessed an enhanced neurotropism, but was found to have lost 
much of its viscerotropism. Sawyer et al. (1932) successful used this virus as a 
vaccine, administered with protective immune serum, but this method was not 
suitable for mass vaccination. The virus was serially passaged a further 50 times 
in whole chick embryo tissue and 108 times in chick embryo tissue from which 
the CNS had been removed. The original attenuated YF variant was identified at 
passage 176. This virus, known as 17D, had greatly diminished neurotropic and 
viscerotropic properties in rhesus monkeys and also was no longer mosquito- 
competent, but still retained its antigenic properties. The attenuation of this 
candidate vaccine virus was unique among other isolates derived at the time 
using a similar method (17A, 17B, 17C etc.) and proved to be irreproducible in 
later experiments (Theiler & Smith, 1937a & b, Theiler, 1951). The 17D virus 
strain was subsequently passaged in chick embryo, with nervous tissue removed,
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until passage 204.
Today, two substrains of the 17D vaccine are manufactured: 17D-204 and 
17DD. The 17D-204 vaccines are used between passage 233 and 240 from the 
parent Asibi virus. The 17DD substrain diverged from 17D at passage 195 and 
thereafter was passaged independently from the 17D-204 strain. These vaccines 
are currently used between passage 286 and 288 from Asibi. The derivation of 
these substrains is shown in Figure 1.4.
The 17D vaccine was initially evaluated in YF immune and non-immune 
volunteers without apparent side effects (Theiler & Smith, 1937b). Its 
administration was then introduced in Brazil in 1937 and in the following year 
approximately 59,000 doses were successfully administered (Barrett, 1987). Use 
of the 17D vaccines became widespread and YF vaccine production was 
performed in a number of laboratories with no proper quality control procedures. 
In 1943, the first of a number of problems (which are described in Section 1.7.3) 
arose with YF vaccine production.
At present the WHO controls the production of YF vaccine, and 
manufacturers must meet certain criteria. Twelve countries are currently licensed 
to produce YF vaccine, two of which, Russia and Nigeria, have only recently 
commenced production (WHO Technical Report Series, 1981,1988). Vaccine lots 
are required to be safety tested in primates to safeguard against revertant viruses.
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Figure 1.4: Derivation of the yellow fever 17D vaccine viruses 
and their WHO approved manufacturers
Asibi
Original 17D (pl76)
17DD
17D-204(p204)
Low(pl95)
France Colombia S. Africa U.K. India
Senegal
U.S.A
Australia
Holland
WHO ALV free
Australia Russia F.R.G 
(p238-239)
Colombia
17DD
High(p243)
Brazil
Senegal.
(p286-288)
Adapted from Barrett, 1987
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The W HO (WHO Technical Report Series, 1981) specifies that the test animal 
must be a rhesus macaque, or a primate of similar susceptibility. The dose 
administered should be between the thresholds of 5,000 mouse LD50 and 50,000 
mouse LD50 in a 250 j j \ volume which is injected into the frontal lobe of an 
anaesthetised animal. The test subjects are then observed for up to 30 days for 
any signs of encephalitis, such as instability, paralysis or death, which should not 
occur in more than 10% of the study group.
Following 17D vaccination, 96% of human vaccinees seroconvert with 
high neutralization indices (>12.0) (Freestone et a/., 1977). The immunity 
generated is prolonged, and may be life-long following a single vaccination 
(Poland et a/., 1981). Revaccination is, however, recommended by the W HO at 
10 year intervals. Contra-indications include pregnant women, infants under 6 
months of age, and individuals who are allergic to eggs, as the vaccine is 
produced in embryonated eggs. Also, those who are immunocompromised, 
whether due to disease (including clinical AIDS) or treatment with 
immunosuppressive drugs should not receive vaccination (Monath, 1989).
1.7.2 The French neurotropic vaccine
The second live-attenuated YF vaccine strain was developed at the Institut 
Pasteur in Dakar, Senegal, also in the 1930zs. The FVV wild-type virus was also 
isolated in Senegal in 1927 from a Lenanese man named Francios Mayali, who 
had a mild case of YF (Mathis eta/., 1928). Consequently, it is likely that both the
39
Asibi and FVV viruses originate from the same epidemic which had erupted in 
Senegal that year (Deubel eta/., 1986).Theiler's original demonstrations of mouse 
susceptibility and virus adaptation to the host were made with this virus. The virus 
was returned to Dakar via the Institut Pasteur in Paris in 1931, following 128 
serial mouse brain passages (Durieux, 1956). This attenuated virus, designated 
FNV, had lost its viscerotropism for monkeys and its mosquito-competence, but 
displayed an enhanced neurotropism for both mice and monkeys, particularly 
following intracerebral inoculation. This was probably as a result of the prolonged 
passage in brain tissue. The first vaccine viruses were established and used at 
mouse brain-passage 238, but later vaccines were from the 258th to 260th mouse 
brain-passage (Figure 1.5).
Vaccination against YF was practiced widely in the French territories of 
western Africa between 1939 and 1980. Peltier et al. (1939) reported that the 
application of FNV virus to the skin followed by a mild scarification as practiced 
in smallpox vaccination resulted in the development of immunity to YF. The first 
trials of the "Dakar scratch method" of vaccination were carried out using virus 
material from the 238th passage, but subsequently, so as to avoid possible 
variations in the properties of the strain, the frequency of the maintenance 
passages was reduced. Thus, between 1939 and 1956 FNV virus was carried to 
passage 260, and the 258th, 259th and 260th passages were employed in vaccine 
preparation.
In French-speaking areas of Africa more than 84 million vaccinations were
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Figure 1.5: Derivation of the French neurotropic vaccine viruses
Mayali* (Senegal, 1927) 
(French viscerotropic virus [FW])
Original FNV virus (pl28)
First FNV administered (p237)
Later vaccines (p258-260)
* Name of the patient, Franscois Mayali, from whom the 
virus was isolated by Mathis et. al., 1928
Figure adapted from Barrett, 1987
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performed between 1939 and 1954 using the Dakar scratch method, resulting in 
a protection rate such that human YF practically disappeared from these areas 
(WHO Monograpg Series, 1956). In a field trial, conducted under the auspices of 
the United Nations Relief and Rehabilitation Administration, the Dakar vaccine 
was shown to produce a greater degree of imuunity than the 17D vaccine.
1.7.3 Historical problems with yellow fever vaccines
Although the FNV strain of YF vaccine was more efficacious and easier to 
administer than the 17D vaccine, this was accompanied by a greater risk of post­
vaccinal encephalitis, as well as the risk of extraneous infections from latent 
viruses of mice, such as lymphocytic choriomeningitis virus. Outside the French 
territories there were reports of encephalitis following administration of the Dakar 
vaccine and some of these incidents assumed serious proportions. In Nigeria, 
approximately 42,000 people were vaccinated, and 83 cases of post-vaccinal 
encephalitis were recorded, of which 32 proved to be fatal (McNamara, 1953). 
YF virus was isolated from the brains of four fatalities. However, many cases and 
fatalities probably went un reported, leading to the speculation that incidences of 
encephalitis and death were higher than the respective 0.2% and 0.08% figures 
presented in this study (Barrett, personal communication). The incidence of 
encephalitis among children was particularly high (0.3-0.4%), with a 40% chance 
of the outcome proving fatal. This led to the prohibition of its use in children 
under the age of 14 years by the WHO in 1959 (WHO Monograph Series, 1959). 
Satisfactory experience with the 17D vaccine in large-scale immunisation
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campaigns and its greater safety recommended it above the Dakar vaccine for 
general use and, as a result, the latter lost popularity and production was 
discontinued in 1980. The last dose of FNV was administered in Malawi in 1981 
(Barrett, personal communication).
In the early phase of the 17D vaccination programme there were also 
problems. The vaccine production was not standardised; vaccine lots were 
prepared by inoculation of chicken eggs with the current in vitro  subculture of the 
virus. By 1943, certain 17DD vaccine lots that had been subcultured in excess of 
300 times were found to have become overattenuated, resulting in loss of 
immunogenicity for man (Theiler, 1951). Conversely, others demonstrated 
increased neurovirulence, with clinical encephalitis in a number of human 
vaccin ees and an unusually high incidence of encephalitis in monkeys (Fox et a/., 
1942). These problems were addressed by the introduction in 1945 of standards 
for YF vaccine production, including the adoption of a seed-1 ot system (WHO 
Monograph Series, 1956). Primary and secondary seed-lots must passs satisfactory 
monkey safety and immunity tests. Vaccine batches prepared from the same 
secondary seed lot are therefore stabilised as to passage level and biological 
characteristics (Monath et a/., 1983).
1.7.4 Modern problems with 17D vaccines
VF 17D vaccines are currently manufactured with approval of the WHO 
in 12 countries. Many millions of vaccine doses have been administered and
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these vaccines have proven both efficacious and safe, with 21 cases and one 
death since the introduction of the seed lot system in 1945. The only death due 
to post-vaccinal encephalitis for the 17D vaccine was reported in 1965 
(Anonymous, 1966). However, despite this admirable record, several problems 
remain. ^
First, there is a disparity between vaccines in their substrain origin. The 
latest vaccines are derived from two distinct 17D substrains (designated 17D-204 
and 17DD) representing independently maintained passage series from the 
original. The 17D-204 substrain is derived from the 204th passage of the Asibi 
virus and is now at 233rd-239th passage. Passage 221 and all passages after 225 
have been cultured in chick embryo tissues from which the nervous tissue has 
been removed. Substrain 17DD diverges from 17D at passage 195 and, from then 
on, it has been passaged in chick embryo tissue or embryonated chicken eggs to 
produce 17DD vaccines at passages 286-288, in South America.
Second, certain manufacturers have used various techniques to free vaccine 
seed lots from the avian leukosis virus (ALV) contaminant. Both ALV-free and 
ALV-contaminated strains are currently used, but the WHO encourages the 
adoption of a stable ALV-free seed lot (17D-204-WHO) by manufacturers, which 
has been shown to confer solid protection and few si de-effects in recipients 
(Moss-Blundell et a/., 1981). In addition to the potential threat posed by any 
contaminating virus (although there have been no recorded problems resulting 
from ALV; Waters et a/., 1972), the presence of ALV in vaccine preparations
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reduces the heat stability of the vaccine batch. This can cause major problems 
when a reliable cold chain for the transport of vaccine, especially to tropical and 
sub-tropical areas, is not available (Lloyd, 1977). Several attempts have been 
made to improve the thermal stability of the 17D vaccine since the abortive 
addition of human serum, including the addition of lactose, sorbitol, histidine and 
alanine to the lyophilised preparation (Barme & Bronnert, 1984). In field testing, 
the vaccine was found to have favourable stability, with the lyophilized material 
remaining effective after 5 months storage at 4°C (Georges et al., 1985).
Third, full characterisation of YF 17D vaccines has not been accomplished, 
despite clear indications of heterogeneity and the demonstrated presence of 
plaque mixtures with variable mouse neurotropism following inracerebral 
(Liprandi et al., 1981) and intranasal (Barrett & Gould, 1986) inoculation of mice. 
Biological differences also relate to growth in human monocyte and macrophage­
like cells (Liprandi & Walder, 1983). More recently these studies have been 
extended to show that plaque variants can be distinguished antigenically by 
monoclonal antibodies (MAbs; Gould et al., 1985) and wild-type antigenic 
variants, neurovirulent in mice, have been identified with wild-type virus-specific 
MAbs in YF vaccine pools (Gould et al., 1989). Other variants, lacking this wild- 
type epitope, were avirulent. This not only demonstrates the antigenic 
heterogeneity of 17D vaccine preparations, but also points to the potential risk of 
reversion to virulence by selection of wild-type variants in YF vaccine 
preparations, although this has never been documented.
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Finally there are difficulties in large-scale vaccine production, resulting 
from shortages of suitable embryonated eggs, short shelf-life of vaccines and 
antiquated production methods; also periodic demands for millions of doses must 
be met during epidemics. These problems led to the recommendation that the Pan 
American Health Organisation (PAHO) and the WHO "urgently undertake a 
programme directed at modernising YF vaccine..., evaluate cell cultures as virus 
production substrates..., and determine virus heterogeneity (by) 
molecular...methods (Woodall, 1981).
In contrast to FNV, 17D vaccine strains have largely been free from post­
vaccinal problems, including encephalitis. In fact, the number of documented 
cases of encephalitis following vaccination with 17D strains is less than 21, only 
one of which was fatal. In this incident a 39 month old girl was inoculated with 
batch 6145 of the 17D-204 vaccine produced in the USA by the National Drug 
Company. The child developed encephalitis and died 12 days post-vaccination. 
Neither of her parents, who were vaccinated with the same batch at the same 
time, exhibited any signs of encephalitis. YF virus was subsequently isolated from 
her brain at post-mortem (Anonymous, 1966). This case remains unique in the 
history of the 17D vaccine strains.
1.7.5 The attenuation process in yellow fever virus
The single-stranded, positive-sense RNA YF virus genome is subject to the 
high rate of mutation associated with RNA viruses, attributable, at least in part,
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to the lack of proof-reading activity in RNA repli cases (Holland et al., 1982). 
However, although the wild-type Asibi virus was isolated more than 50 years ago, 
the virus has not yet changed sufficiently to necessitate a new vaccine. The 
relatively low rate of sequence divergence in wild-type YF virus is thought to be 
related to the host vector cycle (Strauss & Strauss, 1988) because two sets of 
incompatible constraints are placed on the virus and/or because fewer replication 
cycles per unit time occur in the cold-blooded vector in the absence of immune- 
pressure. Representative South American and West African YF virus strains, 
isolated for several hundred years in separate ecological systems and evolved 
under different selection pressures imposed by hosts and vectors, are remarkably 
similar at the amino acid level, although many nucleotide changes have occurred 
(Hahn et al., 1987; Ballinger-Crabtree & Miller, 1990; Lepienic et al., 1994; 
Jennings et a/., 1995).
Although any population of RNA viruses, even from a single clone, consists 
of variants that differ from one another at many nucleotide positions, under stable 
conditions selection presumably maintains an average sequence. However, in the 
presence of changing environmental circumstances, the viable mutants constantly 
arising in the virus population may acquire a selective advantage. Attenuation by 
propagation in tissue culture is assumed to result from selection for variants which 
are better adapted for replication in tissue and, conversely, less well adapted for 
replication in their natural hosts, although accumulation and fixation of non­
selected mutations may also be important. In particular, variants might be selected 
that bind more readily to receptors on cultured chicken cells, leading to more
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rapid attachment and penetration. Such an alteration in binding could, as a 
consequence, lead to less efficient binding to receptors found on hepatocytes or 
neurones in primates and thus to an alteration in tissue tropism and a reduction 
in virulence (Hahn et a/., 1987).
The target cell for vaccine virus replication in the human host is not clearly 
defined. However, the atypical pattern of IgM and IgG neutralising antibody 
synthesis kinetics in vaccinees, with prolonged IgM antibody synthesis, could be 
explained by the persistence or recurrence of antigenic stimulation through 
establishment of a latent, assymptomatic infection (Monath et a/., 1971). 
Mononuclear phagocytic cells (Schlesinger & Brandriss, 1981a, b) and activated 
lymphocytes (Wheelock et a/., 1970) are likely sites for continued low grade viral 
replication as suggested by pathogenesis studies and their in vitro  susceptibility 
to viral infection (Liprandi & Walder, 1983). Although both wild-type and 
attenuated YF virus strains show a marked tropism for lymphoreticular tissues in 
vitro, most of the attenuated strains exhibit a higher affinity for the cell receptors 
and produce higher virus yields. Indeed, replication of the 17D viral strain 
appears to be confined to lymphoreticular tissue, suggesting that replication in this 
cell system is not related to the expression of virulence for the host (Liprandi & 
Walder, 1983).
Non-transmission of vaccine viruses by mosquitoes may also relate to the 
attenuation process. The attenuated YF virus is unable to disseminate to the head 
tissues or be transmitted (Deubel etaL, 1981, Miller eta/., 1986), while wild-type
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virus can disseminate and be transmitted (Deubel et a i,  1981). This is important 
in that mosquitoes feeding on recently vaccinated individuals cannot transmit the 
virus to non-vaccinated individuals since it is conceivable that the mosquito 
transmission of the attenuated virus could result in the selection of wild-type 
revertant viruses.
1.7.6 Attenuation of yellow fever virus by HeLa cell-passage
In addition to the vaccine strains of empirically derived YF vaccine viruses 
described above, YF virus has also been shown to become attenuated following 
limited HeLa cell-passage. The HeLa cell line was isolated in February 1951, from 
a cervical adenocarcinoma of a 31 year old woman, who subsequently died from 
the cancer (Gey et a/., 1952; Jones et a/., 1971). HeLa cells were the first human 
tumour cells to be established as a continuous cell line.
The alphavirus, Venezuelan equine encephalitis (VEE), was the first virus 
to be attenuated by passage through HeLa cells. After 23 consecutive passages, 
the virus exhibited a reduced virulence for mice inoculated by the intraperitoneal 
route. Following 65 passages, the virus was found to be avirulent (Murphy et a/., 
1955a, b).
In 1963, Hardy passaged the wild-type YF virus strain Asibi six times 
consecutively in HeLa cells (Hardy 1963a, b). The resulting virus, Asibi HeLa-p6, 
dsiplayed an enhanced virulence for mice, manifested as a reduced average
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survival time (AST). However, unlike the wild-type parent Asibi virus, the Asibi 
HeLa-p6 virus did not cause a lethal infection in monkeys following subcutaneous 
inoculation. Thus, the passage of the Asibi virus in HeLa cells resulted in the loss 
viscerotropism for monkeys.
In 1965, Hearn et a/, examined this phenomenon further by characterising 
the intermediate viruses (Asibi HeLa-pl and p3). This study demonstrated that 
biological changes occurred much earlier than passage six. The Asibi HeLa-pl 
virus T T was no longer cytopathic in cell culture, although this property was 
regained following three passages. The Asibi HeLa-p3 virus was attenuated for 
monkeys. Furthermore, this virus required a reduced incubation period for peak 
infectivity titre (three days, as opposed to five days for Asibi virus). However the 
HeLa-pl and p3 virus populations appeared to be genetically very unstable. 
Hearn et al. (1966) also characterised an Asibi virus that had been passaged seven 
times through HeLa cells. This virus was found to be highly attenuated, requiring 
inoculation of over 700,000 mouse infectious doses to elicit the same virulent 
response in monkeys as one to 10 infectious doses of the wild-type parent Asibi 
virus.
The attenuation of wild-type YF viruses by passage through HeLa cells was 
examined in more detail in studies performed by Dunster (1990), Barrett et a i,  
(1990) and Sil et al. (1992)a.This work not only repeated and confirmed the 
earlier results obtained for Asibi virus, but also showed that other wild-type YF 
viruses, FVV and B4.1 (a South American YF virus), could also be attenuated in
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the same way. In addition, studies with MAbs revealed that wild-type YF viruses 
attenuated in this manner exhibited E protein epitopes previously found to be 
specific for the YF vaccine viruses, 17D and FNV. Therefore, despite the 
employment of very different attenuation processes in the derivation of these 
attenuated YF virus variants, similarities were evident (Barrett et a l,  1990; Sil et 
a l,  1992)V>The implications of this work are discussed further in Chapter 5.
1.8 Molecular biology of the flaviviruses
Studies on the molecular biology and sequence analyses of flaviviruses 
have trailed behind those of other virus families. Flowever, in recent years 
understanding of the significance of the flavivirus-specified proteins has increased 
dramatically. This has depended largely on the determination of the complete 
nucleotide sequences of a number of flaviviruses, the first being that of YF virus, 
the prototype flavivirus (Rice et a l,  1985), and the partial determination of those 
portions encoding specific genes for many others (Table 1.2). The information in 
the following sections is drawn from research on many different flaviviruses, but 
is applicable to YF virus.
1.8.1 Genome organisation and processing
The flaviviral genome is a single-stranded, positive-sense, infectious RNA, 
approximately 11 kb in length (Deubel et a l,  1983). In the case of YF virus the
51
Virus Strain Reference
YF viruses Asibi Hahn etal. (1987)
DEN viruses
DENI, 8275/90 
DEN 2, SI 
DEN 2, Jamaica 
DEN 2,16681 
DEN 3, H87
Fu etal. (1992)
Hahn etal (1988) ' 
Deubel f/aX (1988) 
m & etal (1992)
Osamatomi etal (1990)
WN viruses Nigeria Castle etal (1986)
KUN viruses E101 CoiafA?/ (1988)
TBE viruses
Neudorfl
RSSE
Powassan
Mandl^/s/ (1989a) 
Pletnev d/aZ(1990) 
Mandl etal (1993)
JE viruses Beijing 1 
JaOARS982
Hashimoto etal (1988) 
Sumiyoshi etal (1992)
Table 1.2: Flaviviruses which have been sequenced to date.
Only wild-type flaviviruses for which the entire genomic sequence 
a
is availble have been included.
A
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genome is 10,862 nucleotides long (Rice e ta l., 1985). No subgenomic mRNAs 
have been identified in fIavivirus-infected cells; all the encoded flavivirus proteins 
are translated from a single open reading frame (ORF). In YF virus, 10,233 
nucleotides are present in the ORF (Rice et a/., 1985).
Flanking the ORF are 5' (118 bases) and 3Z(511) non-coding regions. The 
5' terminus of the genome is type 1 capped (m^OpppAmpN,) followed by a 
conserved dinucleotide AG sequence, probably involved in RNA binding to 
ribosomes (Mathukrishnan et a/., 1975, 1976; Wengler et a/., 1978; Cleaves & 
Dubin, 1979). The 3' terminus of the genome of mosquito-borne flaviviruses is 
not poly-adenylated (Deubel et a/., 1983; Brinton, 1986, Rice et a/., 1986), but 
instead terminates with UOH (Wengler et a/., 1978; Wengler & Wengler, 1981; 
Deubel et a/., 1983). The 3z-terminal nucleotides form a very stable stem-loop 
structure (Brinton et a/., 1986). The shape of this structure is highly conserved 
among flaviviruses, even though the sequences composing the stems of the 
structure are not conserved (Brinton et a/., 1986). These terminal structures are 
thought to function as signals for initiation of RNA synthesis. The 3Z non-coding 
sequence of tick-borne flaviviruses appears to be much shorter and also appears 
to lack a number of RNA sequences and structures found in the mosquito-borne 
group (Mandl et a/., 1989a). Furthermore, some TBE virus genomes have been 
demonstrated to possess a poly(A) tract (Mandl et a/., 1989a). Nucleotide 
conservation is seen between the 5 '-terminus of the plus strand and the 3Z- 
terminus of the minus strand, serving as common recognition sequences for the 
viral polymerase.
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The polyprotein translated from the single genome ORF is processed by 
proteolytic cleavage (Rice et al., 1985; Chambers et al., 1990). The structural 
proteins C (capsid; the C precursor is called anchored C), M (membrane; the M 
precursor is called prM) and E (envelope) are encoded by the 5 -quarter of the 
genome, while the non-structural (NS; replicative) proteins are encoded by the 
remaining three-quarters at the 3 '-end. The non-structural proteins include the 
large, highly conserved proteins NSI, NS3, NS5 and the four small, hydrophobic 
proteins NS2A, NS2B, NS4A and NS4B (Rice et al., 1986; Figure 1.6).
The order of proteins encoded in the flavivirus long ORF was found to be; 
5 -C-prM(M)-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3'.The currentview is that 
translation of the long ORF initiates near the 5Z end of the genome and processing 
of the polyprotein involves a remarkable progression of cleavages mediated by 
proteases of both host and viral origin (Chambers et al., 1990). The locations of 
the protease cleavage sites in the polyprotein were predicted by comparison of 
the polyprotein sequence with the N- and C-terminal amino acid sequences, 
derived from the mature proteins. The cellular protease, signalase, cleaves after 
serine, alanine, or other short side-chain amino acid residues (Rice et al., 1986). 
Signalase cleavage sites follow the C, prM, E and NS4A proteins. The cleavage 
sites that generate the N-termini of NS2B, NS3, NS4A and NS5 are highly 
conserved among flaviviruses. Cleavage at these sites occurs after two basic amino 
acids such as Lys-Arg, Arg-Arg, Arg-Lys or occasionally Gln-Arg. A viral protease 
located in the NS3 protein is thought to mediate these cleavages. NS2B is 
required as a cofactor for NS3 protease activity (Chambers et al., 1991). The
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Figure 1.6: Notes
NC - untranslated non-coding region. Boxes below the genome indicate precursors and 
mature proteins generated by combinations of host and virus encoded proteinases.
Structural proteins 
Non-structural proteins 
H  Long stretches of uncharged amino acids
* Probable NH^linked glycosylation site for YF virus in pre-M and NS1
Proposed cleavage sites and their mechanisms
XT' Signalase, rapid lumen 
xjj/ Dibasic, rapid lumen
Dibasic, delayed?, cytoplasm 
^  Dibasic, delayed, lumen 
M  Novel, slightly delayed, lumen
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cleavage of anchored-C to virion C and of prM to M are thought to be linked to 
virion assemply and release. Flavivirus polyprotein processing is reviewed in 
detail by Chambers et al. (1990).
1.8.2 Virion structure and assembly; the structural proteins
The icosahedral virions of YF virus contain a nucleocapsid 25-30 nm in 
diameter composed of C protein units, surrounded by a lipid bilayer derived from 
host-membranes which contains the membrane-associated proteins, E and M (or 
prM). The diameter of the virion is approximately 40 nm, with surface projections 
of 5-10 nm (Murphy, 1980).
The capsid protein:- The C protein forms the structural part of the virus 
nucleocapsid, and is present in virions as a small (predicted MW 12-14 kDa) 
highly positively charged protein (27% lysine and arginine for YF virus (Rice et 
a/., 1986; Chambers et a/., 1990). The anchor-C precursor protein contains a 20 
amino acid C-terminal hydrophobic segment (for YF) which is not found in mature 
virions (Nowak et a/., 1989b), important in the initiation of cotranslational 
translocation of prM as well as in cleavage at the prM N-terminus (Markoff, 1989; 
Markoff et a/., 1994). The basic nature of C is believed to offset the charged RNA 
molecule with which it is associated (Rice et a/., 1986). Although the amino acids 
that make up the C protein exhibit little homology amongst the flaviviruses so far 
sequenced, regions of hydrophobicity and hydrophilicityare conserved, including 
the C-terminal hydrophobic domain that is immediately preceded by a hydrophilic
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region, and also a central hydrophobic region (Mandl et a/., 1988). The N- 
terminal portion contains a hydrophilic section which, in mosquito-borne 
flaviviruses is interrupted by a hydrophobic insert that is not found in tick-borne 
flaviviruses (Mandl et a/., 1989b). Purified C does not elicit neutralizing antibody 
when injected into mice (Brinton e ta /.,  1986).
The membrane protein:- Two morphologically indistinguishable virion 
forms have been characterised: intracellular virions contain only prM, whereas 
extracellular virions, released into the culture fluid, contain mostly M. The prM 
protein is a glycoprotein precursor (MW 18.1-19.0 kDa) to the structural protein, 
M. The function of prM appears to be the protection of protein E from irreversible 
conformational changes during passage through acidic compartments of the 
secretory pathway (Heinz & Mandl, 1994). prM undergoes a delayed cleavage to 
form the mature M protein and the N-terminal zprz segment, the fate of which is 
unknown (Chambers et al., 1990). This cleavage is linked to viral maturation or 
release and triggers changes in the E protein that promote infect!vity.
The N-terminal pr segment is predominately hydrophilic, and contains six 
conserved cysteine residues, all of which are involved in disulphide bridging 
(Nowak & Wengler, 1987). Serologically related flaviviruses show conservation 
of potential N-linked glycosylation sites (Asn-X-Ser/Thr); in YF virus there are three 
potential sites within the pr region; data suggests that two are utilized, although 
which two is not known (Chambers et a i,  1990). The C-terminal M portion 
contains a shortened ectodomain and retains the two potential membrane-
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spanning domains. At the C-terminus, a structurally conserved hydrophobic signal 
sequence has been identified (15 amino acids in YF; Depres et al., 1988), which 
is required for stable membrane insertion of prM and efficient cleavage at the 
prM-E junction (Markoff et a/., 1994).
The M protein is associated with the E protein, but in the mature form is 
not glycosylated. It is a minor component of the envelope (MW 7-9 kDa), and 
may play a role in virus/cell interactions, as Banzi virus is unable to attach to cells 
which have been pre-treated with purified Banzi M protein (Lee & Schloemer, 
1981) and prM-containing virions were unable to mediate "fusion from without" 
(Guirakhoo et a!., 1991). Unlike C, purified M protein does elicit a neutralizing 
antibody response following inoculation into mice (Brinton, 1986).
The envelope protein:- The E protein, with a predicted molecular weight 
of 53-59 kDa, is the major structural protein of the virus and the major 
component of the virion surface (Chambers et al., 1990). As such, it possesses 
most of the sites concerned with biological activity including binding to cell 
receptors (tropism and haemagglutination), invoking immunological responses 
(neutralization, passive protection and antibody dependent enhancement), virion 
assembly and fusion activity at low pH (Monath, 1989).
The E protein is glycosylated in some, but not all flaviviruses, and appears 
to be a typical membrane protein consisting of a large N-terminal ectodomain, 
anchored in the bi-layer by means of a hydrophobic C-terminal domain
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(Chambers et a i,  1990). As in prM, the cysteine residues within the E protein are 
strictly conserved within all flavivirus E proteins so far studied; there are 12, and 
all are involved in the formation of di-sulphide bridges (Nowak & Wengler, 
1987). Within the E proteins there are regions which exhibit high degrees of 
homology, particularly at the amino acid level, and others where both nucleotide 
and amino acid homology is low.
The molecular interactions involved in the assembly process have not been 
clearly defined, but E and prM or M, as present in intracellular and extracellular 
virus respectively, appear to be associated as detergent-stable dimers (Heinz & 
Kunz, 1980). Both prM/M and E are predicted to have only small cytoplasmic 
domains, but unlike simple transmembrane anchors, their hydrophobic C-termini 
are highly conserved and could be involved in E-prM or envelope-nucleocapsid 
interactions. The E protein and its role in viral pathogenicity are discussed further 
in Section 1.9.
1.8.3 The non-structural proteins
The functions of the non-structural proteins remain largely undefined, but 
roles in viral replication (NS3 and NS5) and virion assembly, transport and release 
(NS1) have been proposed. The NS1 glycoprotein exists as cell-associated 
(Westaway, 1987), ce 11-surface (Schlesinger et a/., 1985; Westaway, 1987) and 
extracellular, non-virion (Smith & Wright, 1985; Winkler et a/., 1988; Lee et a/., 
1989; Mason, 1989) forms. The NS1 protein has a predicted MW of 39-41 kDa,
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with additional modification by N-linked glycosylation. NS1-specific antibodies 
can provide protective immunity (Schlesinger et a i,  1985, 1986, 1987; Zhang et 
a/., 1988; Bray et a/., 1989).
NS3, the second largest viral protein (predicted MW 68-70 kDa), is highly 
conserved among flaviviruses (Mandl et a/., 1989; Rice et a/., 1986) and contains 
no long hydrophobic stretches. A role for NS3 in viral RNA replication has been 
postulated and recent sequence comparisons and in vitro expression studies 
suggest that it is probably at least bifunctional, containing both a protease activity 
(Bazan & Fletterick, 1988, 1989; Chambers et a/., 1990; Falgout et a/., 1990; 
Gorbalenya et a/., 1989a; Preugschat et a/., 1990) and a nucleotide 
triphosphatase/he!icase activity (Gorbalenya et a/., 1989b). These properties 
suggest a cytoplasmic localisation for NS3, with membrane association via 
protein-protein interactions which have not been defined.
NS5 is the largest (predicted MW 103-104 kDa), and most highly 
conserved of the flavivirus proteins (Mandl et a/., 1989). NS5 has a net basic 
charge and contains several sequence motifs, including Gly-Asp-Asp (Rice et a/., 
1985; Rice et a/., 1986), which are believed to be characteristic of RNA- 
dependent RNA polymerases (Inokuchi & Hirashima, 1987; Kamer & Argos, 1984; 
Poch et a/., 1989; Rice et a/., 1986).
The NS2A, NS2B, NS4A and NS4B polypeptides are poorly conserved 
among flaviviruses (Mandl et a/., 1989; Rice et a/., 1986), but contain similar
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structural features, consisting mainly of multiple hydrophobic, potential 
membrane-spanning domains. NS2A has been implicated in the processing of 
NS1. The NS2B and NS4B proteins are readily identifiable in infected cells, but 
a discrete NS4A protein has been definitively identified only for Kunjin virus 
(Speight & Westaway, 1989). It has been hypothesised that these proteins are 
membrane-associated and may participate in assembly of viral replication 
complexes by localisation of NS3 and NS5 to membranes via protein-protein 
interactions.
1.8.4 Flavivirus replication strategy in cultured cells
The first steps an enveloped virus takes to infect cells are those of 
attachment and fusion. Virions attach to target cells via interactions with specific 
cellular receptors (Figure 1.7, step 1). It is this mechanism that directs tissue 
tropism and the pathogenesis of many viruses. To date, none of the host cell 
proteins that function as flavivirus receptors have been characterised. In contrast 
viral fusion has been well studied, although not without some controversy. Many 
investigators have provided considerable evidence that flaviviruses are taken up 
by vertebrate cells via receptor-mediated endocytosis followed by a pH- 
dependent, acid-catalysed, fusion event (Gollins & Porterfield, 1985, 1986; 
Kimura et ah, 1986; Ng & Lau, 1988; Ishak et a/., 1988). More recent research 
has shown that fusion of DEN, YF and JE viruses may in fact involve fusion of the 
virus directly with the cell's plasma membrane (Hase et a/., 1989; Summers et a/., 
1989), but it is not known whether entry by this mechanism leads to infection.
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Figure 1.7: Schematic representation of the replication cycle of the flaviviruses.
The various steps are designated by number and are described in 
the text. Adapted from Brinton (1994).
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A conformational change occurs in the E protein at low pH, which may be a 
prerequisite for fusion to occur (Kimura & Ohyama, 1988; Guirakhoo et a/.,
1989). Immune enhancement has been demonstrated with flaviviruses indicating 
that viruses can also enter cells via attachment of immune-complexes to cellular 
Fc receptors (Gollins & Porterfield, 1985).
Once virus has penetrated the cell, replication proceeds with the 
immediate translation of the flavivirus genome (Figure 1.7, step 2). No evidence 
yet exists that flaviviruses undergo cyclization of RNA prior to replication; 
however two short conserved repeat features (named CS1 and CS2) are found 5' 
to the 3' putative secondary structure sequence. It has been postulated that base- 
pairing of these terminal sequences could lead to cyclization of the viral genome 
which may be important for regulating genome translation, replication or 
packaging (Brinton & Dispoto, 1988; Sumiyoshi et al., 1987). Evidence supports 
the cyclization of the genomes of alphaviruses (Frey et a/., 1989; Hsu eta/., 1973) 
and bunyaviruses (Hewlett et a/., 1977), but in flaviviruses the possibility has not 
as yet been investigated (Chambers et a/., 1990). The single polyprotein produced 
is then processed by cleavage (Figure 1.7, step 3) by both cellular and viral 
proteases (Section 1.8.1). The newly translated viral NS proteins then associate 
with the viral RNA (Figure 1.7, step 4a) and copy full-length negative-strand RNA 
from the genome template (Figure 1.7, step 4b). The negative-strand RNAs are 
immediately utilised as templates for positive-sense RNA synthesis (Figure 1.7, 
step 5) and are never found "free" in the cytoplasm. Positive-strand synthesis is 
more efficient than negative-strand synthesis. It is postulated that the different
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stem-loop structures present at the 3 '-terminal ends of the positive and negative 
strands may affect the efficiency of initiation of a replication complex (Brinton & 
Dispoto, 1988). Progeny positive-strand RNAs accumulate and are assembled into 
new virions through association of the RNA with newly synthesised viral structural 
proteins (Figure 1.7, step 6).
Viral RNA synthesis can be detected three to six hours after infection, and 
progeny infectious virus begins to be released by about 12 hours. Enveloped 
progeny virions are seen associated with perinuclear cisternae of endoplasmic 
reticulum vesicles of infected cells (Murphy, 1980; Brinton, 1986), but assembled 
viral nucleocapsids have not been detected (Brinton, 1986; Chambers et al.,
1990). Subcellular transport of immature flavivirus to the cell surface is thought 
to occur by the translocation of immature virion-containing vesicles from 
membranous components of the cell to the plasma membrane. Lipid fusion then 
presumably occurs, thus releasing the vesicle contents extracellularly (Hase et a/., 
1987). Budding from the plasma membrane has only recently been observed (Ng 
et al., 1994). Concurrent with flavivirus translocation and release from cells, a 
proteolytic fusion event takes place in which the amino-terminal portion of the 
prM protein is released forming the mature M protein (Brinton, 1986; Chambers 
et a/., 1990). This proteolytic event is necessary to produce fully infectious virus 
(Wengler & Wengler, 1989). Recent studies have suggested that the processing 
of prM to M is a pH-dependent event, which takes place in post-Golgi vesicles. 
This proteolytic event may be necessary for fusion of virus with susceptible host 
cells (Randolph et a/., 1990; Guirakhoo et a/., 1991). Some flaviviruses may,
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however, be released from cells predominantly in the immature form and contain 
prM (Guirakhoo et a/., 1991).
Although growth kinetics appear similar in vertebrate and arthropod cells, 
maximal titres in different cell types can vary considerably (Mussgay et a/., 1975). 
Even during the peak of virus production, a major inhibition of host 
macromolecular synthesis is not observed (Brinton, 1986). In vertebrate cells, 
dramatic cytopathic and ultrastructural changes can be observed, including a 
vacuolation and proliferation of intracellular membranes (Murphy, 1980); 
infection is commonly cytocidal, although some vertebrate cell types do not show 
these effects and become chronically infected. Arthropod cells may demonstrate 
cytopathic effects, including syncytium formation; generally infections are non- 
cytopathic (Mussgay et a/., 1975) and persistent infections are more easily 
established in arthropod than in vertebrate cells.
1.9 The flavivirus envelope protein
1.9.1 The structure of the envelope protein
The E proteins of all flaviviruses sequenced so far show perfect 
conservation of 12 cysteine residues which form six disulphide bridges. In 
addition, they exhibit highly homologous hydrophilicity profiles, suggesting that 
all members of the flavivirus family share a fairly common architecture of their E
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protein. Consequently, data accumulated during the study of several different 
flaviviruses has been used to determine the E protein structure and elucidate its 
structure-function relationships. These studies have included: (1 ) the determination 
of the intramolecular disulphide bridges for WN virus (Nowak & Wengler, 1987); 
(2) study of the biological and topological properties of E protein epitopes defined 
by MAbs (reviewed by Heinz, 1986); (3) physical and immunological 
characterisation of E protein fragments derived by protease or chemically induced 
cleavage (Guirakhoo et a/., 1989b; Mandl et a/., 1989b); (4) localization of 
antibody binding sites to the deleted forms of the JE virus E protein expressed in 
bacteria (Mason et a/., 1987; Mason, 1989); (5) reactivity of anti-peptide sera with 
native E protein from MVE and DEN-2 viruses (Roehrig et a/., 1989) and; (6) 
nucleotide sequencing of MAb neutralization escape (MAbR) variants (discussed 
in Section 1.9.2).
The assignment of disulphide bridges for WN virus by Nowak and Wengler 
(1987) was a major breakthrough toward the elucidation of the E protein structure. 
Based on these analyses, it was proposed that the E protein was composed of 
three major regions, separated by two intervening sections, as well as two 
transmembrane segments at the carboxy-terminus. By using a direct approach, 
including the analysis of antigenic variants and immunoreactive fragments, Heinz 
and coworkers were able to determine the location of structurally defined 
epitopes on the TBE virus E protein. Compilation of all the above data led to the 
proposal of a model showing the arrangement of the polypeptide chain into three 
distinct protein domains (A, B and C), which also correspond to the antigenic
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domains (Mandl et al., 1989b; Figure 1.8).
Domain A is a disulphide-rich, discontinuous structure, composed of 
distant regions of the primary sequence; residues E-50 to E-125 (numbered from 
the amino-terminus of the E protein), and residues E-200 to E-250. This is the only 
domain in which flavivirus cross-reactive epitopes have been identified. This is 
consistent with the presence of several highly conserved regions, including one 
spanning amino acid residues E-98 to E-111 which is almost totally conserved 
among flavivirus E proteins studied to date (Heinz et a/., 1990; Roehrig et al., 
1989). Domain A undergoes a pH-dependant conformational change consistent 
with a possible role in acid-catalysed endocytotic fusion events (Guirakhoo et al., 
1989a). In addition, domain A epitopes of CE-TBE virus are sensitive to 
dénaturation with sodium dodecyl sulphate (SDS), reducing agents and trypsin 
and carries several epitopes involved in neutralisation, haemagglutination- and 
fusion-inhibition (Guirakhoo et a/., 1989a).
Domain B is located between residues E-300 and E-395 bordered by 
trypsin-cleavage sites. It contains one disulphide bridge and apparently represents 
an independently folding protein domain with a strong tendency for renaturation 
(Winkler et al., 1987). Domain B seems to be strongly folded and stabilised by 
its single disulphide bond and probably additional intramolecular forces as 
suggested by the presence of several potential tryptic cleavage sites which are 
apparently inaccessible in the native form of this domain (Mandl et al., 1989b). 
It displays epitopes which are resistant to SDS, acidic pH and trypsin, but
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Figure 1.8: Structural model of the E protein. Circles indicate amino acids in the
TBE virus E protein. Highly conserved amino acids are black, partially conserved 
amino acids are shaded. Disulphide bridges are indicated by lines, while potential 
N-linked glycosylation sites are indicated by diamonds. Thin curved lines denote 
hypervariable regions, while the thick curved line indicates a highly conserved 
domain proposed to be involved in membrane fusion. Adapted from Chambers 
e ta / .  (1990).
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sensitive to reducing agents (Guirakhoo et al., 1989a). A role in tissue tropism, 
and possibly virus-receptor interaction, has been tentatively assigned to this 
domain based on the analysis of MAbR variants.
Domain C is shown as a single highly variable loop made up of amino 
acids E-131 through E-177, which does not contain any disuphide bridges 
(Chambers et a/., 1990; Figure 1.8). Epitopes in this domain are not denatured by 
SDS, but are sensitive to protease treatment (Guirakhoo et al., 1989a). In several 
flaviviruses, potential N-linked glycosylation sites have been identified within the 
primary amino acid sequence of this region (Section 1.9.2). Denaturation- 
resistance is lost when the carbohydrate side chain is removed, suggesting that 
glycosylation stabilises domain C, although domain C epitopes do not directly 
depend on the presence of these sugar residues (Guirakhoo et a/., 1989a). So far, 
no specific function has been assigned to this sequence element.
1.9.2 Molecular basis of flavivirus virulence
Knowledge of the complete sequence of the flavivirus genome provides the 
foundation for studies on the molecular basis of virulence. There is evidence from 
many viral systems (Tyler & Fields, 1990) that envelope glycoproteins, due to 
their importance for virus entry, represent important determinants of virulence. By 
the use of neutralising MAbs, neutralisation resistant escape variants or MAbR 
variants can be selected, each differing from the parent virus by a single amino 
acid substitution in the E protein. Several such studies have been performed with
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flaviviruses in recent years and have aided in the elucidation of the E protein 
structure-function relationships and role in virus pathogenesis.
The majority of MAb neutralisation escape mutations identified to date 
have mapped to domains A and B. Several analyses have revealed that regions 
from the A domain (E-1 through E-130) and the B domain (E-300 through E-400) 
may overlap in the folded E protein (Aaskov et a/., 1989; Roehrig et al., 1989; 
Hasegawa et al., 1992; Megret et al., 1992). It has been proposed by a number 
of investigators that the B domain possesses important determinants of flavivirus 
virulence and attenuation. Amino acid mutations at E-384 (TBE virus; Holzmann 
et al., 1990), E-333, E-384, E-367 (JE virus; Cecilia & Gould, 1991; Hasegawa et 
a i,  1992), E-308, E-310, E-311 (LI virus; Jiang et al., 1993) and E-401 (DEN 4; 
Kawano et al., 1993) have all been associated with altered virulence for mice 
following peripheral inoculation. However, when inoculated intracerebrally, these 
variant viruses were shown to be as lethal as their parent viruses. Thus, the 
variants have reduced neuroinvasiveness, but not reduced neurovirulence in mice. 
This idea is supported by the B domain location of nonconservative amino acid 
exchanges in the VF 17D vaccine strain (Rice et al., 1985) and the attenuated 
DEN 2 SI strain (Hahn et al., 1988) compared with the wild-type viruses. The 
importance of domain B is further substantiated by the MVE virus passage variant 
altered at asparagine residue E-390 which was shown to be attenuated for 21-day 
old mice after intraperitoneal injection (Lobigs et al., 1990). Residue E-390 forms 
part of an "RGD" sequence motif which has previously been shown to be 
involved in the cell attachment of different extracellular proteins such as
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fibronection, as well as foot and mouth disease virus (Mason et al., 1994), HIV-1 
(Barillari et al., 1993), adenovirus (Bai et al., 1993) and coxsackievirus (Roivainen 
et a/., 1991). However, this sequence is not conserved among all flaviviruses and 
its significance remains to be elucidated. Nevertheless, it is tempting to speculate 
that sequence elements within domain B are involved in putative receptor binding 
site. Subtle changes of receptor specificity or other aspects of early virus-cell 
interactions may affect tropism of the virus and thus lead, or contribute, to 
attenuation.
The region between residues E-200 and E-300 has been associated with 
induction of neutralising antibodies and has been identified as the possible 
contact region of the prM with E proteins in the immature virion (Guirakhoo et 
al., 1992). Association of the E protein with prM confers acid resistance to the 
virion and blocks virus-mediated membrane fusion (Guirakhoo et al., 1991, 
1992). Following cleavage of the prM protein, it has been proposed that the C 
domain serves as a site of protonation or acts as a molecular hinge so that, at low 
pH, E protein conformation is changed, permitting membrane fusion and exposing 
new sites (Roehrig et al., 1990). Variants of DEN 2 virus, selected for their 
resistance to acidic pH, were demonstrated to possess an amino acid substitution 
at E-153, ablating a potential N-linked glycosylation site (Guirakhoo et al., 1993). 
Furthermore, a mutation at E-171 in TBE virus also resulted in altered membrane 
fusion activity (Guirakhoo et al., 1991). The C domain has also been associated 
with DEN 2 virus attenuation indirectly. Although many amino acid substitutions 
in the structural and non-structural proteins occurred during the derivation of the
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attenuated DEN 2 vaccine strain, 16681 PDK-53, only three were found in the E 
protein and all in the C domain (Blok et a/., 1992). To date, there are no 
comparable studies with YF virus. The only report on YF virus is the identification 
of a YF type-specific epitope in the A domain mapped to positions E-71, E-72 and 
E-125 (Lobigs et al., 1987).
Recently, the E protein of TBE virus has been isolated in a soluble form 
and crystallized (Heinz et al., 1991). It is to be hoped that X-ray crystallographic 
analysis will resolve the three-dimensional structure of the E protein and greatly 
assist in elucidating its functional activities and antigenic properties.
1.10 The search for the molecular determinants of attenuation
1.10.1 Monoclonal antibodies to yellow fever viruses
Compared to molecular studies, there is a relatively large volume of data 
available examining YF virus biologically, with most of the recent publications 
involving the use of MAbs. In 1983, MAbs were reported which distinguished 
between the wild-type Asibi strain and it's vaccine derivative, substrain 17D-204 
(MAb 8A3; Schlesinger et al., 1983). Gould et al. (1985) included the other 
vaccine strains, FNV and 17DD, and a number of wild-type strains of YF virus in 
a study which showed that 17D-204, 17DD and FNV vaccine strains could be 
distinguished from each other and from wild-type viruses by MAb 864 and MAb
411. Each of the three vaccine substrains was shown to exhibit unique epitopes. 
In addition, MAbs were identified which recognised epitopes present on all 
flaviviruses examined, including tick-borne viruses and those with no known 
arthropod vector.
In addition to those studies detailed above, work in the University of 
Surrey has examined MAbs raised against both vaccine and wild-type strains of 
YF virus (Ledger et a/., 1992; Sil et al., 1992), and has identified, amongst others, 
the presence of an epitope (termed the "vaccine-specific epitope"and recognised 
by MAb H5) which is present on the E protein of all attenuated YF virus strains, 
including the Asibi HeLa-p6 virus, but absent on wild-type YF viruses. Also, four 
YF wild-type-specific MAbs (SI 7, SI 8, S24 and S56) were identified.
1.10.2 Biological analysis of yellow fever vaccine viruses
Monath et a/. (1983) observed that all vaccines derived from the 17D-204 
substrain, with one exception (the vaccine produced in South Africa), yielded 
identical T, oligonucleotide maps. No antigenic differences between 17D-204 
derived vaccines were demonstrated by neutralisation tests using monoclonal 
antibody. Vaccine viruses derived from the 17DD substrain consistently differed 
from the 17D-204 vaccines by the absence of one oligonucleotide and a clear 
antigenic difference was shown between 17DD and 17D-204 substrain vaccines 
using MAbs. This change probably occurred during the 40 additional egg passages 
in development of 17DD vaccines. Gould et a/. (1985) and Schlesinger et a/.
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(1983) were also able to distiguish 17D-204 vaccine viruses from all other YF 
viruses by their reactivity with a MAb 864 or MAb 8A3, respectively. This subtle 
antigenic difference does not seem to be important for the production of 
protective immunity, since both vaccines induce a broad neutralising antibody 
response against YF virus in vaccinees.
Other workers have found that MAbs will distinguish different vaccine 
viruses in neutralisation assays. Buckley and Gould (1985) found that a MAb 
raised against the 17D-204 vaccine virus manufactured in the UK (17D-204-UK) 
would neutralise 17D-204 vaccines manufactured in different laboratories to 
different extents. Since Gould et al. (1985) and Barrett et al. (1989) have reported 
similar results using MAbs prepared against different 17D-204 vaccine viruses, it 
would appear that variation in epitopes that elicit neutralising antibody and 
passive protection is a common phenomenon of YF vaccines manufactured in 
different centres around the world. Why this takes place is not clear, but may 
relate to different methods of vaccine production, including the source of eggs 
used to prepare the vaccine and the growth conditions of the vaccine virus. 
Whether or not these variations are of practical importance is uncertain. First no 
comparison has been made on the efficacy of vaccines produced by different 
manufacturers and, second, the neutralisation differences have been detected 
using MAbs raised in mice and the extrapolation to the human situation must be 
questioned.
Cane and Gould (1989) compared strains of YF virus by immunoblotting
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using polyclonal and monoclonal antibodies. The 17D-204 vaccine strains differed 
radically from the wild-type strains in that cells infected with 17D-204 did not 
accumulate intact E protein. The authors suggested that failure to accumulate the 
major viral surface protein is due to its increased susceptibility to breakdown and 
that this property may be a contributing factor in the attenuation of the vaccine 
strains. Lack of intact E protein does not necessarily mean complete lack of 
antigenic determinants in the cells infected with 17D-204, since smaller 
polypeptides bearing some epitopes were detected. One of the 12 amino acid 
changes (E-380) shown to occur between the E proteins of Asibi and 17D-204 
viruses (Hahn et al., 1987) lies in a region which, for WN virus, is susceptible to 
attack by proteases leading to the appearance of a cleavage product (Wengler et 
a/., 1987). Therefore, it may be that changes in the 17D virus have made the E 
protein more susceptible to proteolysis than that of the wild-type virus strains. It 
is well known that YF vaccine is unstable and must be stored under special 
conditions, and this may be also due to the instability of the E protein.
1.10.3 Nucleotide sequence analysis of yellow fever vaccine viruses
The determination of viral sequences is now seen as a prerequisite to 
analysing the molecular biology of viruses and investigating the molecular basis 
for phenotypic differences between related virus strains. Currently the interest in 
YF virus lies in investigating the molecular basis of attenuation of virulence of the 
17D vaccine strains. In 1985, the sequence of the entire genome of the 17D-204 
strain of YF vaccine virus was published (Rice et al., 1985). This sequence has
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since been amended (Rice, personal communication). This was the first full-length 
sequence of a flavivirus to be determined, providing an understanding at the 
molecular level of the structure, organisation and processing of the genome. Two 
years later the entire sequence of the wild type Asibi virus, from which the 17D 
vaccines were derived was also determined (Hahn et a/., 1987).
Comparison of the nucleotide sequence of the parental Asibi virus with the 
17D vaccine strains would be expected to yield equivocal results due to the large 
number of passages separating wild-type parent from attenuated variant. However, 
very few genetic changes are likely to be associated with the attenuation of 
virulence since attenuated derivatives of wild-type YF viruses were obtained by 
very limited HeLa cell-passage (Hardy, 1963; Hearn, 1965; Barrett et a/., 1990; 
Dunster, 1990). Comparison of nucleotide sequences for Asibi virus (Hahn et a/., 
1987) and a 17D-204 vaccine derivative (17D-204-ATCC; Rice et a/., 1985) 
revealed only a 0.63% nucleotide (0.97% amino acid) divergence, despite the 
243 passages separating these two viruses (Table 1.3). However, despite the low 
divergence rate, those nucleotide changes specifically involved in attenuation of 
virulence could not be identified.
The nucleotide changes were found to be scattered throughout the 
genome, but amino acid substitutions were not randomly distributed among the 
viral proteins (Hahn et al., 1987). The capsid protein is unchanged, while proteins 
NSI, NS3 and NS5 contain 0.5% amino acid substitutions, and proteins NS4A 
and NS4B average 0.8% substitutions. Whatever the role of these non-structural
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Table 1.3: Summary of the nucleotide and amino differences between 
Asibi virus and i t’s vaccine derivative, 17D-204 (ATCC)
Region Total n t /  AA
Change 
nt /  AA
% Change 
nt /  AA
5’ noncoding 118/- 0 /- 0 /-
C 363/121 2/0 0.55/0
prM 267/89 0/0 0/0
M 225/75 2/1 0.89/1.89
E 1479/493 15/12 1.01/2.43
NS1 1227/409 -5/2 0.41/0.49
NS2a 501/167 6/5 1.20/2.99
NS2b 390/130 4/2 1.03/2.31
NS3 1869/623 9/2 0.48/0.32
NS4a 861/287 6/3 0.70/0.78
NS4b 336/112 2/1 0.60/0.89
NS5 2715/905 11/4 0.40/0.44
3’ noncoding 511/- 6 /- 1.17/-
Total 10862/3411 6 8 /3 2 0.63/0 .97
Adapted from Hahn etal , 1987.
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proteins, they obviously require a precise conformation for that function and, 
therefore, amino acid changes might be selected against during continued 
passage. In contrast, proteins NS2A and NS2B have 3.0 and 2.3% amino acid 
divergence, respectively. The hydrophobicity profiles of these proteins are 
remarkably conserved, however, suggesting that as long as hydrophobicity is 
unchanged, a large number of amino acid substitutions can be accommodated 
without affecting their normal function. This may result from lower selective 
pressure against alteration in this region; among flaviviruses these polypeptides 
are much less highly conserved than NSI, NS3 and NS5. The E protein also has 
a relatively high rate of amino acid change (2.4%) and many of these amino acid 
substitutions are non-conservative. It seems likely that at least some of the 
difference in virulence between the two strains of YF virus result from changes in 
the E protein that affect virus binding to host receptors. Such differences in 
receptor binding could result in the reduced neurotropism and viscerotropism 
exhibited by the vaccine strain.
1.11 Infectious clone technology
1.11.1 Recovery of infectious flavivirus RNA from cDNA
For a number of positive-strand, and more recently, negative strand animal 
RNA viruses recovery of biologically active RNA molecules and/or infectious 
genome RNAs from cDNA clones has yielded significant new information on the
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function of viral proteins and RNA elements in replication and packaging and on 
the genetic determinants of virulence. Recently YF cDNA clones of the 17D 
vaccine strain have been constructed from which genome length RNA transcripts 
can be generated via in vitro  transcription. Capped RNA transcripts were 
infectious when used to transfect appropriate host cells and the virus produced 
was indistiguishable, by several criteria, from the parental strain used for cDNA 
cloning (Rice et a/.,1989). Diverse mutagenesis strategies can now be used to 
generate transcripts with novel mutations, either lethal, viable or conditional, to 
facilitate study of viral functions, both in vivo and in vitro. Although attempts to 
construct biologically active full-length flavivirus cDNA clones using plasmid 
vectors and E. co li hosts have not been generally successful, but have now been 
reported for YF (Rice et al., 1989), JE (Sumiyoshi et al., 1992), DEN 4 (Lai et al., 
1991) and Kunjin (Khromykh & Westaway, 1994) viruses. It is likely that other 
flaviviruses will soon be rescued from cDNA.
1.11.2 Uses of flavivirus cDNA clones for vaccine development
Besides their application to molecular genetic study of flavivirus 
replication, functional flavivirus cDNA clones and recombinant DNA technology 
are useful for exploring diverse approaches for vaccine design. Some of these 
include (1) the expression of flavivirus-specific proteins for subunit vaccines, (2) 
the engineering of infectious recombinant viruses, using vectors such as vaccinia, 
which express flavivirus antigens important for protection or, (3) the construction 
and/or propagation of live-attenuated flavivirus vaccine strains. For all of these
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strategies, the single most important concern for evaluating candidate vaccines is 
the establishment of biological test systems and a set of criteria relevant to the 
prevention of human disease.
One use of flavivirus cDNA clones from which infectious virus can be 
recovered is the identification of attenuating mutations. cDNA clones can be used 
to define precisely the sequence changes responsible for the phenotype of any 
flavivirus variant, by the strategy of exchanging segments of the parental clone 
with cDNA of the variant and determining the phenotype of the resultant 
recombinant virus. In the case of polio virus, this approach has been successfully 
used to map changes between different strains important for attenuation in murine 
(La Monica et a/., 1986) and primate models (Omata et a/., 1986). One point to 
emerge from these and other studies is that changes throughout viral RNA 
genomes, including the non-coding regions, can affect virulence. In the case of 
the flaviviruses, complete cDNA libraries and genome sequences have been 
determined for parental and attenuated strains of YF (Hahn et a/., 1987; Rice et 
a/., 1985), JE (Nitayaphan et a/., 1990) and DEN 2 (Blok et a/., 1992) viruses. 
Identification of attenuating mutations should facilitate monitoring of different lots 
of live-attenuated vaccine strains and may also provide useful information for 
engineering live-attenuated strains of heterologous flaviviruses.
Flavivirus cDNA clones may also be used to engineer mutations (either 
substitutions, insertions or perhaps more genetically stable deletions) which 
attenuate a virulent parental virus. Unfortunately, at this time, too little is known
80
regarding the structure and functions of flavivrus proteins and RNA sequences in 
replication and virulence to predict, a priori, which changes might be attenuating. 
Although it will be possible to introduce changes into flavivirus genomes, the 
resulting phenotype and the genetic stability of each mutant virus will need to be 
evaluated using relevant biological tests. It has also been proposed that a proven 
live-attenuated flavivirus vaccine strain, like the 17D strain, might be useful as a 
carrier for protective epitopes from heterologous flaviviruses. In the simplest 
scenario, a region of the YF ORF would be replaced with the homologous region 
from a different flavivirus, such as a DEN serotype or JE virus, resulting in a 
chimeric flavivrus. There are several caveats to this approach. First, B and T cell 
epitopes important for human immunity have not yet been identified for most 
flaviviruses. Second even when such epitopes are elucidated, it may be difficult 
to construct chimeras which are viable, since virtually nothing is known regarding 
the protein-protein and protein-RNA interactions involved in flavivirus replication. 
In this regard, initial attempts to construct chimeras which contain either a 
replacement in the E protein with the corresponding region for MVE virus or 
substitution of nearly the entire YF NS1 protein with DEN 2 NS1 have been 
unsuccessful (Weir eta/., unpublished data). It is likely, however, that with further 
effort it will be possible to recover viable chimeras. As with any other candidate 
vaccine the genetic stability and phenotype of such flavivirus chimeras, with 
regard to attenuation and their ability to elicite appropriate immune responses for 
long-lasting protection, would then need to be carefully assessed.
The most straightforward application of systems allowing regeneration of
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flaviviruses from cDNA is for storage and propagation of live-attenuated vaccine 
viruses, as has been shown for the Sabin vaccine strain of poliovirus (Kohara et 
al., 1986). This approach can now be tested for YF virus derived from VF 17D 
cDNA clones as they become available. For YF, the early years of 17D vaccine 
production were marked by occasional batch variability, reversions to virulence 
(Fox et a/., 1942) and over-attenuation (Soper & Smith, 1938). These problems led 
to the development of a seed-lot method for propagating virus to limit the number 
of serial passages. However, this approach does not eliminate serial passaging and 
the virus inoculum used for vaccine production can continue to change, 
especially given the high error frequency associated with RNA-dependent RNA 
replication. Propagation of RNA virus vaccine strains as DNA, with its 
correspondingly lower mutation frequency (Reanney, 1982) combined with 
efficient production of vaccine virus in cell cultures, should improve the reliability 
and may lower the cost of live-attenuated vaccines.
Although the specific genetic changes responsible for attenuation could not 
be identified by this analysis, the recent development of a system for generating 
YF 17D virus from cDNA (Rice et a i,  1989) should allow their identification. 
However, the YF virus recovered from cDNA has not yet been fully characterised 
in primate hosts and in this regard it is relevant to compare the sequence of the 
cloned 17D-204 virus with those of other biologically well-characterised YF 
vaccine strains. This approach may facilitate the use of the cloned YF cDNA to 
stabilise the vaccine phenotype and for vaccine production. In addition, more 
data would be obtained to characterise nucleotide and amino acid sequence
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differences, observed between Asibi and 17D-204, which are possibly related to 
adaptation to growth in cultured vertebrate cells and attenuation. Finally, the 
analysis of YF vaccine viruses with different passage histories should reveal the 
extent of genetic variability among 17D virus seeds and vaccines.
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12.1 Aims of the thesis
As mentioned above, despite the determination of full-length genomic 
sequences for the wild-type Asibi virus and the 17D-204-ATCC vaccine virus 
strain, the molecular basis of attenuation has yet to be elucidated (Rice et a/., 
1985; Hahn et a/., 1987). However, several lines of evidence have previously 
suggested that the E protein may have a critical role in the expression of virulence 
phenotype. Accordingly, in this thesis the association of structural protein amino 
acid substitutions and altered pathogenesis of disease was investigated, with 
particular emphasis on the E protein.
This was investigated by comparing the sequence of three 
attenuated/virulent pairs of YF viruses (17D-204/Asibi, FNV/FVV and Asibi/HeLa 
cell-passaged Asibi). Subsequently, E protein variants with and without MAb- 
defined epitopes were examined in detail to identify molecular determinants of 
YF virus pathogenicity in the mouse model. Finally, studies were undertaken to 
investigate the interaction of the E protein with cell binding site(s). From these 
studies a number of amino acids are identified as putative molecular determinants 
of attenuation of YF virus.
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3CHAPTER 2 
Materials and Methods
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2.1 Cell culture
2.1.1 Cell lines
All cell lines employed in the study were stored in liquid nitrogen stocks 
at the University of Texas Medical Branch (UTMB), USA. Vero and HeLa cell lines 
were used. Vero cells derive from African Green Monkey (Cercopithecus 
aethiops) kidney cells (Yasmura & Kawakita, 1963) and were obtained from the 
Center for Disease Control (CDC), USA. HeLa cells derive from human cervical 
carcinoma cells (Gey et a/., 1952) and were obtained from the Tissue Culture 
Center at UTMB.
2.1.2 Sterilisation of culture media and buffers
All media and buffers were sterilised by autoclaving at 121 °C (15 
pounds/square inch (RSI)) for 15 min or by filtration through a 0.22 //M filter 
(Corning, USA). Milli Q (MQ) grade water was used in the preparation of all 
media and buffer solutions unless otherwise specified.
2.1.3 Maintenance of cell lines
Cells were grown and maintained in 199 medium (Tissue Culture Center, 
UTMB or Sigma, USA), supplemented with 2mM L-glutamine (Sigma, USA) and 
1 mM non-essential amino acids (Sigma, USA). Media was also supplemented with
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20mM sodium bicarbonate (Tissue Culture Center, UTMB), 0.1 mg/ml neomycin 
(Sigma, USA) and 0.1 mg/ml streptomycin sulphate (Sigma, USA). The media 
contained either 2% (v/v) or 10% (v/v) foetal calf serum (PCS; Gibco BRL, USA) 
for maintenance medium or growth medium, respectively. Cells were incubated 
at 37°C in the presence of 5% carbon dioxide.
Subculturing of cells was performed by trypsinization of a confluent 
monolayer (using trypsin 2.5% w/v in Hanks salts (Sigma, USA), triturating the 
cells in fresh medium and then seeding fresh tissue culture flasks (Corning, USA) 
as described by Lenette and Schmidt (1969). Cells were normally split at a 1:5 
ratio.
2.1.4 Cell line storage, preservation and resuscitation
Cell which were approximately 90% confluent were detached from the 
flask in accordance with the method described above and 2-3 ml of cell freezing 
medium (Sigma, USA) was added to the cell suspension. The cells were aliquoted 
into liquid nitrogen ampoules (Nunc, USA) and placed at -70°C for 24 h in a 
polystyrene box. Subsequently, the ampoules were stored in liquid nitrogen (- 
190°C).
When required, one ampoule of the desired cell line was rapidly thawed 
in a 37°C water bath and approximately 1 ml of 10% PCS growth medium 
added. The cells were pelleted by centrifugation at 2000 rpm for 5 min and the
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DMSO-containing supernatant removed. A cell suspension was made in a further 
1 ml of 10% PCS growth medium and pipetted into a 25 cm2 cell culture flask. 
The medium was made up to a volume of 5 ml and the cells incubated at 37°C 
in a 5% C 0 2 atmosphere until a confluent monolayer was formed. Subsequent 
passages were performed as described above.
2.2 Viruses
The origins and derivations of the YF virus strains employed in this study 
are shown in Table 2.1.
2.2.1 Virus propagation in cell culture
Viruses were grown by infecting Vero or HeLa cell monolayers at 80-90% 
confluency. Cell monolayers were washed twice with phosphate buffered saline 
(PBS). Inoculation of most viruses was performed at a multiplicity of infection 
(moi) of 0.1-1.0 plaque forming units (pfu)/cell. He La-passaged viruses (HeLa-p2 
and p5) were inoculated at an moi of 1-5 pfu/cell. Virus was allowed to absorb 
to the cell sheet by incubation at room temperature for 30 min prior to the 
addition of 2% PCS cell maintenance medium. Cultures were incubated (37°C/ 
5% C 0 2) until 90-100% cytopathic effect (cpe) was evident. The virus-containing 
cell culture supernatant was then harvested, clarified by low-speed centrifugation 
(2000 rpm, 5 min), aliquoted and stored at -7O°C in cryotubes (Nunc, USA).
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VIRUS SOURCE
17D-204-UK Welcome Biotechnology Laboratories
17D-204-SA National Institute for Virology
17D-204-Russia Institute for poliomyelitis and viral encephalitis
RF312 Rockefeller Foundation
FNV-Yale Yale University
FNV-FC Center for Disease Control
FNV-NT PHLS CAMR
Asibi HeLa-p6 Derived by HeLa cell-passage of wild-type
Asibi HeLa-p3 Asibi virus (Dunster, 1990)
ITD(-wt) Plaque-purified variants with and without
17D(+wt) wild-type epitope (Gould et al 1989)
8 6 f (-wt)-l
86# (-wt)-2
86# (+wt)-l MAb neutralisation escape variants selected
86# (+wt)-2 with 17D-204 substrain specific MAb 864
86# (+wt)-3
86# WHO-1
86# WHO-2
17D(LP) Variant viruses selected from 17D-204-SA
17D(864)
B39R WHO-1 MAb neutralisation escape variants selected
B39R WHO-1 with YF type-specific MAb B39
Table 2.1: The YF viruses used in this study
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2.2.2 Virus infectivity titrations
Infectivity was determined by plaque assay performed on Vero cell 
monolayers seeded in six well cell culture plates (Corning, USA) as previously 
described by Barrett et al. (1989). Briefly, a 10-fold dilution series from 10"1 to 10's 
’ of the virus stock was prepared in PBS. RBS-washed cell monolayers were 
infected with 100 j j \ of the appropriate virus dilution per well. The sixth well was 
used as a PBS control. Following adsorption of the virus for 15-30 min at room 
temperature, monolayers were overlaid with 5 ml of 2% PCS minimal essential 
medium (MEM; Sigma, USA) supplemented with 1% agar (Sigma, USA) and 
0.01% DEAE-dextran (Sigma, USA) and incubated inverted (37°C, 5% C 0 2). Six 
days post-infection cell monolayers were stained by the addition of a second 2 
ml overlay, containing 0.008% neutral red (Gibco-BRL, USA). Viral plaques were 
counted after a further overnight incubation (day seven) and the infectivity titre 
calculated in pfu/ml of virus stock.
2.3 Biological assays
2.3.1 Monoclonal antibodies
A number of MAbs, both prepared in this laboratory and obtained from 
outside, were used in this study. Their derivations, origins and spécificités are 
shown in Table 2.2.
117 YF wild-type YF Asibi
E.A Gould
B39 YF type ITDD-Brazil
University of Surrey
2E10 YF type 17D-204-USA
J.J. Schlesinger
G23 YF type ITDD-Brazil
University of Surrey
m YF type ITDD-Brazil
University of Surrey
H33 YF type ITDD-Brazil
University of Surrey
H5 YF vaccine ITDD-Brazil
University of Surrey
8A3 YF vaccine 170-204
T. Monath
H10 17DD substrain ITDD-Brazil
University of Surrey
864 17D-204 substrain 17D-204
E.A Gould
Table 2.2: MAbs used or mentioned in this study
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2.3.2 Virus plaque-reduction neutralisation tests
Plaque-reduction neutralisation tests (PRNTs) were performed using the 
plaque assay technique (Section 2.2.2) with the exception that, prior to infection 
of the cell monolayer, the virus was incubated with a 1:20 dilution of MAb- 
containing ascitic fluid at 37°C for 30 min. Neutralisation titres were expressed 
as the log10 reduction in virus titre.
2.3.3 Preparation of mouse and monkey brain membrane receptors
Membrane receptor preparations (MRP) had previously been made in this 
laboratory from both mouse (MS-MRP) and monkey (MK-MRP) homogenised brain 
tissues (Cao, 1991). The brain of a Cynamolgos monkey was obtained from the 
National Institute for Biological Standards and Control (NIBSC). Mouse brains 
were harvested from outbred TO strain mice (Harlan, UK). The method for 
generating MRPs was based on that of Witkin and Herden (1981). The brain tissue 
was homogenised in 10 volumes of homogenisation medium (145mM sodium 
chloride, 2mM magnesium chloride, 20mM Tris; pH 7.5) using a Kinematron 
homogeniser. The homogen ate was subjected to a low speed/high speed 
centrifugation regime (Cao, 1991) and the resultant purified brain MRPs were 
resuspended in storage medium (250 mM sucrose, 5 mM magnesium chloride, 
50 mM Tris; pH 7.5). MS-MRP was resuspended at 20 mg wet weight/ml and MK- 
MRP at 40 mg wet weight/ml. MRPs were then snap-frozen in liquid nitrogen and 
stored at -70°C for use in 5 ml aliquots.
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2.3 .4  Virus-MRP binding assays
Priorto performing the experiment, aliquot(s) of frozen MRP were removed 
from the -70°C freezer, rapidly thawed in a 37°C water bath and kept on ice 
(4°C). A 100 //I aliquot of neat virus stock was added to 900 j j \ of the MRP in a 
microcentrifuge (MCC) tube and vortexed to mix. Control virus samples were 
prepared in the same way, but mixed with 900 j j \ of Tris buffer (50 mM Tris, pH 
7.6) instead of MRP. MCC tubes were incubated at 37°C for 30 min on a rotating 
stand. After incubation, the virus-MRP suspension was centrifuged at 13,000 rpm 
for 10 min to remove the membrane material and bound virus. Residual virus 
infectivity in the supernatant was determined by plaque assay (Section 2.2.2) and 
the percentage of virus binding calculated by comparison with the control virus 
infectivity titre.
2.3.5 Selection of MRP-binding escape variants
Following titration of residual infectivity by plaque assay, viruses which 
remained unbound were plaque-purified. This involved the use of a sterile 1 ml 
pipette to remove an agar plug (containing the virus plaque) to a fresh tube. The 
agar was resuspended in 1 ml 2% PCS 199 medium and frozen at -70°C to 
further disrupt the agar. For amplification, the variant virus was then thawed at 
37°C and 100 j j \ was used to infect a Vero cell monolayer as described in 
Section 2.2.1. Binding assays were subsequently repeated with the variant viruses 
to confirm their loss or reduction in binding activity.
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2.4 Mouse pathogenesis studies
2.4.1 Virus pathogenicity in adult outbred mice
Female outbred (strain TO, Harlan, UK or strain NIH Swiss, Harlan Olac, 
USA), 3-4 weeks of age and weighing between 25.-30 g were used to determine 
virus pathogenicity. All mice were anaesthetised prior to inoculation with 
halothane (Halocarbon Laboratories, USA). Mice were inoculated with virus 
(diluted in PBS as required) by one of two routes. Virus was administered 
intranasally (i.n.) by placing 20 //I of virus dilution on the nostrils of a partially 
anaesthetised mouse or intracerebral ly (i.e.) by inoculation of approximately 20 
//I of virus dilution into the brain.
Following inoculation, mice were routinely monitored for a period of up 
to 30 days, although in one case mice were observed for over six months. The 
animals were observed daily for signs of encephalitis, manifested by erratic 
activity, ruffled fur and ultimately partial or total paralysis and death. After mice 
died or were sacrificed results were tabulated and the average survival time ± 
standard error of the mean (AST ± SEM) was calculated where appropriate using 
the formula below:
AST ± SEM -> No. of deaths/day ± <Sn'1
In  Vn
where; n = the number of mice per group
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2.4.2 Virus pathogenicity in adult inbred mice
Three strains of inbred mice with three different haplotypes were used in 
this study (Chapter 8); C3H (H-2^ C57BL/6 (H-2b) and Balb/c (H-2d)(Harlan Olac/ 
USA). These mice were inoculated by the i.e. route and monitored as described 
above for outbred adult mice and the AST ± SEM was calculated.
2.4.3 Virus pathogenicity in suckling outbred mice
Suckling NIH Swiss outbred mice (Harlan Olac, USA) between the ages of 
five and eight days (as specified in the appropriate chapter) were inoculated by 
the intraperitoneal (i.p.) route with 20 jj\ of virus dilution and returned to their 
mother. As before, these mice were monitored for up to 30 days and their AST 
± SEM calculated.
2.4.4 Preparation of mouse brain homogenates
At different time-points mice were sacrificed and their brains harvested for 
infectivity titration. Whole brains were frozen at -70°C for storage until use. . 
The brains were homogenised to release the virus. This was achieved by rapidly 
thawing the brains at 37°C and adding 1.2 ml of PBS over each brain. The brains 
in PBS were vortexed and passed through the barrel of a 3 ml luer syringe to form 
a crude suspension. The brain suspensions were forced through a 21 gauge 
needle 10-15 times to produce a homogenate and then freeze-thawed at -70°C
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to lyse cells and release intracellular virus particles. Finally, the homogenate was 
centrifuged (13,000 rpm; 5 min; 4°C) to remove the majority of brain tissue and 
the supernatant analysed further as described below.
2.4.5 Determination of virus infectivity titre in mouse brain
The infectivity titration of mouse brain homogenates was performed by 
plaque assay on Vero cells as described in Section 2.2.2, except that a dilution 
series of 10° to 10"4 was prepared. This modification was made to the method in 
order to maximise the sensitivity of the assay for detection of infectious virus in 
the brain.
2.4.6 Detection of viral RNA persisting in mouse brain
Viral RNA was extracted from the remainder of the homogenised mouse 
brain suspension as described in Section 2.5.2 and a 1.3 kb region of the RNA 
within the E protein-encoding gene was amplified by reverse transcriptase- 
polymerase chain reaction (RT-PCR) using primer pair AJ7UP-YF100, as described 
in Sections 2.5.4 and 2.5.5.
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2.5 Amplification of viral RNA
2.5.1 Diethyl pyrocarbonate treatment of glassware
Diethyl pyrocarbonate (DERC) is a strong, but not absolute, inhibitor of 
RNAases (Fedorcsak & Ehrenberg, 1966). Several of the solutions used were 
employed in the isolation, extraction or treatment of RNA, and so glassware to be 
used for this purpose was soaked in a 0.1% (v/v) DERC solution overnight. The 
glassware can then rinsed with ethanol and autoclaved before use.
2.5.2 Extraction of viral RNA
The methodology of Lewis et al. (1992), which described extraction of 
flavivirus RNA for RT-PCR directly from small volumes of cell culture fluid using 
a tRNA carrier, was employed. In general, each RT-PCR required extraction of 
viral RNA from 500 //I of cell culture fluid, although the RNA was not subjected 
to spectrophotometric analysis, and so the concentration of RNA was unknown.
The purified virus in cell culture supernatant was dispensed into sterile 
if\
MCC tubes/^500 //I aliquots. Viral protein was digested with 100 of
autodigested (37°C; 15 min) proteinase K for 30 min at 37°C. 10% (w/v) sodium 
dodecyl sulphate (SDS) was added to a final concentration of 1 %, and the sample 
incubated for a further 15 min at 37°C. Carrier tRNA (Sigma, USA) was then 
added to a final concentration of 10 //g/ml.
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Protein was removed by extraction with an equal volume of equilibrated 
phenol/chloroform/isoamyl alcohol (PCI; 25:24:1 v/v; Gibco-BRL, USA). The 
sample was thoroughly vortexed to form an emulsion, which was then centrifuged 
at 13,000 rpm in an Eppendorf 5415C benchtop centrifuge (microfuge) for 5 min 
at room temperature to separate the phenol and aqueous phases. The aqueous 
phase containing the nucleic acid was transferred to a fresh MCC tube taking care 
to avoid the interface.
For extraction of viral RNA from mouse brain homogenates (Section 
2.4.4), several modifications were made to this method. Due to the large amount 
of residual cellular protein, a double quantity (200 //g/ml) of proteinase K was 
added for protein digestion and further PCI extractions were required. After this 
first PCI extraction only, the aqueous phase was stored whilst the phenolic phase 
was 'back-extracted' by the addition of an equal volume of Tris-EDTA buffer (10 
mM Tris-HCI, 1 mM EDTA; pH 8.0), vortexing and centrifugation as described. 
This second aqueous phase was then combined with the first and a second PCI 
extraction was performed. For some very "dirty" mouse brain preparations, a third 
PCI extraction was performed.
Viral RNA was ethanol precipitated by the addition of 2 volumes of chilled 
ethanol (-20°C) and a final concentration of 300 mM sodium acetate (pH 5.2). 
RNA was allowed to precipitate for 2 h at -70°C and was pelleted by 
centrifugation (13,000 rpm; 20 min; 4°C). The pellet was washed with 70% 
ethanol and dried in a warm oven (40°C). Resuspension was effected in high
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performance liquid chromatography (HPLC) purified water (Sigma, USA). Each 
pellet was resuspended in 5 //I of HPLC water per 500 //I of cell culture 
supernatant extracted and stored at -20°C prior to amplification if necessary.
2.5.3 Design and synthesis of oligonucleotide primers
The oligonucleotide primers used in this study, both for RT-PCR and DNA 
sequencing (Table 2.3), were designed by reference to the published genomic 
nucleotide sequence of the 17D-204-ATCC vaccine virus (Rice et a/., 1985). The 
primers were commercially synthesised and column-purified (Biosynthesis, USA). 
On arrival, the freeze-dried primer preparations were resuspended in HPLC water 
to a final concentration of 2 mg/ml to form a primer stock, which was stored at 
-20°C . Before use, a working stocks of 500 ng///l for RT-PCR or 20 ng///l for 
sequencing were prepared by dilution in HPLC water.
2.5.4 Reverse transcription of viral RNA
Viral RNA, in a volume of 5 //I was heat-denatured in the presence of 100 
ng///l (500 ng) of the appropriate antisense primer (boiling water bath; 5 min) 
according to the method of Lewis et al. (1992). The RNA/primer suspension was 
quick-chilled on ice, microfuged briefly and placed back on ice. The timing and 
temperature were critical for total dénaturation of RNA secondary structure. The
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SENSE PRIMERS
PCR fragment 
(bp)
ANTISENSE PRIMERS
B5 1-25 677 YF300 652-678
CAO 625-642 687 YF7 1293-1312
AJ7UP 1223-1245 550 YF302 1749-1773
YF301 1686-1711 562 YF597 2220-2248
EBIT 2120-2143 434 YF100 2531-2554
AJ7UP 1223-1245 1331 YF100 2531-2554
SNSla 2394-2415 685 ANSla 3057-3079
SNSlb 2984-3006 747 ANSlb 3710-3731
SNS2A 3604-3624 615 ANS2A 41994219
SNS2B 41384158 531 ANS2B 46464669
SNS3a 4612-4633 620 ANS3a 5210-5232
SNS3b 5174-5195 702 ANS3b 5855-5876
SNS3c 5834-5855 709 ANS3c 6522-6543
SNS4A 6338-6359 896 ANS4A 7213-7234
SNS4B 7165-7189 528 . ANS4B 7671-7693
SNS5a 7663-7684 668 ANS5a 8352-8331
SNS5b 8270-8297 668 ANS5b 8917-8938
SNS5c 8895-8916 711 ANS5c 9585-9606
SNS5d 9557-9578 673 ANS5d 10209-10230
SNS5e 10167-10188 695 ANS5e 10838-10862
SEQ4 239-255 SEQ1 1995-2013
SEQ2 459477 ANS4A3 6947-6981
SEQ5 820-836
SEQ6 1553-1568
SEQ3 1895-1911
Table 2.3: PCR and sequencing primers used in this study
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annealed RNA/primer in 1x RT buffer (50 mM Tris, 50 mM potassium chloride, 
10 mM magnesium chloride, 3 mM dithiothreitol (DTT) final concentration) was 
treated with 1.8 units (U)///l reverse transcriptase (RAV-2 RT; Amersham, USA) in 
the presence of 1 mM of each deoxynucleotide triphosphate (dNTR; Pharmacia, 
USA) and 1.4 U///I RNAse inhibitor (Boehringer, USA). RAV-2 RT, isolated from 
Rous-associated virus, is reported to synthesis cDNA with a particularly high 
fidelity. High dNTR concentrations were essential to prevent premature 
termination of newly synthesised cDNA molecules. The reaction mixture was 
incubated at 55°C for 1-2 h. The reaction was subsequently stopped by placing 
on ice and the RAV-RT was inactivated in the first PCR dénaturation step.
2.5.5 Amplification of cDNA by polymerase chain reaction
Prior to the PCR, cDNA was heat-denatured, as described above, in the 
presence of 50 ng///l (500 ng) of the appropriate sense primer. The cDNA/primer 
was quick-chilled on ice, microfuged briefly and placed back on ice.
The optimal conditions for PCR (incubation times and temperatures, and 
concentrations of Taq DNA polymerase, template cDNA and primers) had 
previously been determined (Jennings et a/., 1992).The cDNA/primer mixture was 
diluted 5 fold to give a total volume of 50 //I, comprising 11 jj\ of the 
cDNA/primer, 5 //I of lOx PCR buffer (supplied with the Taq DNA polymerase 
enzyme) giving a final concentration of 1x, 0.05 U//vl Taq DNA polymerase 
(Boehringer, USA) and HPLC water.
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PCR amplification was performed in ultra-thin walled PCR reaction tubes 
on a Perkin Elmer PCR system 9600 temperature cycler. The following cycle of 
incubations was employed:-
-Cycle la  Extension 72°C 10 min
-Cycle 1b Dénaturation 96°C 5 min
-Cycle 1c Primer annealing 52°C 2 min
-Cycle Id  Extension 72°C 5 min
-Cycle 2a Dénaturation 96°C 1 min
-Cycle 2b Primer annealing 52°C 2 min 30 times
-Cycle 2c Extension 72°C 5 min
-Cycle 3a Dénaturation 96°C 1 min
-Cycle 3b Primer annealing 52°C 2 min
-Cycle 3c Extension 72°C 10 min
After the final cycle the PCR machine was programmed to hold the 
reactions at 6°C if the reactions were set up overnight; otherwise they were 
subjected to analysis by agarose gel electrophoresis immediately following 
completion.
2.5.6 Gel electrophoresis of amplified PCR products
The PCR reaction was terminated by the addition of 10.//I loading dye 
(30% (v/v) glycerol, 0.05% (w/v) bromophenol blue). The PCR products were than 
separated by electrophoresis on a  2% (w/v) agarose gel prepared in TAE buffer (40 
mM Tris-acetate, 1 mM EDTA) alongside 0X174 Haelll molecular weight markers 
(Gibco-BRL). The gel was stained in ethidium bromide (0.5 //g/ml in TAE buffer) 
for 15-30 min and visualised on a UV transilluminator.
2.5.7 Recovery of cDNA from agarose gels
DNA bands of the expected size were purified from the gel using a Bio 
101 USA Geneclean II™ kit (Stratech) according to the manufacturers instructions. 
This system exploits the affinity of DNA molecules to silica matrices. The kit 
contains a specially formulated suspension of silica matrix called Glassmilk™ 
which specifically binds DNA.
Briefly, gel slices containing the appropriate amplified cDNA fragments 
were excised and dissolved in 2-3 volumes (w/v) of 6 M sodium iodide (45-550C, 
5-15 min). After 2-3 min, the mixture was thoroughly vortexed. DNA was bound 
to silica matrix Glassmilk™ added at a concentration of 1 //I/I //g estimated DNA 
(5 min, room temperature). The Glassmilk™/DNA was then pelleted by brief 
microfuging and the supernatant containing the dissolved agarose was removed. 
The Glassmilk™/DNA pellet was washed three times with 50 volumes (v/v) of 
ice-cold New buffer (supplied with Geneclean ll™kit-composition not available). 
After the third repeat, the supernatant was removed very carefully with a fine , 
pipette tip. DNA was then eluted from the silica matrix by incubation in 10 //I 
HPLC water at 45-55°C for 3 min. The Glassmilk™ was pelleted by a further brief 
centrifugation, resulting in approximately 80% recovery of DNA in the 
supernatant. The DNA suspension was stored at -20°C until use.
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2.6 Cloning of the DNA fragments
2.6.1 Ligation of cDNA fragments into plasmid vector
The technique employed for cloning of the PCR products obtained 
employed the TA cloning kit (Invitrogen, USA) which provided the pCR II™ 
plasmid vector, competent INVoF' Escherichia coli (E. coii) cells and other 
necessary reagents. This system takes advantage of the non-template dependent 
activity of Taq DNA polymerase which adds single dA molecules to the 3Z end 
of the double-stranded PCR product. The vector is designed to provide single 
overhanging 3' dT molecules at the insertion site, thus specifically accepting the 
insertion of the PCR fragment. The insertion site is found within the lac Z gene 
to enable blue/white screening for positive colonies in addition to ampicillin 
antibiotic resistance selection. The competent INVoT' E coli carry the F' episome 
effecting the ^-complementation of the R-galactosidase gene where no insert is 
present. Consequently, recombinant bacteria are unable to synthesise &- 
galactosidase, cannot metabolise X-gal and are white in colour.
The pCR II™ vector was supplied at a concentration of 25 Five jj\
of the purified cDNA product was added to 25 j jg  of vector in 1x ligation buffer 
and in the presence of 0.4 \J/jj\ T4 DNA ligase. The tube was vortexed, 
microfuged briefly and incubated from 4 h to overnight at 12-14°C. This ligation 
mix was stored at -20°C until needed.
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2.6.2 Transformation of competent £. coli bacteria
A 50 j j\  aliquot of INVoF' £. coli cells was thawed on ice. A final 
concentration of 20 mM of (S-mercaptoethanol and 5 //I of ligation mix were 
added to the bacteria, gently swirled to mix and placed on ice for 30 min. The 
bacteria were heat-shocked for 45 sec in a 42°C water bath and quick-chilled on 
ice for 2 min; the timing was critical for high transformation efficiency. The 
bacteria were diluted 10-fold in prewarmed (42°C) SOC medium (2% (w/v) 
bacto-tryptone, 0.5% (w/v) yeast extract, 10 mM sodium chloride, 10 mM 
magnesium chloride, 10 mM magnesium sulphate, 20 mM glucose) and incubated 
to allow recovery and expression of the ampicillin resistance marker encoded by 
the plasmid (37°C, 1 h, agitated at 225 rpm). Aliquots of 75 j j \ and 150 j j \ of the 
bacteria were plated on supplemented LB agar (1 % (w/v) bacto-tryptone, 1 % (w/v) 
yeast extract, 86 mM sodium chloride, 1.5% (w/v) bacto-agar, 1 mM magnesium 
sulphate supplemented with 50 //g/ml ampicillin, 10 //g/ml IRTG and 20 //g/ml 
X-gal). The plates were inverted and incubated overnight at 37°C. The blue 
colour was allowed to develop fully at 4°C  for 1 h. Independent white colonies 
were subcultured onto a new supplemented LB agar plate, sealed and stored at 
4°C.
2.6.3 Screening for recombinant cDNA clones
Subcultured white colonies were screened using a rapid screening 
methodology which identified recombinant pCR II™ plasmid by its higher
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molecular weight in agarose gel electrophoresis relative to plasmid without insert. 
Small scale preparations were then made of the putative recombinant plasmids 
using the "Magic Miniprep" plasmid purification system (Promega, USA). Purified 
plasmid weas screened by restriction digestion and agarose gel electrophoresis to 
confirm the presence of a DNA insert and to ascertain the size of this insert.
2.6.4 The "cracking" procedure
In order to rapidly pre-screen white colonies for the presence of a 
recombinant plasmid the "cracking" procedure was employed. This methodology 
is described in the Promega Protocols and Application Guide (1991).
Briefly, colonies were picked with a sterile toothpick and smeared into a
0.5 ml MCC tube containing 50 j n \  of 10mM EDTA (pH 8.0). 50 j j \ of freshly 
prepared 2x cracking buffer (584 mM sucrose, 200 mM sodium hydroxide, 0.5% 
SDS) was added and the tubes vortexed. The samples were then incubated at 
70°C for 15 min, and allowed to cool gradually to room temperature. 
Bromophenol blue dye and 58 mM potassium chloride were added in a volume 
of 1.5 j j \ .  The samples were vortexed, placed on ice for 5 min and centrifuged for 
5 min at 4°C. Finally, 50 j j \ of the supernatant was loaded onto a 1 % agarose gel. 
Electrophoresis in TAE buffer was performed, the gel stained in ethidium bromide 
and the samples compared against molecular weight markers and circularised pCR 
II™ plasmid.
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2.6.5 Small scale extraction of plasmid DNA.
The commercially available Magic Miniprep system (Promega, USA) was 
used for the purification of plasmid DNA from small-scale bacterial broth cultures. 
The purification was performed essentially as described in the manufacturers 
instructions (Promega methodologies booklet), with one modification. This 
technique produces 3-5 //g of plasmid suitable for restriction digestion or DNA 
sequencing.
Briefly, bacteria from a subcultured colony were inoculated into 5 ml of 
L-broth (1.5% (w/v) bacto-tryptone, 0.5% (w/v) yeast extract, 86 mM sodium 
chloride) supplemented with 50 jug/ml ampicillin and grown overnight at 37°C 
and 225 rpm. The bacteria from 3 ml of overnight culture were pelleted in an 
MCC tube (2 min, 13,000 rpm) and the supernatant removed. The bacterial cells 
were resuspended by vortexing in 200 //I Solution I (10. mM EDTA, 25 mM 
Tris-HCI; pH 8.0) and lysed by the addition of 200 //I of freshly made Solution II 
(1 % v/v SDS, 200 mM sodium hydroxide). The bacterial lysate was then mixed 
thoroughly with 1 5 0 //I of Solution III (5 M potassium acetate; pH 4.8 instead of 
the solution recommended). Precipitated chromosomal nucleic acids and 
proteinaceous material were pelleted (13,000 rpm, 5 min). A 500 jul aliquot of the 
supernatant was carefully removed to a fresh tube and mixed with 2 volumes of 
Magic Miniprep DNA purification resin by inversion. The mixture was transfered 
to a 3 ml luer lock syringe barrel attached to a mini-column and pushed through 
the column. The DNA/resin adhered to the column was washed with 2 ml
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column wash solution (100 mM sodium chloride, 10 mM Tris-HCI; pH 7.5, 2.5 
mM EDTA, 50% ethanol) and eluted with 50 //I HPLC water by centrifugation.
2.6.6 Restriction digestion of purified plasmid
Routinely, the restriction enzyme EcoRI (Boehringer) was used, with the 
supplied xIO Buffer H (50mM Tris, lOOmM sodium chloride, 10mM magnesium 
chloride, ImM dithiothreitol, pH 7.5) as this restriction site was duplicated on 
either side of the insert sequence. Restriction digestion was performed on 5 //I 
aliquots of the plasmid preparations using 10 units of the EcoRI restriction enzyme 
in a final volume of 30 //I. Samples were incubated at 37°C for 30 min and the 
digestion pattern analysed by gel electrophoresis alongside 0X174 Haelll 
molecular weight markers.
2.6.7 Long-term storage of colonies
Following identification of colonies containing plasmids with the expected 
insert by restriction digest and confirmatory sequence, these colonies were then 
maintained by freezing them in duplicate.
Two MCC tubes containing 300 //I of L-broth plus ampicillin were 
inoculated with the colony by toothpick, and the tubes incubated at 37°C 
overnight with shaking at 225 rpm. Glycerol was added to a final concentration 
of 15% and the tubes stored; one at -20°C and one at -70°C. Subsequently, only
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the -20°C aliquot was used as an inoculum for amplifying the cells. The -70 °C 
aliquot was stored as a backup.
2.7 Dideoxynucleotide chain termination DNA sequencing
Recombinant pCR II™ plasmids, containing cDNA inserts of the correct 
size, were subjected to confirmatory sequencing of the termini. The sequence 
data produced was analyzed by computer comparisons with relevant sequences 
of YF virus (Rice et al., 1985; Hahn et al., 1987). Confirmed cDNA inserts were 
then sequenced in their entirety, in duplicate or more when required. These were 
subjected to more thorough computer comparisons and analyses.
2.7.1 Dideoxynucleotide chain termination sequencing
DNA sequencing was performed on recombinant plasmid clones using the 
dideoxynucleotide chain termination methodology (Sanger et al., 1977). This 
methodology consists of three different stages;
1. Annealing of the primer to the template DNA.
2. Extension of cDNA from the annealed primer using limiting concentrations 
of dNTPs (including one radiolabelled dNTP) to extend the primer by a 
few, or by several h undreds of, nucleotides.
3. Termination of the labelling reaction by the incorporation of a
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dideoxynucleoside (ddNTP); one in each of four tubes. During this step,
the chains are extended on average by 20-50 nucleotides.
The reactions are terminated by the addition of stop solution (EDTA, 
formamide), heat-denatured (80°C, 5 min) and separated by polyacrylamide gel 
electrophoresis.
All DNA sequencing reactions were performed using a Sequenase Version 
2.0 kit (United States Biochemicals). This kit contains the enzyme Sequenase 
Version 2.0 (Tabor & Richardson, 1987) which is a genetic variant of the 
bacteriophage T7 DNA polymerase. This enzyme is a superior enzyme for 
sequencing, having amongst its properties high processivity, high speed, the 
ability to use popular nucleotide analogues and no 3' to 5Z exonuclease activity.
2.7.2 Preparation of the polyacrylamide sequencing gel
DNA sequencing was performed on 40 cm-long, 0.4 mm thick, 
acrylamide-bisacrylamide (19:1) gels. The percentage composition of the gel 
varied from 6% to 4% depending on the size of fragments to be separated.
The front and back glass plates were thoroughly cleaned with detergent 
and hot water, rinsed with distilled water and then with ethanol and placed in a 
fume hood to dry. The larger back plate was coated with 10 ml silane solution 
(0.3% (v/v) gamma-methacryloxypropyltrimethoxysilane (Sigma, USA), 0.15%
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acetic acid in ethanol); the excess was removed with a lint free tissue. The smaller 
front plate was siliconised by the application of 10 ml Sigmacote (Sigma, USA) 
and similarly the excess was removed. The two treated surfaces of the plate were 
clamped together, separated by a 0.4 mm spacer arranged down each side. The 
plates were then taped together along both sides and the base, using 3M yellow 
electrical tape.
For each gel, 75 ml of gel mix was required which contained 7 M urea 
(Sigma) and 5% (v/v) acrylamide:bis-acrylamide, 19:1 (Gibco-BRL, USA) in TBE 
buffer (89 mM Tris-borate, pH 8.3, 2 mM disodium EDTA). The solution was 
heated to 37°C to dissolve the urea and immediately before casting the gel, 0.1 % 
(v/v) N,N,N%N'-tetramethylethylene-diamine (Temed; Gibco-BRL, USA) and 
0.06% (w/v) ammonium persulphate (freshly made) were added. The solution was 
mixed (avoiding bubbles) and then injected from a 60 ml syringe into the gel 
plate assembly, taking care to avoid trapping bubbles. Sharkstooth combs were 
correctly orientated and the gel was allowed to set for at least 1 hour. Prior to 
electrophoresis of the sequencing reactions, the electrical tape along the base of 
the gel was removed, the plate was placed in a Sequencing gel electrophoresis 
system, model S2 (Gibco-BRL) and the gel electrophoresed for 30 mins in TBE 
buffer. The sharkstooth combs were re-orientated correctly during this stage.
2.7.8 DNA sequencing reactions
Alkaline dénaturation of the recombinant plasmid: In order for the primer
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to be able to bind to the priming site in the recombinant plasmid, the two DNA 
strands must first be separated. An alkaline dénaturation method based on that of 
Chen and Seeburg (1985) and Zhang et a/. (1988) was employed.
3-5 //g plasmid DNA (section 2.6.5) was denatured by the addition of 200 
mM sodium hydroxide and 0.2 mM disodium EDTA. The preparation was mixed 
and incubated at room temperature for 30 min. Neutralisation and precipitation 
were effected by the addition of 300 mM sodium acetate pH 4.8 and 3 volumes 
of chilled ethanol and immediate placement in a dry-ice/ethanol bath for 5 min. 
The DNA was pelleted by centrifugation at 14,000 rpm for 20 min at 4°C, 
washed with 70% ethanol and dried in a cool oven. The pellet was resuspended 
in 7 / j \ HPLC water and immediately taken onto the next stage of sequencing.
Annealing template and primer: A single annealing reaction was set up. 
The following were added to the 7 //I of denatured plasmid suspension: 1 j j \ 
primers (0.5 pmol), and 2/yl of X 5 reaction buffer (200 mM Tris-HCI pH 7.5, 100 
mM magnesium chloride, 250 mM sodium chloride) to give a final volume of 10 
//I..The reaction mix was heated to 65°C for 4 min, cooled slowly to room 
temperature over a period of 30 min and placed on ice.
Labelling reaction: The following were added to the annealed
template-primer suspension: 1 //I 0.1 M DTT, 1 //I dATP 5'-(a-[35S] thio) 
triphosphate (specific activity > 1000 Ci/mmol) (10 //Ci), and 2 //I of a 1:5 
dilution of the x5 labelling mix in HPLC water (7.5 //M dGTP, 7.5 //M dCTP, 7.5
//M dTTP). Finally 2 //I of Sequenase Version 2.0 enzyme diluted 1:8 in ice-cold 
enzyme dilution buffer (10 mM Tris-HCI pH 7.5, 5 mM DTT, 0.5 mg/ml bovine 
serum albumin) were added, the reaction was carefully mixed and incubated at 
room temperature for 3 min.
Termination reactions: 3.5 //I of the resultant labelling reaction mix was 
aliquoted into each of four 0.5 ml MCC tubes which contained 2.5 //I of one of 
each of the four termination mixes:
ddG Termination mix: 80 //M dGTP, 80 //M dATP, 80 //M dCTP, 80 //M 
dTTP, 8 //M ddGTP, 50 mM sodium chloride.
ddA Termination mix: 80 juM dGTP, 80 //M dATP, 80 //M dCTP, 80 //M 
dTTP, 8 jl/M  ddATP, 50 mM sodium chloride.
ddT Termination mix: 80 jl/M  dGTP, 80 jjM  dATP, 80 //M dCTP, 80 jl/M  
dTTP, 8 //M ddTTP, 50 mM sodium chloride.
ddC Termination mix: 80 pM  dGTP, 80 pM  dATP, 80 pM  dCTP, 80 pM  
dTTP, 8 pM  ddCTP, 50 mM sodium chloride.
The reactions were incubated at 42°C for 5 min, and then terminated by 
the addition of 4 pi of stop solution (95% formamide, 20 mM EDTA, 0.05% 
bromophenol blue, 0.05% xylene cyanoI FF) and thorough mixing was effected. 
The samples were then stored for up to one week at -20°C.
2.7.9 Sequencing primers
Confirmatory sequencing was usually effected using the (-40) Universal 
primer (5'-GTTTTCCCAGTCACGAC-3') (Sequenase kit) and Ml 3 reverse primer
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(5Z-AACAGCTATGACCATG-3') which anneal to the plasmid on either side of the 
insert. All other YF virus specific primers used during sequencing are listed in 
Table 2.3. These primers enabled sequence data to be obtained from regions 
placed more centrally in the longer (500-1200bp) cDNA fragments. They were 
also used to prime to the opposite strand of regions of cDNA containing strong 
secondary structure, thereby clarifying regions of sequence which were difficult 
to elucidate. In all cases the primers used were made to a concentration of 0.5 
pmol///l.
2.7.10 Alterations of sequencing reaction conditions
It is possible to alter sequencing reaction conditions to read sequences 
closer to or more distant from the primer. The alterations used were based on 
information given in the manufacturer's protocol.
Reading sequences close to the primer: These changes to the standard 
protocol were used to obtain sequence data close to the primer (0-120 bases): (1) 
double the amounts of template and primer were used; (2) the labelling mix, used 
during the annealing of the primers, was diluted 1:10; (3) the labelling and 
termination reactions were both reduced to 3 min and; (4) electrophoresis was 
stopped when the first dye front (bromophenol blue) ran 80% of the length of the 
gel (bromophenol blue co-mi grates with DNA 50 bp long in a 6% gel).
Reading sequences more distant from the primer:- These changes were
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used to obtain sequence data more distant from the primer (350-500 bases): (1) 
the labelling mix, used during the annealing of the primers, was undiluted and 
1 .5 //I of [ar-35S]dATP was added; (2) the labelling reaction was extended to 5 min; 
(3) the gel concentration was reduced to 4% aery I amide; (4) electrophoresis was 
continued for up to 2-3 h past the second (xylene cyanoI FF) dye front (xylene 
cyan o I co-mi grates with DNA 350 bp bases long in a 4% gel).
2.7.11 Denaturing gel electrophoresis
Prior to loading, the samples were heated at 75°C for 2 min and then 2-5 
jj\ was immediately loaded into adjacent wells in a noted order. Electrophoresis 
was effected at 65 watts for 1.5-8 h. After electrophoresis, the front plate was 
removed and the gel on the back plate was fixed in a solution of 10% methanol 
and 10% glacial acetic acid in water. The gel was then washed in cold running 
water for 20 min and dried in a hot (80°C) oven for 1 hour. The radioactivity of 
the gel was monitored with a geiger counter. The gel was then exposed to 
BioMax X-ray film (Kodak, USA) in a spring loaded metal cassette at room 
temperature. The film was developed after 1-3 days, depending on the intensity 
of the monitored counts.
2.8 Computer analyses
The majority of the computer analyses performed during the course of this
115
study employed the Beckman Microgenie program (Queen & Korn, 1984) or the 
PCGENE program (IntelIigenetics Inc., USA) for sequence analysis and 
comparisons. The PCGENE program was used to predict the hydrophobicityof the 
deduced protein sequence.
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CHAPTER 3
Comparison of the nucleotide and deduced amino acid 
sequences of the structural protein genes of different 
yellow fever 17D-204 vaccine viruses
3.1 Introduction
YF 17D vaccine substrains are currently manufactured with W HO approval 
in 12 centres worldwide. The early years of 17D vaccine production were marked 
by occasional batch variability, reversions to virulence (Fox et a/., 1942) and 
overattenuation (Soper & Smith, 1938). The seed lot system, established in 1945 
by the W HO to address these difficulties (WHO Technical Report Series, 1945, 
1956), requires that no vaccine should be manufactured that is more than one 
passage level from a seed lot that has passed all safety tests. Since 1945, a total 
of 21 cases of 17D vaccine-associated encephalitis have been reported, only one 
of which was fatal (Anonymous, 1966). Nevertheless, the disparate substrain 
origin and passage level of early vaccines continue to be reflected in 
contemporary vaccine manufacture (Monath et a/., 1983; Figure 3.1), and both 
ALV-free and ALV-contaminated vaccines are used.
Monath et al. (1983) carried out a comprehensive RNA fingerprint analysis 
of 17D vaccines and seed viruses obtained from all producers worldwide and 
demonstrated only minor heterogeneity. However, different 17D vaccine strains 
can be distinguished on the basis of mouse neurovirulence (Barrett & Gould, 
1986; Gibson et al., 1990) and their ability to replicate in human macrophages 
(Liprandi & Walder, 1983). Furthermore, each 17D-204 vaccine substrain was 
found to be heterogeneous, consisting of variants clearly distinguishable in terms 
of plaque size, replication in macrophages and virulence for mice (Liprandi, 
1981).
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Asibi
Original 17D(pl76)
17DD
17D-204(p204)
Low(pl95)
RF312
France
Colombia S. Africa U.K. India
Senegal
U.S.A
Australia
Holland
WHO ALV free 17DD
High(p243)
Australia Russia F.R.G 
(p238-239)
Colombia
Brazil
Senegal.
(p286-288)
Figure 3.1: The 17D vaccine viruses manufactured today. Viruses for which sequence is 
available are underlined; viruses included in this study are bolded.
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MAb binding, haemagglutination inhibition (HAI) and neutralisation studies 
have shown that variation in biological assays of E protein epitopes is also a 
common phenomenon in 17D vaccines from different centres (Schlesinger et al., 
1983; Buckley & Gould, 1985; Gould e ta l., 1985; Barrett et a/., 1989; Ledger et 
a i,  1992; Sil et al., 1992). Ledger and coworkers were also able to demonstrate 
that plaque-purified isolates from 17D virus populations differed from their parent 
virus in biological assays (Ledger et al., 1992).
Clearly, it is important to analyse the nucleotide and amino acid sequence 
of 17D vaccine viruses with different passage histories in order to reveal the 
extent of genetic variability among YF 17D virus seeds and vaccines. The virus 
strains included in this study were specifically selected in order to address some 
of the concerns presented above. In addition, these studies will also be beneficial 
to our understanding of the genetic basis of the attenuation of the parental wild- 
type Asibi strain.
3.2 Results
3.2.1 Passage histories and passage levels of the 17D vaccines
The first requirement for studying genetic variability of virus genomes and 
its relationship to virus phenotype is a detailed passage history of the viruses 
concerned. This is shown in Figure 3.1 and was compiled from different sources
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(Fox & Ferma, 1943; Monath et al., 1983; Barrett, 1987; Post et al., 1992). The 
17D-204 vaccine viruses included in this study are summarised in Table 3.1. 
together with, those 17 0  virus strains for which nucleotide sequence data is 
currently available.
RF312 virus represents an early 17D-204 substrain vaccine batch prepared 
at the Rockefeller Foundation (RF), New York in 1941, before the introduction of 
the seed lot system (Fox & Penna, 1943). Previously, in this laboratory, RF312 
was found to be lethal for mice when inoculated intranasally with an LD50 of 104 
pfu (Gibson e ta l., 1990).
The modern 17D-204 substrain vaccines derive from a common seed 
(Colombia 88) at passage 228. All of the 17D-204 vaccine strains for which 
sequence data has previously been accumulated derive from the same Colombia 
88-derivative (RF145-3). The vaccines manufactured in the United Kingdom (17D- 
204-UK) and South Africa (17D-204-SA) were selected as representatives of the 
second lineage of 17D-204 vaccine viruses, which were passaged independently 
after passage 228 from RF505. This group also includes the 17D-204 vaccines 
manufactured in India and Colombia.
The WHO recommend vaccine production from an ALV-free 17D-204 seed 
(17D-204-WHO; primary seed 213/77) at passage 237, which is derived from the 
primary seed lot of the Robert Koch Institut in Germany (FRG 83-66). At present, 
however, its use has been adopted by only a few manufacturers for the
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production of an ALV-free 17D-204 seed. One of these, the 17D-204 vaccine 
manufactured in Brazil (17D-204-Brazil) at passage 239, was the subject of E gene 
sequence analysis by Post et al. (1992). Another, the vaccine produced in Russia 
(17D-204-Russia) at the same passage level, was included in this study.
3.2.2 Amplification, cloning and sequencing of the viral RNA
After extraction of viral RNA from virus in tissue-culture supernatant, the 
M and E protein-encoding genes were amplified in two overlapping fragments by 
RT-RCR covering nt-625 to nt-1312 and nt-1223 to nt-2554 using primer pairs 
CAG-YF7 and AJ7UR-YF100, respectively, as described in Chapter 2. W here the 
C protein gene was also included, this region was amplified in a third overlapping 
fragment from nt-43 to nt-678 using primer pair LEE1-YF300. PCR products were 
separated by agarose gel electrophoresis (Figure 3.2) and extracted from the 
agarose by Geneclean™. The PCR-amplified DNA fragments were then cloned 
into the pCRII™ plasmid and transformed into competent INVaFz E. coll. Colonies 
containing plasmid with the appropriate insert were selected by restriction 
digestion (Figure 3.3). Purified plasmid was sequenced using the 
dideoxynucleotide chain termination method of Sanger et al. (1977). An 
autoradiograph of a sequencing gel is pictured in Figure 3.4. It should be noted 
that none of the viruses were plaque-purified, and therefore the sequences 
reported here represent an average sequence of the vaccine population.
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1 2 3 4 5 6
1 3 5 3
1 0 7 8
Figure 3.2: The RT-PCR amplified cDNA fragments of YF virus,
separated by gel electrophoresis.
Lane 1 SNS3a—ANS3a 620 bp
Lane 2 SNS3b-ANS3b 702 bp
Lane 3 SNS3c—ANS3c 709 bp
Lane 4 SNS4B-ANS4B 528 bp
Lane 5 SNS5a-ANS5a 668 bp
Lane 8 Negative control
Lane 9 AJ7UP-YF100 1331 bp
Lane 10: CAG-YF7 687 bp
Lane 6 and 7: 0X174 Haelll molecular weight markers
1 2 3 4 5 6 7 8 9 10 11 12 13
Figure 3.3: Gel-electrophoresis of restriction digests of
plasmids digested with EcoRI enzyme. Insert is CAG-YF7 
fragment (678 bp)
Lane 1: 0X174 Haelll molecular weight markers
Lanes 2, 4, 6, 8, 10 and 12: Purified plasmid digested with
EcoRI enzyme.
Lanes 3, 5, 7, 9, 11 and 13: Undigested plasmid.
I 2  3  4
Figure 3.4: Autoradiograph of polyacrylamide -urea sequencing gel. Reaction sets 
were loaded G, A, T, C.
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3.2.3 Comparison of nucleotide and deduced amino acid sequences of the 
structural proteins of the 17D vaccine viruses
Table 3.2 provides a comparison of the nucleotide and deduced amino 
acid sequences of the structural protein genes of the Asibi virus (wild-type parent 
of the attenuated 17D strain; Hahn et a/., 1987) with those of the 17D-204 
substrain vaccines prepared at different centres worldwide (both published 
previously and obtained in this study). Sequence heterogenity, an inherent 
characteristic of RNA viruses (Holland et a/., 1982; Strauss & Strauss, 1988), was 
not evident. However, genetic variants representing only a minority of the 
predominant sequence would be difficult to detect by this method.
3.2.4 Sequence comparison of the early 17D-204 vaccine strain RF312 with the 
vaccine strains manufactured today
The nucleotide sequences of the M and E protein genes of the RF312 virus
were found to be homologous to the sequences previously published for the 17D-
A
204-ATCC, 17D-204-France and 17D-204-USA vaccine viruses. A total of 19 
nucleotide differences were identified, encoding 13 amino acids substitutions 
from the wild-type Asibi parent strain; one in the M protein and 12 in the E 
protein.
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nucleotide Asibi
RF312
17D-204-UK
17D-204-SA
17D-204-ATCC
17D-204-France
17D-204-USA
17D-204-Russia
17D-204-Brazü amino acid substitution
304 G A A -
370 T C C - -
854 C T T M-35 L to F
883 A G G - -
1127 G A A E-52 G to R
1140 C T T E-56 A to V
1431 A A C E-153 N to T
1482 C T T E-170 A to V
1491 C T T E-173 T to I
1572 A C C E-200 K to T
1750 C T T - -
1819 C T T - -
1870 G A A E-299 M to I
1887 C T T E-305 S to F
1946 C T T E-325 P to S
1965 A G G E-331 K to R
2112 C A A E-380 T to R
2193 C T T E-407 A to V
2219 G A A E-416 A to T
2356 C T T - -
Table 3.2: Comparison of the nucleotide and deduced amino acid sequence of Asibi virus and
the 17D-204 vaccine viruses. Viruses underlined were sequenced in this study.
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3.2.5 Sequence comparison of the modern 17D-204 vaccine strains
Previous comparison of the genomic sequence for isolates of 17D-204- 
ATCC and 17D-204-France indicated almost complete homology, except for two 
nucleotide differences in the 3 ' non-coding region and four nucleotide changes 
in the non-structural proteins, three of which encoded amino acid substitutions 
(Dupuy et a/., 1989). The nucleotide sequence of these two virus isolates, and 
also that of 17D-204-USA, were found to be identical over the 5Z non-coding 
region and structural protein genes Uennings, 1993, Jennings et a/., 1993).
In this study, the 5Z non-coding region and structural protein genes of the 
17D-204-UK virus, and the M and E protein genes of the 17D-204-SA virus were 
sequenced. Comparison of the nucleotide and the deduced amino acid sequences 
determined for the 17D-204-UK and 17D-204-SA vaccine strains with the 
published sequences of the 17D-204-ATCC, 17D-204-France and 17D-204-USA 
vaccine strains showed that all were identical.
3.2.6 Sequence comparison of 17D-204 vaccine strains produced from the
WHO-recommended ALV-free seed
Comparison of the M and E protein gene sequence of the 17D-204-Russia
A
virus with those described above identified the same 19 nucleotide changes (and 
resulting 13 amino acid substitutions) from the nucleotide sequence of the 
parental Asibi virus strain. However, an additional nucleotide mutation from the
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Asibi parent virus was identified in the E protein gene at nucleotide (nt)-1431, 
which encoded the substitution of an asparagine with a threonine residue at E 
protein amino acid 153 (E-153). Comparison with the published E protein 
sequence of the 17D-204-Brazil virus (also derived from the WHO-recommended 
seed; Post et al., 1992) revealed that these two viruses were identical. The E-153 
amino acid substitution creates a potential N-linked glycosylation site in the E 
protein at position E-151 (Asn^-Trp-Thr), which was shown to be utilised in the 
case of 17D-204-Brazil (Post et a i,  1992).
3.3 Discussion
Contrary to previous indications, this study demonstrates that there is 
extremely little sequence heterogeneity between the 17D-204 vaccine strains in 
use today. Furthermore, few mutations have been fixed in the genome since 
1941, prior to the introduction of the seed lot system. Although the entire genome 
has not been sequenced for these viruses, the structural protein genes represent 
almost one quarter of the whole genome. Therefore, the sequence conservation 
observed in this study, is likely to provide a good indication of stability 
throughout the genome. This finding is similar to the results obtained for the live- 
attenuated vaccines of certain other RNA viruses such as the Edmonston measles 
virus vaccine (Rota et al., 1994). This is reassuring, given the variable nature of 
RNA viruses (Holland et al., 1982; Strauss & Strauss, 1988), and probably reflects 
the strong selective fitness of certain genomic species that, under appropriate
conditions, dominate the population. Overall, these results show the success of 
the seed lot system in limiting genetic heterogeneity among the 17D-204 substrain 
vaccines.
Although the 17D YF vaccines have proven to be among the safest and 
most efficacious viral vaccines available, the molecular determinants of 
attenuation of virus virulence have yet to be elucidated. The original 17D 
attenuated variant, which was identified at passage 176 in the 1930's, has long 
since been lost. However, sequence analysis of the structural proteins has 
identified 10 amino acid substitutions from the wild-type Asibi strain common to 
all 17D-derived vaccine viruses, one in the M protein and nine in the E protein 
(Table 3.3). It seems reasonable to propose that these substitutions existed in the 
original 17D attenuated variant and, consequently, may have been important in 
the attenuation process.
Over the 2334 nucleotides encoding the structural proteins, the 17D-204 
and 17DD substrain viruses differ by only 13 nucleotides (0.5 % variance). Thus, 
the two virus substrains are almost identical, despite their divergent passage 
history from passage 195, after which 17D-204 was passaged a further 35-40 
times and 17DD a further 92-93 times (Monath et al., 1983). Interestingly, the 
highest rate of nucleotide change and all five coding changes (three in 17D-204 
and two in 17DD) were found in the E protein gene, resulting in amino acid 
differences between the two vaccine strains at positions E-56, E-155, E-325 and 
E-416 (Table 3.4). These changes equate to a 0.8 % amino acid divergence
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Amino acid position Asibi 17D
M-35 L F
E-52 G R
E-170 A V
E-173 T I
E-200 K T
E-299 M I
E-305 S F
E-331 K R
E-380 T R
E-407 A V
Table 3.3: Amino acid substitutions in the structural proteins 
common to all 17D vaccine viruses.
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Amino acid position Asibi 17D-204 17DD
E-56 A V A
E-vSS D L S
E-325 P S P
E-416 A T V
Table 3.4: Amino add substitutions in the E protein which are unique to the
17D-204vacdne viruses, or th e  Macôfve v iru ses.
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between the E protein sequences of the two viruses, and further suggest that, as 
the major structural protein of the virus, the E protein appears to be subject to 
greater selective pressure during passage in vitro.
Comparison of all available sequence data for the structural protein genes 
of the 17D-204 vaccine strains now supports the hypothesis that, during the 33 
tissue culture passages after divergence from the 17DD substrain, but before 
divergence of virus strain RF312 and introduction of the seed lot system, a further 
six nucleotide mutations accumulated, which encode three amino acid 
substitutions in the E protein at E-56, E-325 and E-416, corresponding to a 0.25 
% nucleotide or 0.38 % amino acid difference. This equates to 7.7 x 10"5 
nucleotide mutations fixed per base per passage, or 0.8 nucleotide changes in the 
genome per passage.
The two 17D substrains can be distinguished from one another by MAb 
binding reactivity in indirect immunofluorescence tests. In particular, MAb 864 
has previously been characterised as 17D-204 substrain-specific, recognising an 
E protein epitope only present on the surface of 17D-204 substrain viruses. 
Cammack and Gould (1986) also stated that MAb 864 defines a very important 
functional site on the virus. Identification of the three amino acid substitutions 
unique to the 17D-204 substrain viruses at E-56, E-325 and E-416 implicates one 
or more of the substituted amino acid residues in the appearance of the 
conformational 17D-204 substrain-specific epitope.
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Although a remarkable stability has been demonstrated, passage history of 
the 17D vaccine viruses has been implicated in sequence heterogeneity. Two 
17D viruses, 17D-204-Russia and 17D-204-Brazil, derived from the WHO- 
recommended ALV-free seed, have now been shown to have a potential N-linked 
glycosylation site (Asn151-Trp-Thr), created by an amino acid substitution at 
position E-153. Consequently, it can be assumed that this amino acid substitution 
is also to be found in the E protein of the WHO seed virus. This acceptor site is 
used in 17D-204-Brazil for the addition of a high-mannose carbohydrate side 
chain, as shown by endoglycosidase analyses of immunoprecipitated E protein 
(Post et a/., 1992).
Nucleotide sequence analysis of 17D-204-ATCC (Rice et a/., 1985) 
revealed two potential N-linked glycosylation sites. One is a "weak" acceptor site 
(Asn309-Rro-Thr) and the other is a site in the putative carboxy terminal 
transmembrane domain (Asn470-Met-Thr), suggesting that the YF virus E protein 
may not normally be glycosylated. However, the E proteins of 17DD-Senegal and 
17DD-Brazil have been shown to have a potential N-linked glycosylation site at 
position E-153 (Asn153-Thr-Ser; Jennings et a/., 1992; Post eta l., 1992), which was 
shown to be utilised in 17DD-Brazil.
The observation that viruses of both substrains contain independent 
mutations creating functional N-linked glycan acceptor sites suggests that E protein 
glycosylation might have some positive adaptive value for YF virus growth in 
chick embryo cells. The E protein of other flaviviruses exists in both non­
135
glycosylated and glycosylated forms with N-linked oligosaccharides containing 
high-mannose and complex-type carbohydrates depending on the virus and cell 
type used (Chambers et a/., 1990). Flavivi ruses which possess potential N-linked 
glycosylation sites include all members of the DEN and TBE serocomplexes, as 
well as JE, MVE and SLE from the JE serocomplex (Rice et a/., 1990). However, 
these sites are not always used, as shown for DEN-2 strain Jamaica (Johnson et a/.,
1994). W hether or not the differences in glycosylation of the 17D vaccine viruses 
are of practical concern is uncertain as no comparisons have been made as to the 
efficacy of vaccines produced by different manufacturers. However, it raises a 
question as to the advisability of adoption of the 17D-204-WHO seed by all 
manufacturers before these issues are resolved.
The original intention of this study was, in part, to examine the role of the 
virus structural proteins in the heterogeneity observed among the 17D-204 
substrain vaccines. As there was found to be almost complete sequence homology 
in this region, the interpretation of these observations is now somewhat altered, 
but some conclusions can be drawn in terms of vaccine heterogeneity and the 
involvement of non-structural protein genes or non-coding regions of the genome.
Ledger et a/. (1992) have reported a systematic comparison of the 
biological function of E protein epitopes in HAI and neutralisation tests using 
samples of vaccines from many manufacturers, past and present. These authors 
concluded that YF vaccines manufactured in different centres are antigenically 
distinct. However, comparison of the E protein amino acid sequences of different
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17D-204 strains in this study has demonstrated that the heterogeneity observed 
cannot be attributed to genetic diversity alone. It is possible that these biological 
differences are epigenetic, caused by host cell or environmental factors such as 
pH. Alternatively, processing and presentation of the E protein may be affected 
by mutations occurring elsewhere in the virus genome, which were not identified 
in this study.
The early 17D-204 strain, RF312, was found to be neuroinvasive in mice 
inoculated intranasally. Although the molecular determinants responsible for the 
neurotropism of certain YF virus strains have not yet been identified, molecular 
studies on the neurotropic vaccine-revertant virus, PI 6065, have implicated 
proteins E and NS4B (Jennings et al., 1993; E. Wang, personal communication). 
In other flaviviruses, such as TBE virus (Holzmann et al., 1990; Pletnev et al., 
1992), JE virus (Cecilia & Gould, 1991 ; Hasegawa et al., 1992), DEN-4 (Kawano 
et al., 1993), WN virus (Halevy et al., 1994) and Ll virus (Jiang et al., 1993; Gao 
et al., 1994), the E protein has also been implicated in neurovirulence and 
neuroinvasiveness for mice. However, in the case of RF312, the neurotropic 
phenotype must be encoded outside the M and E protein genes and is 
consequently outside the scope of this study.
In the RNA fingerprinting studies of Monath et al. (1983), both the South 
African primary seed and vaccine lacked oligonucleotide 11, while the primary 
seed contained an additional oligonucleotide, and the vaccine contained two 
additional oligonucleotides. Since the M and E protein sequences of 17D-204-SA
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were found to be identical to those of the majority of other 17D-204 viruses 
sequenced to date, it was concluded that the nucleotide difference^ responsible 
for the anomalous RNA fingerprint of this virus occurred elsewhere in the 
genome. The South African vaccine has been implicated in a possible incidence 
of post-vaccinal encephalitis (Schloub et a/., 1990), but whether or not this can 
be attributed to sequence heterogeneity is not known.
Finally, the availability of functional YF virus infectious cDNA clones and 
recombinant DNA technology is likely to revolutionise vaccine development in 
the future (Rice et a/., 1989). The most straightforward application of this system 
is for storage and propagation of live-attenuated vaccine strains, as has been 
shown for the Sabin vaccine strain of poliovirus (Kohara et a/., 1986). This 
approach can now be tested for YF virus derived from YF 17D cDNA clones, and 
should be applicable to other live-attenuated flavivirus strains and corresponding 
cDNA clones as they become available. The development of the seed lot system 
method for propagating vaccine viruses has limited, but not eliminated, serial 
passaging and the virus inoculum used for vaccine production can continue to 
change. Propagation of RNA virus vaccine strains as DNA, with its 
correspondingly lower mutation frequency (Reanney, 1982), combined with 
production of vaccine virus in cell cultures, should improve the reliability and 
lower the cost of the YF live-attenuated vaccine in the future. cDNA clones can 
also be used, in combination with sequence studies, for the precise identification 
of attenuating mutations to facilitate the production of a a safer, more stable 
vaccine.
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CHAPTER 4
Comparison of the nucleotide and deduced amino acid 
sequences of the structural protein genes of different 
French neurotropic vaccine virus strains
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4.1 Introduction
Comparison of the genomic sequence of the 17D-204 vaccine substrain 
virus and its wild-type Asibi parent virus has identified a 0.63 % nucleotide and 
0.94 % amino acid divergence over 243 passages, but it has so far proven 
impossible to determine precisely the molecular basis of attenuation of YF virus. 
Accordingly, FNV represents a second opportunity to examine an attenuated YF 
virus at the molecular level, complemented by both biological and antigenic 
studies performed previously (Theiler, 1951; Fitzgeorge & Bradish, 1980; Gould 
et a/., 1985, 1989; Deubel et a/., 1986; Sil et a/., 1992).
Development of the FNV and 17D vaccine strains was almost concurrent, 
but attenuation was achieved by distinctly different methods. The FNV vaccine 
strain was derived by serial mouse brain passage of the wild-type FVV virus, 
isolated in Senegal in 1927 (Mathis et a/., 1928; Durieux, 1956). In contrast, the 
17D vaccine strain was attenuated primarily by passage in extraneural tissues 
(Theiler & Smith, 1932). Although many biological properties are different, 
parallels can, nevertheless, be drawn between the two attenuation processes. Both 
FNV and 17D strains have lost the ability to cause visceral YF in primates, but 
retain their immunogenicity. They are also adapted for mouse neurovirulence. 
Furthermore, neither vaccine strain is mosquito competent; an important 
consideration for a live-attenuated vaccine to prevent reversion to virulence and 
vector transmission.
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E protein antigenic studies with MAbs and polyclonal antibodies in 
binding, HAI and neutralisation tests have revealed, perhaps suprisingly, that the 
FNV and 17D vaccine strains more closely resemble each other than their 
respective parent viruses, FW  and Asibi (Gould et al., 1985, Sil et al., 1992; 
Ledger et al., 1992). In particular, two groups have characterised "YF vaccine- 
specific" MAbs, MAb 411 (Gould et al., 1985) and MAb H5 (Sil et a/., 1992), 
both of which recognise an E protein epitope found on FNV and 17D strain 
viruses, but not on wild-type YF viruses. The epitope(s) defined by these MAbs 
was, therefore, termed the "vaccine-specific epitope". The appearance of this 
epitope during two independent and dissimilar processes of attenuation suggests 
that this conformational change may be important in attenuation of the virus. At 
the least it apparently provides a biological marker for attenuation and implicates 
the membrane-associated proteins in this process.
An RNA fingerprinting study of YF viruses (Deubel et al., 1986) revealed 
that the two wild-type parent viruses, FVV and Asibi, shared 96.4 % homology, 
as might be expected since both originate from Senegal in 1927 and were 
probably isolated during the same epidemic. FW  and FNV were found to differ 
by 16.4 %; Asibi and 17D-204 by 20.4 %.
Today, due to the discontinuation of FNV production in 1980, FNV strains 
are held in only four laboratories worldwide: FNV-1R at the Institut Pasteur, 
France; FNV-FC at the Center for Disease Control (CDC), USA; FNV-NT at Rorton 
Down, UK; and FNV-YA at Yale University, USA (Figure 4.1). The origins and
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French viscerotropic virus (FW ) 
(Isolated in Senegal, 1927)
128 passages in 
mouse brain
Original French neurotropic vaccine (FNV)
First vaccine (p. 237)
I
Later vaccines (p. 260)
FNV-NT
(Porton Down, UK)
FNV-YA
(Yale, USA)
FNV-IP FNV-FC
(Institut Pasteur, France) (Fort Collins, USA)
Figure 4.1: Passage histoiy of the FNV virus strains.
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passage histories of these vaccine strains have not been recorded, but all are 
thought to originate from the Institut Pasteur, Senegal in the 1940's, and so would 
be derived from the 258th to 260th mouse brain passage. In biological analyses 
previously conducted in this laboratory FNV-IP, FNV-FC and FNV-NT were found 
to be readily distinguishable, on the basis of virulence for mice and monkeys, and 
reactivity with MAbs (Gibson et a/., 1990; Ledger, 1990; Ledger et a/., 1992). The 
nucleotide and deduced amino acid sequences of the structural protein genes of 
the wild-type parent FVV strain and FNV-IP have been analysed previously 
Gennings et a/., 1993; Jennings, 1993).
In this study, mouse pathogenicity properties of FNV-YA were ascertained 
and compared with those described previously for the other FNV strains. The 
nucleotide and deduced amino acid sequences of the structural protein genes of 
the remaining three strains of FNV, FNV-FC, FNV-NT and FNV-YA, were 
determined and analysed with reference to the published sequences for F W  and 
FNV-IP Gennings et a/., 1993; Jennings, 1993).
4.2 Results
4.2.1 Virulence of FNV virus strains for mice following i.e. inoculation
Although all four FNV virus strains were lethal for mice by i.e. inoculation, 
significant differences in virulence were observed (Table 4.1). FNV-FC was shown
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Virus Mice
Intracerebral Intranasal
Monkey
Intracerebral
AST Logic Pfa/ 
LD50
AST AST
FNV-IP 5.8± 0.2 4.1 10.3 ± 0.9 6
FNV-FC 11.1± 0.5 ^ 5.6 NA 9
FNV-NT 5 .8± 0.2 4.1 10.0 ± 0.5 >30
FNV-Yale 4 .8± 0.2 4.1 8.1± 0.1 NT
AST: average survival time (days ±  SEM) 
NT: not tested 
NA: not applicable
Table 4.1: Virulence of the FNV and F W  viruses in mice and monkeys 
inoculated by intracerebral and intranasal routes.
144
to be significantly less virulent with an AST of 11.1 ± 0.5, while FNV-Yale was 
significantly more virulent with an AST of 4.8 ± 0.2 (as compared to 5.8 ± 0.2 
AST for FNV-IP and FNV-NT).
4.2.2 Virulence of FNV virus strains for mice following i.n. inoculation
FNV-IP, FNV-NT and FNV-Yale viruses were found to be lethal for mice 
by i.n. inoculation with an LD50 of 1 x 103 pfu (Table 4.1). Of these three virus 
strains, FNV-Yale exihibited the shortest AST and therefore was considered to be 
significantly more virulent. However, the FNV-FC virus was not lethal for mice 
by this route at the highest dose possible (5 x 105 pfu).
4.2.3 Virulence of FNV virus strains for monkeys following i.e. inoculation
Monkey virulence tests were performed according to recommended 
procedures for vaccine control (WHO Technical Report Series, 1959). Male 
Cynomolgos monkeys were inoculated i.e. into the left frontal lobe with 104 pfu 
of virus in a volume of 250 //I. Following inoculation, the animals were 
monitored daily for signs of clinical disease and AST was calculated where 
appropriate (Table 4.1). This work was performed in collaboration with Drs. P. 
Minor and D. Wood at the National Institute for Biological Standards and Control, 
UK. FNV-IP and FNV-FC viruses were lethal for monkeys when inoculated i.e., 
with death at six or nine days post-infection, respectively. The FNV-NT virus was 
not virulent for monkeys by this route. The monkey neurovirulence of FNV-Yale
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virus has not yet been tested.
4.2.4 Amplification, cloning and sequencing of the viral RNA
The genes encoding the structural proteins were amplified by RT-RCR in 
three overlapping fragments, using primer pairs B5-YF300, CAG-YF7 and AJ7UR- 
YF100. PCR fragments were cloned and sequenced, as described in Chapters 2 
and 3. In each case, two or three independent clones were sequenced to confirm 
the nucleotide sequence data obtained. No clonal variation was observed. The 
region examined covered 2553 nucleotides, including the 5Z non-coding region, 
the C, prM, M and E protein genes and the 5' terminal 100 nucleotides of the 
NS1 protein gene. The entire region sequenced encodes a total of 812 amino 
acids.
4.2.5 Comparison of nucleotide and deduced amino acid sequence of the
structural proteins of the FNV strains with the FVV parental wild-type
The nucleotide and deduced amino acid sequences of the structural protein 
genes of the FNV-FC, FNV-NT and FNV-Yale viruses were compared with those 
of FVV and FNV-IP reported previously (Jennings et a/., 1993; Jennings, 1993) in 
Table 4.2.
The structural protein genes of the FNV viruses were shown to differ from 
those of the wild-type FVV parent virus at a total of 37 nucleotide positions; six
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nucleotide F W  FNV-IP FNV-FC FNV-NT FNV-Yale amino acid substitution
250 T A A A A
271 T C C C C - -
357 T C C C C 080 V to A
370 T c c C c - -
373 G A A A A - -
386 A G G G G 090 S to G
554 . G A A A A prM-25 V to M
694 T C C C C - -
844 T T T C T - -
I|:=#imi854 C T T T T M-35 L to F
992 A A A A T 0 7 V to A
1006 C C T C T - -
1036 T C C C C - -
1042 T c C c C - -
1134 g # # # # T NNMUWi T A t o V
1155 A A A A C E-61 Y to S
1156 C C C C G E-61
1306 G A A A A - -
1392 G G G A G E-139 R to K
1395 C C C T C E-140 A to V
1398 A G A A A 0142 ^ Q to R
1424 A A A G A E-151 N to D
1432 T A A T A E-153 N to K
1437 A A A C A E-155 D to A
1653 G A A A A 0227 G to E
1718 A G G G G 0249 N to D
1819 C C T T T - -
1836 C C C A C 0288 S to L
2092 C C T T T - -
2113 A A A G A -
2168 T T C T T - - ;
2182 C C C T C - -
2193 T C T T C E-407 V to A
2239 T C T T C - - ;
2257 T T C C T -
2344 G A A G A E-457 M to I
2437 T C C T C -
Table 4.2: Comparison of the structural protein gene sequence of the F W  wild-type 
virus and its FNV virus derivatives
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X .  nt 
aa
FW FNV-IP FNV-FC FNV-NT FNV-YA
FW 21
(99.2%)
23
(99.1%)
26
(99.0%)
26
(99.0%)
FNV-IP 10
(98.8%)
8
(99.7%)
17
(99.3%)
7
(99.7%)
FNV-FC 8
(99.0%)
2
(99.7%)
12
(99.5%)
7
(99.7%)
FNV-NT 13
(98.4%)
9
(98.9)
7
(99.1%)
18
(99.3%)
FNV-YA 10
(98.8%)
3
(99.6%)
2
(99.7%)
9
(98.9%)
Table 4.3: Summary of the nucleotide and amino acid differences between the 
structural protein genes of the F W  and FNV virus strains.
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in the C protein gene, two in the prM protein gene, two in the M protein gene, 
and 29 in the E protein gene. No variation was observed in the 5 ' non-coding 
region or in the partial NS1 gene. Many of the nucleotide differences identified 
were unique to one or more FNV virus strain. The similarities of the various FNV 
strains and their parent virus are shown in Table 4.3.
4.2.6 Amino acid substitutions from F W  conserved among th e  FNV strains
Seven amino acid positions were identifed in the structural protein 
sequence at which all four FNV strains differed from the FVV wild-type parental 
sequence, but were identical to each other. These common substitutions are 
outlined below with reference to the protein in which they occurred.
C protein: All six nucleotide mutations in the C protein gene were found to be 
conserved among the FNV strains. The nucleotide changes at nt-357 and nt-386 
encoded amino acid substitutions at C-80 and C-90, respectively.
prM protein: Both nucleotide mutations observed in the prM protein gene were 
again conserved among the FNV strains and the mutation at nt-554 coded for one 
amino acid substitution at prM-25.
M protein: One nucleotide mutation at nt-854 was conserved among the FNV 
viruses, resulting in an amino acid substitution at M-35. - ! !  ^ * !
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E protein: In the E protein a total of 13 amino acid substitutions were found, three 
of which were conserved among the FNV strains at positions E-54, E-227 and E- 
249. The remainder of the nucleotide and amino acid changes from FVV are 
variously conserved or unique among the FNV strains and are discussed further 
in Section 4.2.8.
4.2.7 Comparison of the wild-type/vaccine pairs (Asibi/17D and FVV/FNV)
The results presented in this and the previous chapter (Chapter 3) allow 
a comparison of the two vaccine strains, FNV and 17D (further subdivided into 
17D-204 and 17DD substrains), with each other and also their respective wild- 
type parents. Figure 4.2 shows a cluster analysis based on the amino acid 
sequences of the structural proteins of FVV Gennings et a/., 1993; Jennings, 1993), 
Asibi (Hahn e ta /., 1987), FNV-IP Gennings et a/., 1993; Jennings, 1993), FNV-FC, 
FNV-NT, FNV-Yale, 17D-204-ATCC (Rice et a/., 1985) and 17DD-Senegal 
Gennings et a/., 1993b). The dendrogram demonstrates that the viruses form three 
groups; (1) the wild-type viruses, FW  and Asibi, (2) the 17D strain viruses, 17D- 
204-ATCC and 17DD-Senegal, and (3) the FNV strain viruses, FNV-FC, FNV-IP 
and FNV-YA with FNV-NT more distantly related. Figure 4.2 also indicates that 
the FNV and 17D strains are relatively dissimilar to one another. To examine 
these differences at the amino acid level, the changes found in the structural 
proteins of these viruses are tabulated in Table 4.4. Furthermore, it can be seen 
that the FNV strain viruses are more closely related than the 17D strain viruses 
to the wild-type viruses.
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F W
ASIBI
FNV-FC
FNV-IP
FNV-YALE
FNV-NT
17D-204 
17DD
Figure 4.2: Dendrogram of the alignment of the structural protein sequences of
the vaccine/wiId-type virus pairs.
Amino acid position Asibi/FW 17D FNV
M-35 ||#I00I0000I0||||| F F
E-52 G R G
E-54 A A V
E-170 A V A
E-173 T I T
E-200 K T K
E-227 G G E
E-249 N N D
E-299 M I M
E-305 S F S
E-331 K/R R R
E-380 T R T
E-407 A V AJV
Table 4.4: Comparison of the common amino acid substitutions in the 
vaccine/wild-type pairs. The shared M protein substitution is 
highlighted.
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Table 4.4 shows that there is no common amino acid substitution in the 
E protein of FNV and the 17D vaccine strains compared to their parents. As stated 
above, the two vaccine viruses differ relatively greatly from one another. The 
divergence observed in the FVV/FNV attenuation process was, however, of a 
similar degree to that observed in the Asibi/17D-204 attenuation process (0.8-1.0 
% and 0.81 % divergence, respectively).
Interestingly, there is one common amino acid substitution from the wild- 
type viruses which is common to both FNV and 17D vaccine viruses in the M 
protein. The nucleotide substitution C to U at nt-854 encodes the substitution of 
a phenylalanine residue in the vaccine strains for a leucine in the wild-type strains 
at amino acid position M-35.
4.2.8 Amino acid substitutions from FVV unique to one FNV strain
As previously mentioned, there are a number of nucleotide and amino acid 
substitutions in the structural protein genes of the FNV strain viruses which are 
unique to one or more strain. All of the amino acid substitutions were found in 
the E protein.
The FNV-FC virus differs from the wild-type FW  at 23 nucleotide positions 
in the structural protein genes, eight of which encode amino acid substitutions 
(Table 4.4). FNV-IP virus is most closely related to FNV-FC. The FNV-IP virus 
differs from FVV at 20 nucleotide positions in the structural protein genes
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resulting in 10 amino acid substitutions. Two unique nucleotide changes were 
revealed which encoded two unique amino acid substitutions at E-142 and E-407 
(note this is a different amino acid change from FNV-Yale at this position). The 
FNV-Yale virus differs from FVV at 26 nucleotide positions in the structural 
proteins which result in 10 amino acid substitutions. Three of the nucleotide 
changes are unique to FNV-Yale and result in two unique amino acid substitutions 
at E-61 and E-407. Finally, FNV-NT appears to be relatively dissimilar to the other 
FNV strains. This virus differs from FVV at 27 nucleotide positions in the 
structural proteins with 13 resulting amino acid substitutions. Six unique amino 
acid substitutions were identified in the E protein at E-139, E-140, E-151, E-153, 
E-155, and E-288.
4.3 Discussion
Preliminary alignments of the structural protein gene nucleotide sequences 
obtained for the four FNV strains analysed in this study revealed a much greater 
sequence heterogeneity between the FNV strains than was previously observed 
among the 17D vaccine strains in Chapter 3. This may reflect differing unknown 
passage histories in the four laboratories, whereas the 17D vaccines have very 
limited passage variation due to the seed lot system.
Previous studies using MAbs raised against the YF virus E protein (Gould 
e ta /., 1985; Sil e ta /., 1992) have suggested that the FNV and 17D vaccine strains
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of YF virus differ considerably. The results obtained confirm that these two viruses 
are relatively dissimilar over the E protein. In fact, they differ more from each 
other than from the wild-type viruses (Figure 4.2), suggesting that their routes of 
attenuation were indeed very different. Over the structural proteins, the FNV 
strain viruses are more closely related to their FVV parent virus, in terms of amino 
acid divergence, than the 17D strain viruses are to Asibi. Although the distinction 
is minor, it is possible that the lower mutation frequency observed in the FNV 
strains reflects the nature of the attenuation process. The FNV attenuated 
derivative resulted from in vivo passage, while the 17D derivation occurred in 
vitro, perhaps increasing the selection pressure.
The four FNV strains are all reported to originate from approximately the 
260th mouse brain passage of FVV. Seven common amino acid substitutions from 
the FVV wild-type have been identified (C-80, C-90, prM-25, M-35, E-54, E-227 
and E-249) which are speculated to have existed in the original stock from which 
these viruses were amplified. For this reason, these substitutions may contribute 
to the attenuated phenotype of these viruses. In order to discuss the relative 
importance of these substitutions it is necessary to analyse their positions in the 
virion.
C protein: Perhaps one of the suprises regarding the results presented in this study 
was the extent to which FVV and FNV differed over the C protein gene. During 
the attenuation of Asibi, only two nucleotide changes were seen over this region 
for the 17D-204 strains, with an additional tvyo found in 17DD (see Chapter 3).
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None of these changes encoded an amino acid substitution, and thus the C 
proteins of Asibi and 17D vaccine viruses were identical in amino acid sequence.
In the four FNV strains analysed, two common amino acid substitutions 
w ere found at positions C-80 and C-90. Both substitutions are potentially 
conservative with a valine to alanine substitution occurring at position C-80, and 
serine to glycine at C-90. Accordingly, they would not be predicted to have a 
significant effect on the structure of the C protein. Furthermore, as the wild-type 
amino acid residues were substituted with similarly charged hydrophobic amino 
acids, these changes would not be predicted to greatly affect the overall charge 
of the C protein.
Among other flaviviruses sequenced in this region there appears to be 
considerable divergence of the amino acids which constitute the C protein, with 
conserved regions of hydrophobicity or hydrophilicity (Mandl et a/., 1988). The 
highly positively charged C protein is believed to be responsible for offsetting the 
negatively charged RNA with which it is associated. Since the amino acid 
substitutions observed in the C protein were conserved among the four FNV 
strains, there is a possibility that these changes were present in the original FVV 
strain from which the FNV vaccine strain was derived. Alternatively, they may 
have been fixed in the genome very early in the attenuation process when the 
selection pressure was at its greatest. This could have been due to an adaptive 
advantage, description of which is procluded by our limited knowledge of C 
protein structure-function relationship.
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prM protein: In the prM segment of the M protein gene, two nucleotide 
differences between FVV and the FNV strains were identified. One of these (at nt- 
554) gives rise to an amino acid substitution at position prM-25, where the valine 
residue of the wild-type virus is replaced in all four FNV strain viruses with a 
methionine. The prM portion of the M protein is essentially hydrophilic. 
However, this conservative substitution of one hydrophobic residue for another 
may not affect the overall structure of the protein.
As previously described, the prM glycoprotein is the precursor of the M 
protein and forms a heterodimeric complex with the E protein in immature virions 
(Heinz et a/., 1993). The function of prM appears to be protection of the E protein 
from irreversible conformational changes during passage through the acidic 
compartments of the secretory pathway. These changes are necessary, however, 
for fusion activity in the endosome and require the cleavage of prM. Recently, 
failure of the prM protein to cleave has been demonstrated to affect virulence of 
a TBE/DEN-4 chimeric virus (Pletnev et al., 1993). These findings encourage 
speculation that naturally occurring prM protein mutations may be attenuating. 
However, once again, limited understanding of the protein's structure-function 
relationships make the significance of the substitution at prM-25 in FNV viruses 
impossible to interpret.
M protein: Perhaps one of the most interesting results is the identification of a 
common amino acid substitution at position M-35, due to a nucleotide mutation 
at nt-854. An identical substitution of a leucine residue with a phenylalanine at
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this position was also observed to be conserved among the 17D vaccine strains. 
Although this substitution is predicted to be a conservative exchange of 
hydrophobic amino acid residues, the occurrence of an identical substitution in 
both wild-type/vaccine pairs during two very different attenuation processes, 
would suggest that this mutation plays a role in the attenuated phenotype.
Unfortunately, little is known about the function of the M protein. Recent 
studies have shown that flaviviruses virions which contain prM, rather than M, 
have lost or modified E protein epitopes, as recognised by MAbs (Guirakhoo et 
a/., 1992; HeinX et al., 1994). It is also relevant to note that purified DEN-2 M 
protein has been shown to elicit a neutralising antibody response in vivo (Brinton, 
1986), and is thought to be a component of the viral spike, and thus may be 
involved in some way with binding and entry of virus to cells.
The observed conservation of a leucine residue at position M-35 in the M 
protein of all wild-type YF viruses examined to date suggests that amino acid 
substitutions at this position may lead to conformational changes in the E protein 
and, consequently, are selected against. Such a conformational change may 
contribute to the loss of wild-type-specific epitopes and/or appearance of vaccine- 
specific epitopes on the E protein of vaccine viruses. Alternatively, the substitution 
in the M protein may affect the maturation or assembly of the vaccine viruses 
(perhaps in combination with the prM protein substitution), resulting in an 
attenuated phenotype. This amino acid substitution, therefore, merits further 
evaluation in order to elucidate more clearly its potential importance in
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attenuation.
E protein: Discussion of the amino acid mutations observed in the E protein can 
be divided into two areas; (1) the influence of the FNV-common amino acid 
substitutions on the attenuation of these viruses, and (2) the influence of protein 
sequence heterogeneity on the differential biological properties of the FNV strain 
viruses. These two issues are discussed separately below.
Three amino acid substitutions in the E protein at E-54, E-227 and E-249 
were revealed to be common to all four FNV strains. As mentioned previously, 
it has been demonstrated that the E protein of FNV shares an epitope with both 
the 17D-204 and 17DD substrains of the 17D vaccine virus which has been 
termed the vaccine-epitope. (Gould et a/., 1985; Sil et a/., 1992). Since there are 
no 17D/FNV-common amino acid substitutions in the E protein, it must be 
assumed that the appearance of the vaccine-epitope is due to a conformational 
change, not the result of a single specific E protein mutation. However, a 
noteworthy cluster of amino acid substitutions has been identified between E-52 
and E-56 (E-52 in all 17D strains, E-54 in all FNV strains and E-56 in the 17D-204 
substrain). It is, therefore, tempting to propose that these amino acid positions 
contribute to the vaccine-epitope. This would place the epitope in the A domain 
of the E protein (Mandl et a/., 1989). The possible role of this domain in 
endocytic fusion events and its proposed association with the prM protein 
prompts speculation that the prM/M substitutions may also contribute to the 
conformation of this E protein epitope.
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The FNV-common amino acid substitution at E-227, exchanging a glycine 
for a glutamic acid residue is unlikely to be important in the attenuation process 
as many wild-type viruses, including Asibi, also have a glutamic acid residue at 
this position (Hanh et al., 1987; Jennings, personal communication; Chang, 
personal communication).
The third FNV-common E protein amino acid substitution was found at 
position E-249, exchanging an asparagine residue in the wild-type virus for an 
aspartic acid residue in the FNV vaccine strains. Although both residues are 
hydrophilic, this substitution represents a charge change in the E protein with the 
substitution of a negatively charged residue for an uncharged one. This 
substitution occurs in a region which is generally highly conserved among 
flaviviruses and, consequently, may be of importance in the attenuation process. 
This region is not predicted to be within an antigenic domain, but may have a 
critical role in the conformational structure of the E protein.
The second issue to be discussed is the sequence heterogeneity observed 
between the FNV virus strains and how this relates to the different phenotypic 
properties of these viruses. Although all four FNV virus strains are believed to 
have originated from the Institut Pasteur, Dakar, sometime in the 1940's, the 
subsequent treatment and passage history of these viruses is unknown. Since 
divergence of these strains, a relatively high number of mutations have 
accumulated in the E protein, particularly in FNV-NT. One possible explanation 
for this observation is that propagation of the viruses in cell culture has exerted
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a new selection pressure on these viruses.
The mouse and monkey pathogenesis studies have revealed a number of 
interesting differences between the FNV strains, which may be partially due to 
their E protein sequence diversity. The reduced virulence of FNV-FC for mice 
inoculated both i.e. and i.n. cannot be explained on the basis of the findings 
presented here, as FNV-FC was not found to have any unique amino acid 
substitutions in the structural proteins and was shown to be closely related to 
FNV-IP. The biological differences observed between these two viruses are 
presumably encoded elsewhere in the genome. The increased virulence of FNV- 
Yale for mice inoculated by either route may be partially due to the unique amino 
acid substitution at E-61, close to the proposed vaccine-epitope at E-52/54/56. 
Substitution of a tyrosine residue with a serine residue, however, is conservative 
in terms of charge and polarity.
The significantly reduced neurovirulence of the FNV-NT virus strain was 
also noteworthy, as was the higher degree of divergence of this strain from the 
others. In the E protein of this virus strain there were found to be four amino acid 
substitutions over a region spanning only 17 residues, at E-139, E-140, E-151 and 
E-155, in addition to a fifth unique substitution at E-288. The extremely high 
mutation frequency in this region is indicative of a strong selection pressure. 
Furthermore, the previously published E protein sequence of the 17D vaccine- 
revertant, P-16065 (Jennings et a/., 1993), was found to have an amino acid 
substitution at E-155 (although the substituted amino acid is a glycine rather than
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an alanine residue), perhaps implicating this region in virus neurovirulence for 
primates.
In conclusion, it would be intriguing to apply infectious clone technology 
or in vitro  gene expression to investigate the relative importance of these findings, 
particularly the amino acid substitutions at position M-35, E-54 and E-249. 
However, further studies on the binding of these viruses to membrane receptors 
presented in Chapter 10 have contributed to our understanding of the role of the 
E protein in the attenuation of these viruses.
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CHAPTERS
Comparison of the nucleotide and deduced amino acid 
sequences of the structural, NS1 and NS2A proteins 
of the Asibi HeLa-passaged viruses
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5.1 Introduction
The previous two chapters have examined the nucleotide sequences of two 
attenuated YF virus variants; 17D derived by passage in chick embryo tissue and 
FNV derived by passage in mouse brain. In this chapter, a third route of 
attenuation is investigated. In the 1960% it was demonstrated that after only six 
sequential H ela cell passages of wild-type YF virus Asibi, the virus had lost its 
ability to cause viscerotropic disease in monkeys (Hardy, 1963; Hearn et al., 
1965, 1966; Converse et al., 1971). More recently, these results have been 
confirmed and extended by Miller and Adkins (1988), Barrett et al. (1990) and 
Dunster (1990).
Dunster (1990) performed a systematic biological characterisation of the 
series of YF viruses generated by six H ela cell passages of a large-plaque variant 
of wild-type Asibi virus (Asibi-LP; kindly provided by Dr. E.A. Gould) selected by 
pIaque-purification on Vero cells. The viruses were designated Asibi H ela-pl to 
p6. Following six serial passages in H ela cells, the virus became adapted for 
growth in H ela cells (Table 5.1). Evidence of adaptation included increasingly 
rapid appearance of cpe, larger plaque size and higher infectivity titres for Asibi 
Hel_a-p5 and p6 viruses.
Analysis of the Asibi-LP virus and its HeLa-passaged derivatives by IIF with 
a panel of E protein-specific MAbs demonstrated antigenic differences (Dunster, 
1990; Table 5.2). Sequential analysis of the series of HeLa-passaged viruses
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Cytopathic
effect
Infectivity 
titre $
Plaque
size
Asibi large-plaque + 5.2 LP
Asibi HeLa-pl - 4.6 LP
Asibi HeLa-p2 - 42 LP
Asibi HeLa-p3 + 42 LP
Asibi HeLa-p4 + 3.7 LP
Asibi HeLa-p5 + 75
*
LP
Asibi HeLa-p6 + 6.8
*
LP
Table 5.1: Characteristics of Asibi HeLa-passaged viruses. Adapted from Dunster (1990) 
*LP, large plaque: LP, large plaque with diameter >5mm:$ Infectivity titre measured in 
Logiopfu/ml
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S17
MAbs 
S18 S24 H5 H6
Virulence in 
newborn mice*
Asibi large-plaque + + + - 100%
Asibi HeLa-pl - - - - " 100%
Asibi HeLa-p2 - ■ - - - ~ 64%
Asibi HeLa-p3 - - - + + 8%
Asibi HeLa-p4 - - - + + 7%
Asibi HeLa-p5 - - + + <10%
Asibi HeLa-p6 - - - + + 10%
Table 5.2: Comparison of the antigenicity and virulence of the HeLa passaged viruses 
Taken from Dunster (1990). * Newborn mice inoculated with 100 pfu of virus
S17, S18, S24 - YF wild-type specific MAbs 
H5 - YF vaccine-specific MAb 
H6 - 17D substrain-specific MAb
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revealed that the wild-type-specific epitopes (recognised by MAbs SI 7, SI 8 and 
S24) were lost after the first He La passage. Reactivity of virus with vaccine-specific 
MAb H5, and 17D strain-specific MAb H6 commenced between H ela  passages 
two and three (Dunster, 1990).
Progressive HeLa-passaged isolates of Asibi-LP virus displayed a gradual 
attenuation of virulence for newborn mice which had been inoculated by the i.p. 
(Table 5.2). Wild-type Asibi-LP virus and Asibi HeLa-pl were lethal for mice (100 
% mortality), while Asibi HeLa-p2 virus exhibited reduced virulence (64% 
mortality) and the Asibi-LP HeLa p3 virus was attenuated (9% mortality) for 
newborn mice.
Consideration of these results as a whole revealed that attenuation of the 
Asibi-LP virus coincided with the appearance of cpe in HeLa cells and rising 
infectivity titre, and also, perhaps most importantly, with the acquisition of YF 
vaccine-specific epitopes defined by MAbs H5 and H6. However, the loss of the 
YF wild-type-specific epitopes defined by MAbs SI 7, SI 8 and S24 was observed 
in Asibi HeLa-pl virus, a virus which was as virulent as its parent. This provides 
circumstantial evidence that E protein conformational changes were involved in 
the attenuation process.
The passage of wild-type YF virus in HeLa cells provides a model system 
for analysis of attenuated variants of YF virus obtained after very few passages in 
cell culture. As a result, the Asibi HeLa-p6 virus would be expected to have few,
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if any, mutations not associated with the attenuated phenotype. In contrast, the
17D and FNV attenuated variants represent viruses, which were derived by 
- •
extensive empirical passaging, have accumulated many mutations, hindering the 
determination of the molecular basis of attenuation. In this study, nucleotide 
sequence data was accumulated for representative viruses from the HeLa-passaged 
virus series of Dunster (1990) with the intention of contributing to the elucidation 
of attenuating mutations in the virus genome.
5.2 Results
5.2.1 Amplification, cloning and sequencing of the viral RNA
The Asibi HeLa-p3 and p6 viruses derived by Dunster (1990) were selected 
for study, for reasons explained in the following sections. A number of clones of 
each RT-PCR-amplified region were sequenced as clonal variation was observed 
to be relatively high. Table 5.3 shows the number of clones sequenced for each 
RT-PCR-amplified region of the genome.
Asibi HeLa-p3 virus: This virus was selected as it has previously been identified 
as the first passage level at which the virus exhibited the vaccine-specific 
epitope(s) and was completely attenuated for newborn mice (Table 5.2). The M 
and E protein-encoding genes were amplified by RT-PCR in four overlapping 
fragments using primers CAG-YF7, AJ7UP-YF302, YF301-YF597 and EBIT-YF100.
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Number of clones 
sequenced
PCR fragment Size (bp) Asibi HeLa-p3 Asibi HeLa-p6
B5-YF300 677 - 2
CAG-YF7 687 3 7
1 AJ7UP - YF302 550 3
s
1 YF301-YF597 562 3 - ■
EBIT-YF100 434 3 -
AJ7UP - YF100 1331 - 6
1 SNSla-ANSla 685 4
n
$ SNSlb - ANSlb 747 - 3
a
2 SNS2A - ANS2A 615 - 5
Table 5.3: PCR fragments amplified for the Asibi HeLa-passaged viruses.
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Asibi HeLa-p6 virus: The majority of biological and antigenic studies have been 
performed on the Asibi HeLa-p6 virus, and therefore this virus was also selected 
for sequence analysis. The 5' non-coding region and the region of the genome 
encoding the C, prM, M, E, NS1 and NS2A proteins were amplified by RT-PCR 
in seven overlapping fragments using primer pairs B5-YF300, CAG-YF7, AJ7UR- 
YF100, SNSIa-ANSIk, SNSIC-ANSld and SNS2A-ANS2A (see Chapter 2 for 
positions).
Due to difficulties encountered in the RT-PCR amplification of viral RNA 
extracted from H ela cell culture supernatant, the viruses had to be propagated on 
a HeLa cell monolayer using a stock virus of the preceding passage level (i.e. 
Asibi HeLa-p2 or p5) for infection. Virus was harvested at approximately 90% cpe 
and viral RNA was extracted and amplified immediately. As a result, the virus 
sequenced was not identical to the virus characterised by Dunster (1990). To 
address this problem, two separate working stocks of Asibi HeLa-p6 virus were 
generated from the same stock of Asibi HeLa-p5 virus. The CAG-YF7 defined 
region of the second Asibi HeLa-p6 virus isolate was amplified and sequenced for 
comparison.
5.2.2 Comparison of nucleotide and deduced amino acid sequence of Asibi
HeLa-p6 virus with wild-type Asibi virus
The nucleotide sequence for the region extending from the 5' terminus of 
the genome to nt-4219 of the Asibi Hel_a-p6 virus was determined and compared
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with the sequence of the wild-type Asibi virus (Hahn et a/., 1987; Table 5.4). This 
region included the genes which encode the C, prM, M, E, NSI, NS2A and NS2B 
proteins. The sequence of the M and 5Z end of the E protein genes for a second 
isolate of Asibi HeLa-p6, separately amplified from Asibi HeLa-p5, was also 
determined and compared.
Overall, in all of the cDNA clones analysed, 24 nucleotide positions were 
found to differ from the sequence of the wild-type Asibi virus, from a total of 
22,153 nucleotides sequenced. This corresponds to a divergence of 0.11 % after 
adjustment for the number of clones sequenced and the degree of overlap 
between fragments. No nucleotide substitutions were observed in either of the 
two cDNA clones covering the 5' non-coding region and the genes encoding the 
C and prM proteins.
M protein: One nucleotide substitution was identified in the M protein gene, 
which was found to encode the substitution of a valine residue in the wild-type 
virus for an alanine in Asibi HeLa-p6 at position M-67. This amino acid 
substitution was conserved among ALL clones of Asibi HeLa-p6 virus sequenced, 
from two separate derivations of Asibi HeLa-p5.
E protein: A total of 15 nucleotide substitutions were identified in the E protein 
gene, which equates to a 0.15% divergence. Nine of these encoded amino acid 
substitutions; a 0.27% amino acid divergence. However, only two nucleotide 
changes at nt-1054 and nt-1345 were shown to be shared by ALL clones of Asibi
MNucleotide Asibi* Asibi HeLa-p6 Amino acid Substitution Occurrence 5
948 T C M-67 V to A 777
1054 A C E-27 Q to H 777
1345 C T - - 6/6
1365 A T E-130 D to V 1/6
1420 A T E-149 Q to H 1/6
1444 G T E-157 K to N 1/6
1579 C T - - 1/6
1819 C T - - 4/6
1839 C T E-289 A to V 1/6
1948 C T - - 1/6
2017 T C - - 1/6
2052 A G E-360 D to G 1/6
2098 C T E-369 P to S 1/6
2129 A G E-385 T to A 1/6
2217 A T E-415 D to V 1/6
2245 A G - - 1/6
2466 T C 1/10
2669 G C NS1-73 D to H 1/4
1 2971 T C - - 1/4
3032 G A NS1-193 A to T 177
3409 G A - - 1/3
3622 G A - - 2/8
A 3925 A T - - 2/54081 T C - - 2/5
Table 5.4: Comparison of the nucleotide and deduced amino acid sequences of the 
wild-type Asibi virus and its HeLa cell-passaged derivative, Asibi HeLa-p6.
* Asibi sequence taken from Rice et al (1985)
Number of clones sequenced at this position (some are overlapping) and 
the number of times this mutation occurs.
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4Vie.se. (ïnuIaVûAs  were.
HeLa-p6 sequenced. Also,^once again conserved for both derivations of Asibi
HeLa-p5. The former change resulted in a common histidine for glutamine amino 
acid substitution at E-27, while the substitution at nt-1345 was found to be non­
coding. The distribution of the E protein gene mutations among the various clones 
is depicted in Figure 5.1.
NS1 protein: Six nucleotide and two resultant amino acid substitutions were 
identified in the NS1 protein gene, distributed relatively evenly among the cDNA 
clones sequenced. This corresponds to a 0.11% nucleotide divergence, and a 
0.11% amino acid divergence.
NS2A protein: In the NS2A protein gene, two non-coding nucleotide mutations 
were found, representing a 0.07% divergence from the wild-type Asibi sequence.
5.2.3 Comparison of the nucleotide and deduced amino acid sequence of Asibi 
HeLa-p3 and Asibi HeLa-p6 viruses
Due to the sequence diversity observed in the Asibi HeLa-p6 virus, the 
region encoding the M and E proteins of the first mouse-attenuated virus, Asibi 
Hela-p3, was also sequenced for comparison. The results are presented in Table 
5.5.
M protein: The same amino acid substitution found in the M protein of Asibi 
HeLa-p6 at M-67, was also found in all three clones of Asibi HeLa-p3 sequenced
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Figure 5.1. Distribution of the M and E protein gene mutations among clones 
sequenced. Thick line; division between M and E protein genes: thin line; postions 
of mutations: dotted line division between PCR fragments. Above the box is the 
nucleotide position numbered from the 5’-end of the genome; below the line is the 
amino acid position numbered from the N’-end of the protein.
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Nucleotide Asibi Asibi HeLa-p3 Asibi HeLa-p6 Amino acid Substitution
!  948 T C c M-67 V to A
10547 A C c E-27 Q to HJ
1819 C T/C T/C ' - -
Table 5.5: Comparison of the M and E protein gene sequence of Asibi HeLa-p3 and 
Asibi HeLa-p6 viruses.
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in this region. The remainder of this region was shown to be identical to the wild- 
type Asibi sequence of Hahn et a/. (1987).
E protein: Much less diversity was observed in the E protein gene of the Asibi
HeLa-p3 virus than in the Asibi HeLa-p6 virus, with mutations identified at only
three nucleotide positions; nt-1054, nt-1345 and nt-1819. This equates to a 0.07%
nucleotide divergence. Only the first of these nucleotide mutations was found in
all three clones sequenced in this region and resulted in an amino acid
<r
substitution. This amino acid change occurred at position E-27 and was identical 
to the one seen in the Asibi HeLa-p6 virus. This corresponds to a 0.07% amino 
acid divergence.
5.3 Discussion
The data presented in this chapter extends the current knowledge 
pertaining to the attenuation of wild-type YF viruses following six passages in 
HeLa cells by introducing the first information on the genetic processes involved. 
In addition, comparison of the Asibi/Asibi HeLa-p6 pair with the wild-type/vaccine 
pairs examined in the previous two chapters (Chapters 3 and 4) will contribute 
to understanding of the attenuation process.
Hearn et a/. (1965, 1966) previously proposed that during the initial 
passages in HeLa cells (HeLa-pl to p3) YF virus was largely unstable and
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represented a population of virions of mixed biological properties. The authors 
suggested that selection may take place from the parent population with 
subsequent passages in HeLa cells leading to selective amplification, genetic 
modification and to a stable population of virus at higher He La passage levels.
The sequence data presented in this study for the M and E protein genes 
of the Asibi HeLa-p3 virus generated by Dunster (1990) reveals that this virus has 
undergone little genetic divergence from the previously reported sequence of the 
parent virus, Asibi (Hahn et a/., 1987), differing by only 0.07% overall at the 
nucleotide level in this region.
The two amino acid substitutions at M-67 and E-27 observed in this region 
were found to be conserved in all variants analysed. This suggests that, at HeLa- 
p3, the virus represents a relatively stable population and the variants sequenced 
represent the majority of that population. Two possibilities exist to explain these 
findings; either very few mutations have occurred in the passages between the 
plaque-purified Asibi-LP virus and the Asibi HeLa-p3 virus or these particular 
mutations have an adaptive advantage over other mutations arising in the 
genome. The latter hypothesis is supported by the studies of Dunster (1990). 
Although passaging of the virus was performed at high moi (1 to 5), because 
previous work (Hardy, 1963) had shown HeLa cells to be relatively refractive to 
infection by wild-type YF virus, cpe on HeLa cells was not apparent until HeLa- 
p3. The appearance of cpe was coincident with greatly increased virus titre. This 
is suggestive of a selection for a variant in the population which is progressively
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amplified to higher proportions with each passage until it comes to represent the 
dominant population.
During successive passages in HeLa cells the virus accumulates an 
increasing number of mutations, shown by the greater degree of diversity in 
variants of the Asibi HeLa-p6 virus. However, these variants obviously derive from 
the viruses identified at the third pasage level, having identical amino acid 
substitutions at M-67 and E-27, supporting the previous hypothesis that these 
changes were initially selected.
A higher rate of amino acid substitution was found in the E protein of the 
Asibi HeLa-p6 virus than in any of the other proteins analysed (0.27% in the E 
protein as opposed to 0.11% in NS1). This represents a greater proportion of 
mutations encoding amino acid substitutions (60 % in the E protein compared to 
33% in NS1) rather than a higher incidence of nucleotide substitution. 
Accordingly, it is speculated that the E protein amino acid substitutions are being 
selected for, and not arising randomly in the population, as suggested in both the 
Asibi/17D (Hahn et a/., 1987) and the FVV/FNV (Jennings et a/., 1992) wild- 
type/vaccine pairs. These amino acid substitutions may be beneficial to the virus 
for growth in the H ela cell culture system and may contribute to the constantly 
evolving phenotype of the HeLa-passaged viruses. Figure 5.1 shows that the 
additional amino acid mutations appear to be grouped in two regions, both of 
which lie in antigenic domains on the surface of the E protein, possibly indicating 
a role in the receptor-binding, membrane-fusionA packaging of the virus.
It has been suggested that mere selection is not the process by which 
attenuated YF variants arise following passage in H ela cells, because the parent 
virus was plaque purified and, thus, would be expected to represent a relatively 
homogeneous population of virions. Consequently, it has been proposed that a 
combination of primary selection and selective pressure exerted by the HeLa cells 
are manifested as genetic changes rapidly acquired upon passage. The data 
presented here are consistent with such a hypothesis.
It is conceivable that the mutations identified in some but not all cDNA 
clones from the same RT-PCR procedure represent errors introduced by reverse- 
transcriptase or Taq polymerase. This is considered unlikely for a number of 
reasons outlined below. No mutations were observed in the two cDNA clones 
examined for the S'terminal 677 nucleotides of the genome and the seven cDNA 
clones examined, from two independant RT-PCR amplifications of nt-625 to nt- 
1312, contained only two conserved amino acid mutations. Furthermore, the 
three cDNA clones of this same region from the Asibi Hel_a-p3 virus exhibited the 
same two mutations. Thus, it is proposed that the majority, if not all, of the 
mutations observed in the cDNA clones are real and represent variation in the 
HeLa-passaged virus population, not RT-PCR error.
Biological characterisation of the HeLa-passaged virus series by Dunster 
(1990) has identified the third passage in HeLa cells (from Asibi HeLa-p2 to p3) 
as being important in the attenuation process. As discussed previously, cpe and 
high virus infectivity titre were first seen at this passage level. Additionally, the
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vaccine-specific epitopes recognised by MAbs H5 and H6 were first in evidence 
on the E protein of the Asibi Hel_a-p3 virus and attenuation of the virus for 
newborn mice was shown to be coincident with the appearance of these epitopes.
These results suggest that antigenic changes in the viral E protein may 
determine the relative virulence or attenuation of YF virus. Only two amino acid 
substitutions were identified in the M and E protein sequence of Asibi HeLa-p6 
and these were found to be conserved among all variants analysed. Therefore, 
these amino acid substitutions were implicated in the appearance of the vaccine- 
specific epitopes described above, and also in the attenuation of the virus.
The amino acid substitution in the M protein at position M-67 exchanges
a valine residue in the wild-type Asibi virus for an alanine residue in the Asibi
Hel_a-p3 virus. This substitution is relatively conservative, substituting one
hydrophobic, non-polar amino acid for another. However, the mutation lies
within the E protein signal peptide identified by Rice et a/. (1986) and Desprès
et al. (1988, 1990), which extends from M-61 to M-75. It was proposed that the
insertion mechanism of the YF virus E protein into the rough endoplasmic
reticulum membranes requires the 15 amino acid residues preceding the amino
*in$
terminus of the E protein as an internal signal sequence. Accordly, the substitution 
of an amino acid in this region may influence the conformation and presentation 
of the E protein on the surface of the mature virion.
The amino acid substitution at E-27 in the E protein replaces a glutamine
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residue in the wild-type Asibi virus with a histidine residue in the Asibi HeLa-p3 
virus. This substitution results in a charge change at this position, suggesting that 
a conformational change may occur in the E protein. Although this position is 
relatively distant in the primary amino acid sequence from the E-52/E-54/E-56 
amino acid group proposed as the site of the vaccine-specific epitope in the 
previous chapters (Chapters 3 and 4), referral to the two-dimensional E protein 
model of Mandl et al. (1989) indicates that all four changes are located in domain 
A (Figure 5.2). Furthermore, the proposed folding of this domain places these 
amino acids spatially near to each other. If correct this may explain the vaccine 
epitope(s) shared by the three attenuated strains.
Loss of the E protein wild-type-specific epitopes after the first HeLa cell 
passage may be due to an epigenetic change, encoded by the host cell. For 
example, the E protein may undergo different post-translational modification in 
this cell line and, as a result, be presented differently on the surface of the virus. 
Alternatively, either the M or the E protein amino acid substitution may have 
existed at this low passage level. Unfortunately, the non-HeLa-passaged parent 
Asibi-LP virus and the derivative Asibi HeLa-pl and p2 viruses were not available 
for sequence comparison to clarify this point.
In this study, the nucleotide and deduced amino acid sequence was 
determined for more than one third of the genome of the Asibi HeLa-p6 virus. In 
this region amino acid changes conserved among all the variants analysed were 
identified only in the M and E proteins. The existence of the same changes in
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Figure 5.2: The positions of the E-27, E-52, E-54 and E-56 amino acid residues 
on the two-dimensional model of the E protein.
Adapted from Mandl et al. (1989b).
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Asibi HeLa-p3 virus implicates them and the proteins in which they occur in the
attenuation of the Asibi He La-passaged viruses. Conversely, the 5Z non-coding
-
region and the C, prM, NS1 and NS2A proteins appear not to contribute to the 
attenuated phenotype of the Asibi HeLa-passaged viruses.
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CHAPTER 6
Molecular and biological analyses of YF variant viruses with and 
without a wild-type specific E protein epitope
6.1 Introduction
As discussed previously, it is well established that the 17D-204 vaccine 
viruses consist of a heterogeneous population of variants differing in plaque 
morphology (Woodall, 1981; Liprandi, 1981), mouse virulence (Liprandi, 1981; 
Barrett & Gould, 1986; Gibson et al., 1990), oligonucleotide fingerprint patterns 
(Monath et al., 1983) and antigenicity (Gould et al., 1985b; Buckley & Gould, 
1985; Barrett et al., 1989; Gould et al., 1989; Ledger et al., 1992). Gould et al. 
(1989) were able to identify wild-type antigenic variants in several different 17D- 
204 vaccine pools using a YF wild-type-specific MAb (MAb 117), which has been 
demonstrated to react only with an E protein epitope on the surface of wild-type 
YF viruses. When IIF tests were performed with MAb 117, virus-specific 
cytoplasmic fluorescence was occasionally observed in one or two cells infected 
with 17D vaccine virus.
One antigenic variant, isolated by plaque-purification from a 17D-204-UK 
vaccine pool, produced fluorescence with wild-type-specific MAb 117 almost 
equal to that obtained with hyperimmune rabbit antiserum against 17D-204-UK 
virus, demonstrating that most, if not all, of the virus present in the preparation 
contained the wild-type epitope. This antigenic variant, designated 17D(+wt), 
also produced fluorescence with 17D-204 substrain-specific MAb 864, but was 
negative with YF vaccine-specific MAb 411. This suggests that in acquiring the 
wild-type epitope recognised by MAb 117, the E protein had lost some of the 
antigenic characteristics of the parental 17D-204-UK vaccine virus. In IIF tests, no
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other plaques (from a total of 50) produced fluorescence with MAb 117, but all 
were strongly positive with both MAb 864 and MAb 411.
Eight of the 50 plaque-purified variants were compared for their ability to 
produce neurovirulent infections in newborn and adult mice via the i.e. route of 
inoculation (Gould et a/., 1989). All the viruses were highly neurovirulent in 
newborn mice. However, in adult mice only the 17D(+wt) variant was shown to 
equal the neurovirulence of non-plaque purified 17D-204-UK virus and Asibi 
wild-type virus. In contrast, the variants lacking the MAb 117 wild-type epitope, • 
but with vaccine-specific epitopes (identified by MAb 411 and MAb 864), were 
attenuated in adult mice, producing no more than 40% lethality. One of the latter 
variants, designated 17D(-wt), was shown to infect mice and induce antibody 
(Gould et a i,  1989). Viral antigen was still detected in the brains of the surviving 
mice four weeks post-inoculation. The authors suggested that this was due to the 
development of a persistent infection.
In this study, the information accumulated by Gould et al. (1989) regarding 
the pathogenesis of the 17D(+wt) and 17D(-wt) variant viruses in mice is 
expanded. In addition, the molecular determinants of the phenotypic properties 
of these viruses have been investigated.
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6.2 Results
6.2.1 Mouse neurovirulence of the 17D(-wt) and 17D (+w t) variant viruses
The 17D(+wt) and 17D(-wt) variant viruses isolated and characterised by 
Gould et al. (1989) were kindly provided by Dr. E.A. Gould. The variant viruses 
were compared for mouse virulence with Asibi and their parent virus 17D-204- 
UK. These results were tabulated in Table 6.1 alongside the results taken from 
Gould et al. (1989).
Following i.e. inoculation of these viruses into groups of 10 mice (3-4 
weeks old) at concentrations of 1, 10 and 100 pfu, Gould et al. (1989) found that 
the 17D(-wt) variant virus was completely avirulent. In contrast, the 17D(+wt) 
variant, the non-plaque purified 17D-204-UK virus and the wild-type Asibi virus / 
were all equally virulent at all three doses administered.
In this study, to further investigate the virulence of these viruses, virus 
doses of 103 pfu were administered to larger groups of adult mice by the i.e. 
route. The wild-type Asibi virus and 17D-204-UK vaccine virus were found to be 
lethal for all mice. By comparison, the 17D(+wt) variant was found to have 
reduced lethality and the 17D(-wt) variant was greatly attenuated.
The apparent differences observed between the results obtained by Gould 
et al. (1989) and those presented here may be due to either the higher dose of
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Virus Number dead/ number inoculated % mortality
Average survival 
time (AST) in days
17D-204-UK 10/10 100% 10.3+0.6
ITD(-wt) 8/45 17.7% NA
17D(+wt) 17/20 85% 10.1+0.5
ITD(-wt) NK 0% NA
17D(+wt)* NK 100% NK
Table 6.1: Neurovirulence of the 17D(-wt) and 17D(+wt) variant viruses compared with
17D-204-UK. Adult mice inoculated i.c. with lÿ  pfu of virus.
* Taken from Goulds/a/(1989)
NA: not applicable 
NK: not known
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virus administered in this study or the different outbred mouse strain used. 
Alternatively, it may be a reflection of the larger group sizes of mice inoculated.
6.2.2 Replication of the 17D(-wt) and 17D(+wt) variant viruses in mouse brain
In an experiment performed in parallel with the one described above, 
groups of adult outbred NIH Swiss mice were inoculated with 103 pfu of virus by 
the i.e. route. Mice were sacrificed and their brains were harvested at two, three 
and eight days post-inoculation for virus titration, as described previously in 
Chapter 2, and histopathological examination (Section 6.2.4). A group of control 
mice were inoculated with the 17D-204-UK virus.
At the early time-points, two and three days post-inoculation, 17D-204-UK 
virus was detected at titres ranging from 4.5 x 105 to 7.5 x 105 pfu/brain (Table 
6.2). Eight days post-inoculation these titres had increased in excess of 6.8 x 105 
pfu/brain and mice were showing signs of clinical disease.
Two days post-inoculation, 17D(-wt) virus titres ranged from 15 to 3 x 102 
pfu/brain and was detected in all three mice sampled. However, by three days 
post-inoculation infectious virus was detectable in only one mouse out of three 
at 104 pfu/brain. Eight days post-inoculation similar results were obtained: the 
brain of one mouse (which was observed to be sick) had 1.6 x 103 pfu, while 
infectious virus had been cleared from the brains of two more mice to levels 
below the sensitivity of this assay (< 15  pfu/brain).
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Virus Daypost-inoculation
Infectivity 
titre (pfu/brain)
Viral RNA 
detectable by RT-PCR
>7.5 x 105 
>7.5 x 105 
>7.5 x 105
17D-204-UK ' 3
6.0 x 104 
4.5 x 104 
6.3 x 104
- 8
6.8 x 105 
6.0 x 106 
1.7 x 106
+
+
+
15
3.0 x 10 2
3.0 x 10 2
17D(-wt) 3
1.0 x 104
<15
<15
8
1.6 x lO3
<15
<15
’ + 
+ 
4-
2
1.5 x 10 3 
2.4 x 10 4 
9.0 x 10 3
17D(+wt)
8 ' .' ■ ■
7.5 x 103
4.5 x 103
2.0 x 104
3.6 x 105
2.0 x 106 
5.3 x 10s
Table 6.2: Infectivity titres in infected mouse brain homogenate. PCR results taken 
from Figure 6.2
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Two and three days post-inoculation, mouse brains infected with the 
17D(+wt) variant virus held between 1.5 x 103 and 2.4 x 104 pfu/brain. By eight 
days post-inoculation these titres had risen to in excess of 3.6 x 10s pfu/brain and 
all mice were displaying clinical signs of encephalitis.
6.2.3 Histopathologic and immunocytochemical examination of brain sections
Brain sections from mice infected with the 17D-204-UK parent virus or 
with the 17D(-wt) variant virus were examined by Dr. G. Campbell. Routine 
haematoxylin and eosin staining revealed little pathology. In both cases menigeal, 
perivascular and parenchymal inflammation was observed. In the 17D-204-UK- 
infected brain sections microglial nodules were also identified and, by 
immunocytochemical staining, viral antigen was also sporadically detected in 
microglial cells. In contrast, no viral antigen was detected in mouse brain infected 
with the 17D(-wt) variant virus.
6.2.4 Persistence of the 17D(-wt) variant viral RNA in mouse brain
RT-PCR was performed to determine whether any viral RNA persists in the 
mouse brain at time-points after clearance of infectious virions to a level below 
plaqueassay detection. In these preliminary investigations, RT-PCR was performed 
on the mouse brain homogenates assayed in Section 6.2.2 using primers for the 
E protein gene (AJ7UP-YFT00). As shown in Figure 6.1 and Table 6.2, viral RNA 
could be detected in the brains of all three mouse brains at eight days post-
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1 3 5 3  
1 0 78  
872
6 0 3
Figure 6.1: Viral RNA amplified by RT-PCR from homogenised mouse brain, separated by gel 
electrophoresis. RT-PCR primers were AJ7UP-YF100 (1331 bp).
Mice were infected with the 17D(-wt) variant virus by the i.e. route.
Lane 2: 8 days post-inoculation (A)
Lane 3: 8 days post-inoculation (B)
Lane 4: 8 days post-inocualtion (C)
Lane 5: negative control (RNA extracted from uninfected mouse brain
Lane 1: 0X174 molecular weight markers
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inoculation. Negative and positive controls included in Figure 6.1 are an 
uninfected NIH Swiss mouse and viral RNA extracted from cell culture 
supernatant, respectively. The cDNA fragment amplified in these experiments 
represented over 1.3 kb of the genome. Consequently, a positive result suggested 
that the viral genome was intact, not degraded.
6.2.5 Amplification, cloning and sequencing of the viral RNA
17D(+wt) virus: The M and E protein genes of the 17D(+wt) variant virus (which 
possesses the MAb 117-defined wild-type epitope) were amplified by RT-PCR in 
two overlapping fragments using primer pairs CAG-YF7 and AJ7UR-YF100.
17D(-wt) virus: The entire genome of this virus was amplified by RT-PCR in 17 
overlapping fragments using the primer pairs presented in Chapter 2.
Gel-purified cDNA fragments were cloned using the TA cloning system 
(Chapter 2) and sequenced by the dideoxynucleotide chain termination method. 
As described previously, for each cloned cDNA fragment at least two separate 
clones were selected for sequence analysis. No clonal variation was observed, 
however.
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6.2.6 Comparison of the M and E protein gene nucleotide and deduced amino
acid sequence of the parent and variant viruses
In order to locate the wild-type-specific epitope recognised by MAb 117 
in the primary amino acid sequence, the nucleotide sequence of the region which 
encodes the M and E proteins (extending from nt-749 to nt-2453) was determined 
for each of the two variant viruses. Table 6.3 provides a comparison between the 
nucleotide and deduced amino acid sequences of the region encoding the M and 
E proteins for the two variant viruses 17D(+wt) and 17D(-wt), their parent virus 
17D-204-UK (data taken from Chapter 3) and the wild-type Asibi virus (Hahn et 
a/., 1987).
The 17D-204-UKvaccine virus was previously shown in this study to differ 
from its wild-type Asibi parent virus by 18 nucleotide substitutions over the 1704 
nucleotides encoding the M and E proteins. A total of 13 resulting amino acid 
substitutions were identified, one in the M protein and 12 in the E protein.
Comparison of the M and E protein gene nucleotide and deduced amino 
acid sequence of the 17D(-wt) variant virus revealed that this virus was identical 
to its 17D-204-UK parent virus at all of the positions at which 17D-204-UK differs 
from Asibi virus. Additionally, the 17D(-wt) variant virus exhibited four nucleotide 
changes from both the Asibi and 17D-204-UK viruses, one of which (nt-1692) was 
found to encode the substitution of a valine for an alanine residue at position E- 
240 in the E protein. The other three nucleotide mutations (nt-1507, nt-2023 and
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nucleotide Asibi 17D-204-UK I I amino acid substitution
854 C T , T T M-35 L to F
883 A G G G
1127 G A A A E-52 G to R
1140 C T T T E-56 A to V
1482 C T T T E-170 A to V
1491 C T T c E-173 T to I
1507 T T C C -
1572 A C C C E-200 K to T
1692 C , v  c T ' t E-240 À to V
1750 C T T T - -
1819 c T T T - -
1870 G A A A E-299 M to I
1887 C T T T E-305 S to F
1946 C T T T E-325 P to S
1965 A G G G E-331 K to R
2023 T T C C - -
2112 C A A A E-380 T to R
2193 C T T T E-407 A to V
2219 c T T T E-416 A to T
2356 G A A A
2437 T T C C - -
Table 6.3: Comparison of the M and E protein gene sequences of Asibi, 17D-204-UK
17D(-wt) and 17D(+wt). Q  Amino acid substitutions; □  non-coding nucleotide mutations 
Asibi senuence taken from R ( 19R5Y
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nt-2437) were silent.
The M and E protein gene sequence of the 17D(+wt) variant virus 
demonstrated that this virus was identical to the 17D(-wt) variant virus except for 
one nucleotide mutation from the 17D-204-UK and 17D(-wt) viruses at nt-1491. 
This encodes the substitution of a threonine residue in the 17D-204-UK virus for 
an isoleucine residue in the 17D(+wt) variant at position E-173 in the E protein. 
Comparison with the sequence of the Asibi virus at this position reveals that this 
nucleotide and resulting amino acid substitution represent a reversion to the wild- 
type.
To further investigate the molecular basis of the attenuation exhibited by 
the 17D(-wt) variant, the nucleotide sequence for the entire genome was 
determined. Table 6.4 provides a comparison of the nucleotide and deduced 
amino acid sequence of the genomes of the wild-type Asibi virus (Hahn et a/., 
1987), the 17D-204-ATCC vaccine virus (Rice et a/., 1985), the 17D-204-France 
vaccine virus (Deprés et a/., 1987; Grange et a/., 1985; Dupuy et a/., 1989) and 
the 17D(-wt) attenuated variant virus.
Over the entire 10862 nucleotides of the genome, the 17D(-wt) variant was 
shown to be identical to the 17D-204-France vaccine virus, except for the four 
nucleotide changes identified in the E protein gene which were mentioned above 
(Section 6.2.5). Consequently, the alanine to valine substitution revealed in the 
E protein of the 17D(-wt) variant at E-240 represents the only amino acid change
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Nucleotide Amino acid Asibi 17D-204-ATCC 17D-204-France ITD(-wt)
854 M-35 L F - F F
1127 E-52 G R R R
1140 E-56 A V v ;  v  ■ V
1482 E-170 A V V V
1491 E-173 T I I I
1572 E-200 K T T T
1692 E-240 A A A V
1870 E-299 M I I I
1887 E-305 S F F F
1946 E-325 P s s S
1965 E-331 K R . R R
2112 E-380 T R R R
2193 E-407 A V V V
2219 E-416 A T ' T . T
2687 NS1-79 L F F F
3371 NS1-307 I V V V
3860 NS2A-61 M V V V
4007 NS2A-110 T A A A
4013 NS2A-112 L F F F
4022 NS2A-115 T A A A
4056 NS2A-126 S F F F
4289 NS2B-37 I L L L
4505 NS2B-109 I L L L
4507 NS2B-109 I L L L
5153 NS3-195 I V V V
6023 NS3-485 D N N N
6758 NS4A-107 I V I I
6876 NS4A-146 V A A A
7171 NS4B-95 I M M M
7319 NS4B-145 E E K K
7580 NS4B-232 Y H H H
7701 NS5-22 Q R R R
9605 NS5-657 N D N N
10142 NS5-836 E K K K
10338 ' NS5-900 P L L L
Table 6.4: Comparison of the amino acid substitutions between Asibi, 17D-204-ATCC 
17D-204-France and!7D(-wt). The amino acid position at which 17D(-wt) virus differs 
from 17D-204-France is highlighted.
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in the virus structural proteins. No changes were found in the non-structural 
proteins or in the non-coding regions at the 5 ' and 3' termini of the genome.
6.3 Discussion
Study of the 17D(+wt) and 17D(-wt) variants of the 17D-204-UK vaccine 
viruses has contributed to our knowledge of the attenuation of wild-type YF 
viruses in two areas. Firstly, the position of the wild-type-specific epitope 
recognised by MAb 117 in the primary amino acid sequence has been mapped. 
This is the first wild-type epitope mapped for YF virus. Secondly, the entire 
genomic sequence of the 17D(-wt) variant, which was more attenuated than its 
parent virus, has been determined and the attenuating mutation identified at E- 
240. These findings are discussed in more detail below.
The 17D(-wt) variant virus has been clearly demonstrated to be attenuated 
for neurovirulence in the mouse model, as compared to the 17D-204 vaccine 
viruses examined which are invariably lethal. As the first example of a YF virus 
attenuated for mouse neurovirulence, the pathogenesis of the 17D(-wt) variant 
was considered to be worthy of further analysis. Viral pathogenesis can be 
described as a series of steps, analogous to a biochemical pathway, whose 
endpoint is disease in the infected host. Consequently, attenuation of virulence 
may result from blocking of virus replication at different steps in the pathogenesis 
pathway.
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In the study of Gould et al. (1989) the 17D(-wt) variant was shown to be 
completely avirulent at doses of 1, 10 and 100 pfu of virus administered by the 
i.e. route to adult mice. However, in this study, a higher dose of virus (103 pfu) 
was found to kill 17.7% of the mice. Therefore, it appears that the 17D(-wt) 
variant virus was able to replicate in mouse neural tissues, but that fatal 
encephalitis did not necessarily ensue.
The attenuated 17D(-wt) variant was shown by Gould et al. (1989) to 
replicate to lower titre in mouse brain than the parent 17D-204-UK virus and 
other neurovirulent YF viruses. In this study, virus infectivity titrations performed 
on infected mouse brain two, three and eight days post-inoculation revealed that 
the course of infection differed between strains. The 17D-204-UK virus quickly 
establishes an infection of the CNS and continues to replicate until the mouse 
dies. The 17D(+wt) variant virus behaves similarly and, although it replicates to 
lower titre, the AST is not altered.
Infection with the 17D(-wt) variant virus was, however, quite distinctive. 
Virus infection of the brain was established at a slower rate and virions were only 
detectable in one out of three mice sacrificed at days three and eight post­
inoculation. This intermediate virulence phenotype appears to reflect differences 
in the susceptibility of individual mice to viral infection. The level at which 
resistance to infection occurs cannot be identified at this time. Further studies to 
investigate the pathogenesis of this variant virus in inbred mouse strains are 
necessary to determine whether or not a host genetic restriction is responsible.
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Such a phenomenon has previously been observed in the murine immune 
response to JE virus infection (Wills et al., 1993), but this is only one of a many 
possibilities.
Both virus variants 17D(+wt) and 17D(-wt) were found to have four 
identical nucleotide mutations from the 17D-204-UK virus (Chapter 3) in the E 
protein gene, one of which encoded an amino acid substitution. The existence of 
identical mutations in two separate variant viruses, plaque-purified from the same 
parent virus population, suggests that these mutations were also present in the 
majority of variants in the non-plaque-purified 17D-204-UK parent virus. The 
17D-204-UK virus from which the variants were selected by Gould et al. (1989) 
and the 17D-204-UK virus analysed in Chapter 3 originated from different 
vaccine batch numbers (YF 1/274 and BYF 1228, respectively). Therefore, the 
possibility exists that the predominant population of variants in the two 17D-204- 
UK viruses differ in sequence.
At the amino acid level the attenuated 17D(-wt) variant was shown to differ 
from the 17D-204-France vaccine virus (Deprés et al., 1987; Grange et al., 1985; 
Dupuy et al., 1989) at only one position. The conservative substitution of a valine 
residue in the 17D(-wt) variant for an alanine residue in the parental 17D-204-UK 
virus at position E-240 in the E protein is consequently speculated to be 
responsible for the attenuated properties of the variant virus.
The E-240 mutation maps to the A domain of the E protein, as defined by
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the two-dimensional model of Mandl et al. (1989). Domain A undergoes a pH- 
dependent conformational change (Guirakhoo et al., 1989) which is consistent 
with its possible role in endocytic fusion events (Heinz, 1990; Roehrig et al.,
1989). Substitution of a valine for an alanine residue at E-240 increases both the 
hydrophobicity of the E protein in this region (Figure 6.2). Theoretically, this may 
alter the E protein structure and resistance to low pH-induced conformational 
changes. However, further investigation would be necessary to determine the role 
of any such conformational changes in the attenuation of the virus for 
neurovirulence in mice.
Identification of a single unique E protein amino acid substitution in the 
17D(+wt) variant mapped the wild-type epitope recognised by MAb 117 to 
residue E-173 in the primary sequence. Appearance of the epitope recognised by 
MAb 117 was also shown previously to be coincident with loss of the MAb 411- 
defined YF vaccine-specific epitope (Gould et al., 1989), thus suggesting that 
these MAbs define structurally overlapping epitopes on the E protein.
The recreation of the wild-type specific epitope was demonstrated to 
involve a reversion to the wild-type sequence of Asibi virus at position E-173. A 
second amino acid change from wild-type Asibi virus to the 17D vaccine virus 
strains is located close to this mutation at E-170. It is proposed that this amino 
acid substitution may also contribute to the loss of the wild-type epitope 
recognised by MAb 117 in the 17D vaccine virus strains. The threonine residue 
found at position E-173 in the wild-type Asibi virus was also found to be
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Figure 6.2: Hydrophobicity of the 17D(-wt) and 17D(+wt) variant virus E proteins 
between E-220 and E-260, plotted on the "Soap" program on PCGENE
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conserved among all other wild-type YF viruses sequenced to date (Jennings eta/./ 
1995; Chang, personal communication). However, a threonine is not found at this 
position in other members of the flavivirus genus. These observations are 
consistent with the hypothesis that this region defines the YF wild-type-specific 
MAb 117-defined E protein epitope.
A TBE virus E protein epitope mapped at E-171 (corresponding to E-170 in 
YF virus)(Mandl et a/., 1989) has been shown to undergo acid pH-induced 
conformational changes which were proposed to interfere directly with processes 
necessary for membrane fusion (Guirakhoo et a/., 1989). The corresponding MAb 
escape variant virus exhibited a significantly lower pH threshold for the induction 
of its fusion activity. The single amino acid substitution at E-171 was speculated 
to strengthen the oligomeric E protein structure and thus lower the pH 
requirement for the structural rearrangements necessary for membrane fusion 
(Guirakhoo et a/., 1991).
Further examination of the 17D(+wt) variant is necessary to reveal whether 
or not the equivalent epitope on the YF virus E protein is also involved in acid 
pH-induced membrane fusion events. However, Figure 6.3 indicates that this 
region becomes more hydrophilic when isoleucine is replaced with threonine, 
possibly inducing conformational changes and exposing the wild-type epitope on 
the surface of the E protein.
As previously stated the 17D(-wt) variant is attenuated for mouse
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Figure 6.3: Hydrophobicity of the ITD(-wt) and 17D(+wt) variant virus E proteins 
between E-150 and E-190, plotted on the "Soap" program on PCGENE
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neurovirulence, but was found to be identical in sequence to other 17D-204
viruses over the whole genome, except for one amino acid change at E-240. This
«
finding has implicated the E-240 mutation in the attenuation of this virus. 
However, the 17D(+wt) variant possesses an identical amino acid mutation and 
is not significantly attenuated for mice. Therefore, one or more mutation(s) 
elsewhere in the genome of the 17D(+wt) variant virus are speculated to have 
restored its neurovirulent phenotype. One such mutation was identified at E-173 
and consequently may contribute to the reversion to virulence of this virus. 
Infectious clone technology and site-directed mutagenesis will allow this theory 
to be tested in the future.
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CHAPTER 7
Molecular and biological analyses of YF variant viruses without 
the 17D-204 substrain-specific E protein epitope
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7.1 Introduction
The pathogenesis of VF virus in mice is believed to involve distinct viral 
functions which may be critical at each required step. The membrane-associated 
M and E proteins comprising the viral "spikes" perform many important functions. 
Among these are attachment of virus to specific host cell binding sites, fusion of 
the viral envelope with host cell membranes, virion assembly and release. 
Accordingly, the conformation of the E protein can ultimately influence viral 
pathogenicity in vivo.
The elements in a genetic study of the role of the E protein in the 
pathogenesis process are single-site virus variants which fail to induce fatal 
encephalitis because they are blocked at different steps in the pathogenesis 
pathway. Neutralising MAbs can be used to select antigenic virus variants in vitro  
which are termed MAb neutralisation-resistant escape (MAbR) variants. This 
approach has been used successfully to isolate MAbR variants for several 
flaviviruses, includingTBE (Mandl e ta/., 1989; Holzmann e ta /., 1990), JE (Cecilia 
& Gould, 1991; Hasegawa et a/., 1992), LI (Jiang et a/., 1993), DEN (Lin et a/., 
1994) and VF (Lobigs et a/., 1987; Ledger, 1990) viruses. Single E protein amino 
acid mutations reducing the pathogenicity of the virus by peripheral inoculation 
of mice were observed in a number of cases (Holzmann et a/., 1990; Hasegawa 
et a/., 1992; Cecilia & Gould, 1991). However, to date no such variant viruses 
have been characterised for YF virus.
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The 17D-204 substrain-specific MAb 864 (Buckley & Gould, 1985) is 
considered to define an important functional site on the 17D-204 virus E protein, 
as exemplified by the high reactivity exhibited by this MAb in neutralisation, HAI 
and passive protection studies (Cammack & Gould, 1986). Moreover, the 
presence of the epitope recognised by MAb 864 exclusively on 17D-204 vaccine 
viruses may be indirectly relevant to the virulence of the YF vaccine viruses. In 
this laboratory, Ledger (1990) isolated three series of MAbR variants to MAb 864 
from the 17D-204-WHO vaccine virus and 17D-204-UK variant viruses, 
17D(+wt) and 17D(-wt). Comparison of the corresponding parent and MAbR 
variant viruses in PRNT, HAI and IIF assays revealed differential biological 
characteristics and antigenicity.
In this study, the pathogenicity of the "864R" variant viruses selected by 
Ledger (1990) was examined in the mouse model. In addition, the molecular 
determinants of MAb neutralisation-escape were identified by sequence analysis 
of the M and E protein-encoding genes.
7.2 Results
7.2.1 Derivation and characterisation of the MAb 864R variant viruses
As outlined above and illustrated in Figure 7.1, three series of MAbR 
variant viruses were isolated by Ledger (1990), selected for neutralisation-
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17D-204-UK
Ç Selection with wild-type specific MAb 117 ^
ITD(-wt) 17D(+wt)
(selection for resistance to 17D-204 substrain-specific MAb 864)
I 1
86# (-wt)-l 
86# (-wt)-2
86# (+wt)-l 
86# (+wt)-2 
86#(+wt)-3
17D-204-WHO
( selection for resistance to 17D-204 substrain-specific MAb 864 )^
I
86# WHO-1 
86# WHO-2
Figure 7.1: Derivations of the 864R variant viruses.
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resistance to the 17D-204 substrain-specific MAb 864. The selection method 
employed by Ledger (1990) is described below.
In PRNT assays performed on monolayers of Vero cells (Chapter 2), MAb 
864 neutralised the 17D-204-WHO vaccine virus and the 17D-204-UK variant 
viruses, 17D(+wt) and 17D(-wt), by greater than 104-fold. Viruses which escaped 
neutralisation were plaque-purified (Ledger, 1990). The authenticity of these 
candidate 864R variants was assessed by IIF and PRNT assays, which revealed loss 
of binding and neutralisation by MAb 864, and thus confirmed the disappearance 
of the corresponding E protein epitope. A total of seven 864R variants were 
characterised; three from the 17D(+wt) virus, two from the 17D(-wt) virus and 
two from the 17D-204-WHO vaccine virus. The designations of these 864R variant 
viruses are shown in Figure 7.1.
7.2.2 Mouse neurovirulence of the 864R variant viruses in adult mice
Groups of adult outbred TO mice were administered 104 pfu of virus by the 
i.e. route. The 864R variant viruses exhibited degrees of mouse neurovirulence 
ranging from complete avirulent through to highly lethal (Table 7.1).
864r (+wt) variants: The 17D(+wt) variant virus was shown in the previous 
chapter (Chapter 6) to be virulent for adult mice by this route of inoculation, with 
a mortality rate of 87% and an AST of 10.1 ± 0.5 days. The three 864R variants 
prepared from the 17D(+wt) variant virus were found to be attenuated for mouse
Virus Number dead/ number inoculated % mortality
Average survival 
time (AST) in days
17D-204-UK 10/10 100% 10.3+0.6
17D(-wt) 8/45 17.7% NA
864R (-wt)-l 0/26 <4% NA
864R (-wt)-2 9/9 100% 9.2 ± 1 .1
17D(+wt) 17/20 85% 10.1+0.5
864R (+wt)-l 0/8 <12.5% NA
864R(+wt)-2 1/9 11% NA
864R(+wt)-3 1/8 12j% NA
17D-204-WHO 8/8 100% 11.0+0.7
864R WHO-1 4/8 50% NA
864R WHO-2 8/8 100% 9.6 + 0.5
Table 7.1: Neurovirulence of the 86# variant viruses compared with their parent viruses 
17D(-wt), 17D(+wt) and 17D-204-WHO. Adult mice were inoculated i.e. with 104 pfu of virus 
NA: not applicable
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neurovirulence; 864R(+wt)-1 was avirulent (killed 0/8 mice), while 864R(+wt)-2 
and 864R(+wt)-3 killed 11% (1/9) and 13% (1/8) of infected mice, respectively.
864 (-wt) variants: The 17D(-wt) variant virus was shown in the previous chapter 
to be attenuated for mouse neurovirulence, killing only 17% of infected mice 
(8/45). Variant virus 864R(-wt)-1 proved to be further attenuated, being completely 
avirulent for mice (0/26). However, the 864R(-wt)-2 variant virus was found to 
have reverted to the virulent phenotype of the non-plaque-purified 17D-204-UK 
vaccine virus, displaying a 100% mortality rate (9/9) and an AST of 9.2 ± 1.1 
days.
864r W HO variants: The 17D-204-WHO vaccine virus has been shown 
previously to be lethal for all mice inoculated by the i.e. route (Gibson et a/.,
1990). This result was confirmed in these studies. The 864R WHO-2 variant virus 
was neurovirulent, killing all mice inoculated (8/8) with an AST of 9.6 ± 0.5 
days. Conversely, the 864R WHO-1 variant virus was significantly attenuated with 
respect to the parent virus, killing only 50% of infected mice (4/8). The mice 
which survived, however, were observed to develop clinical signs of encephalitis.
7.2.3 Mouse neuroinvasiveness of the 864R(-wt)-2 variant virus in suckling mice
In order to further delineate the neurotropic properties of the 864R(-wt)-2 
variant virus, groups of 11 outbred NIH Swiss suckling mice (eight days old) were 
inoculated by the i.p. route with 103 pfu of either the 17D-204-UK vaccine virus,
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the 17D(-wt) parent virus or the 864R(-wt)-2 variant virus. All three viruses were 
found to be avirulent for suckling mice administered by this route. In contrast, 
wild-type Asibi virus was shown to be lethal for eight day old mice by this route 
of inoculation (Fitzgeorge & Bradish, 1980). Therefore, the 864R(-wt)-2 variant 
virus has not reverted to the wild-type phenotype for neuroinvasiveness in young 
mice.
7.2.4 Replication of the 864R variant viruses in mouse brain
Groups of eight adult outbred NIH Swiss mice were inoculated with 104 
pfu of the 864R(+wt) or 864R(-wt) variant viruses by the i.e. route. Mice were 
sacrificed and brains were harvested eight or eleven days post-inoculation for 
histopathological examination (described in Section 7.2.4) and for titration of 
infectious virus (Table 7.2). The eight day time-point was necessary for mice 
inoculated with the 864R(-wt)-2 variant virus, as the majority of these mice died 
at approximately day nine post-inoculation. Additionally, mice infected with either 
the 864R(-wt)-1 or the 864R(-wt)-2 variant virus were sacrificed on days two and 
three post-inoculation and their brains harvested for infectivity titration.
No infectious virus was detectable (< 1 5  pfu/brain) in mice infected with 
the 864R(-wt)-1 virus, even two and three days post-inoculation, or in mice 
infected with the 864R(+wt) variant viruses. Virus infectivity titrations of 864R(-wt)- 
2 virus-infected mouse brains yielded varying results. By day two post-inoculation 
a viral infection had been established in two out of three mice with titres of
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Virus post-inoculation
Infectivity. 
litre (pfu/brain)
Viral RNA 
detectable by RT-PCR
. -
15
2 3.0 x 102
3.0 x 10 2
1.0 x 104
ITD(-wt) 3 <15
<15
1.6 x 103 +
8 <15 +
<15
<15
2 <15
<15
<15
864r (-wt)-l 3 <15
<15
<15 -
8 <15 -
<15
15 '
2 1.0 x 104
3.0 x 10 2
4.5 x 104
864R(-wt)-2 3 3.0 x 103
3.6 x 105
<15 -
8 7.0 x 103 +
3.4 x 102 +
1.5 x 103
2 2.4 x 104
9.0 x 103
7.5 x 103
17D(+wt) 3 4.5 x 103
2.0 x 104
3.6 x 10s
8 2.0 x 10*
5 3  x 10s
<15
864R(+wt)-l 11 <15 -
<15 -
<15 -
864R(+wt)-2 11 <15 -
<15 -
<15 -
864R(+wt)-3 11 <15 -
<15
Table 7.2: Infectivity titres in infected mouse brain homogenate. PCR results taken 
from Figure 7.2.
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between 3 x 102 and 1 x 104 pfu/brain; higher titres than seen for its parent virus, 
17D(-wt). Mouse brains harvested day three post-inoculation were all positive for 
infectious virus and the viral titres appeared to be increasing. However, by day 
eight post-inoculation virus titres had fallen to below 7 x 103 pfu/brain despite the 
clinical signs of encephalitis displayed by all three mice.
7.2.5 Persistence of the 864R variant viral RNA in mouse brain
In a parallel study, RT-RCR was performed as described in Chapter 6 on 
the same mouse brain homogenates assayed in Section 7.2.3 above for infectivity. 
As shown in Figure 7.2 and Table 7.2, viral RNA could be detected only in the 
brains of mice inoculated with the 864R(-wt)-2 variant virus, which were tested 
eight days post-inoculation. Two out of three mouse brains tested by RT-RCR were 
shown to contain viral RNA and these results were found to correlate with the 
infectivity titres presented above; brains containing infectious virus were also 
positive by RT-RCR.
RT-RCR of brain homogenates from mice inoculated with the 864R(-wt)-1 
and all of the 864R(+wt) variant viruses revealed no detectable viral RNA, 
suggesting that it did not persist in the brain by day 11 post-inoculation. Negative 
and positive controls included in Figure 7.2 are brain homogenates from an 
uninfected mouse and a mouse infected with the 17D-204-UK vaccine virus 
(replicated to a  titre of approximately 1 x 1 0 *  pfu/brain), respectively.
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1 2  3 4
Figure 7.2: Viral RNA amplified by RT-PCR from homogenised mouse
brain, separated by gel electrophoresis. RT—PCR primers were 
AJ7UP-YF100 (1331 bp). Mice were infected with the 864R variant 
viruses by the i.e. route.
Lane 1 : 0X174 Haelll molecular weight markers
Lane 2: 8 days post-inoculation — 864R(-wt )-2 vi rus (A)
Lane 3: 8 days post-inoculation — 864R ( —wt ) —2 vi rus (B)
Lane 4: 8 days post —i noculat ion - 864R(-wt )-2 vi rus (C)
Lane 5: 8 days post — i noculat ion - 86 4 R (—w t )—1 vi rus (A)
Lane 6: 8 days post-inoculation - 864R(-wt)-1 vi rus (B)
Lane 7: 8 days post —i noculat ion — 864R(—w t )—1 vi rus (C)
Lane 8: 11 days post —i noculat ion - 864R ( + wt )-1 vi rus (A)
Lane 9: 11 days post-inoculation — 864R(+wt)-1 vi rus (B)
Lane 10: 11 days post —i noculat ion — 864R ( + wt )-1 vi rus (C)
Lane 11 11 days post-inoculation — 864 R (+wt )-2 vi rus (A)
Lane 12: 11 days post-inoculâtion — 864R(+w t )-2 vi rus (B)
Lane 13: 11 days post-inoculation — 864 R (+w t )-3 vi rus (A)
Lane 14: 11 days post-inoculation — 864R(+w t )-3 vi rus (B)
Lane 15: Positive controi ; 17D-204-UK virus-infected mouse 
Lane 16: Negative control ; RNA extracted from uninfected 
mouse brain
7.2.6 Histopathologic and immunocytochemical examination of brain sections
Brain sections from one mouse inoculated with 864R(-wt)-1 and one 
inoculated with 864R(-wt)-2 (both harvested eight days post-inoculation) were 
examined by Dr. G. Campbell. Haematoxylin and eosin staining revealed very 
little pathology of the brain in either case. Some focal meningeal, perivascular and 
parenchymal inflammation was observed in brain sections from both mice. 
Additionally, possible ventricular inflammation and microglial nodules were found 
in the mouse infected with the 864R(-wt)-2 variant virus. Immunocytochemical 
staining was unable to detect any viral antigen in either brain.
7.2.7 Amplification, cloning and sequencing of the viral RNA
Since MAb neutralisation-resistance could potentially result from amino 
acid changes in the M or the E protein, both genes were sequenced to determine 
the molecular basis of MAb neutralisation-escape. For each of the seven 864R 
variant viruses, the region of the genome encoding the M and E proteins was 
amplified by RT-RCR in two overlapping fragments. As described previously, 
primer pairs CAG-YF7 and AJ7UR-YF100 were used. Gel-purified cDNA fragments 
were cloned and two independent clones sequenced. No clonal variation was 
observed.
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7.2.8 Comparison of the M and E protein genes of the 864R(+wt) variant 
viruses with the parental 17D(+wt) virus
The three 864 (+wt) variant viruses were found to be identical in sequence 
for the M and E protein genes (Table 7.3) and possessed an identical C to T 
nucleotide change from the 17D(+wt) parent virus at nt-1947. In the deduced 
amino acid sequence this nucleotide mutation encoded a serine to leucine amino 
acid substitution at position E-325 in the E protein. E-325 was previously shown 
to be the site of a proline to serine amino acid substitution from the wild-type 
Asibi virus to the 17D-204 substrain vaccine viruses due to a mutation of the 
adjacent nucleotide, nt-1946 (Hahn et a/., 1987).
7.2.9 Comparison of the M and E protein genes of the 864R(-wt) variant viruses 
with the parental 17D(-wt) virus
The attenuated 864R(-wt)-1 variant virus was found to have a nucleotide 
mutation compared with its parent virus at nt-1947, which is identical to that 
described above for the 864R(+wt) variant viruses. As before, this nucleotide 
mutation encoded the substitution of leucine for serine at amino acid E-325. 
Consequently, the M and E proteins of the 864R(-wt)-1 variant virus differ from the 
864R(+wt) variant viruses only at position E-173; the difference observed between 
the 17D(-wt) and 17D(+wt) parent viruses (Chapter 6).
In contrast, the virulent 864R(-wt)-2 variant virus was shown to be identical
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E-153 E-173 E-240 E-305 E-325
Asibi N T A S P
17D-204-UK N I A F s
17D(-wt) N I V F S
864R (-wt)-l N I V F L
864R (-wt)-2 N I V S S
17D(+wt) N T V F S
864R (+wt)-l N T V F L
864R (+wt)-2 N T V F L
8 6 ^  (+wt)-3 N T V F L
17D-204-WHO T I A F S
864R WHO-1 T I A V S
864R WHO-2 T I A F L
Table 7.3: Amino acid differences identified between the 864R viruses and their respective 
parent viruses in the E protein. No changes were found in the M protein.
219
to the 17D(-wt) parent virus at nt-1947/E-325. However, this virus differed from 
the parent by a T to C nucleotide mutation at nt-1887. This nucleotide mutation 
encoded a phenylalanine to serine amino acid substitution at position E-305. 
Position E-305 was previously shown to be the site of a mutation from the wild- 
type Asibi virus, conserved among all 17D viruses (Jennings et a/., 1993b). 
Comparison with the E protein gene sequence of the wild-type Asibi virus 
revealed that both the nucleotide and amino acid substitution represent reversions 
to the wild-type (Hahn et a/., 1987).
7.2.10 Comparison of the M and E protein genes of the 864R WHO variant
viruses with the parental 17D-204-WHO virus
The 864R WHO-1 variant virus exhibited a T to G nucleotide mutation at 
nt-1886. In the deduced amino acid sequence of the E protein this nucleotide 
mutation resulted in the substitution of a phenylalanine residue in the 17D-204- 
W HO virus for a valine residue in the 864R WHO-1 variant virus at E-305. This 
was, therefore, a substitution at the same amino acid position as described for the 
864R(-wt)-2 variant, but the adjacent nucleotide was mutated resulting in the 
substitution of a different amino acid.
The 864r WHO-2 variant virus was shown to possess the identical 
mutation at nt-1947/E-325 previously identified in 864R(-wt)-1 and all three 
864R(+wt) variant viruses. It should also be remembered that the 864R W HO 
variant viruses and the parental 17D-204-WHO virus differ from other 17D-204
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viruses by the presence of an N-linked glycosylation site at E-151 (Post et a/.,
1992; Chapter 3).
7.3 Discussion
Although virus virulence is likely to be multigenic, this study presents the 
first indication that the pathogenesis of YF virus in vivo may be directly linked to 
the conformation of the E protein. As mentioned previously, the 17D-204 
substrain-specific epitope recognised by MAb 864 is involved in a number of 
biological activities; neutralisation (Buckley & Gould, 1985), HAI (Gould et a/., 
1986), haemolysis (Cammack & Gould, 1985) and passive protection (Gould et 
a/., 1986). This study has revealed that loss of the MAb 864-defined epitope may 
result in the expression of a significantly altered mouse neurovirulence phenotype. 
Clearly, therefore, this epitope is also important in determining the neurovirulence 
of YF virus in mice.
The virulence-altered phenotypes displayed by the 864R YF virus variants 
were particularly noteworthy as they are the first reported flavivirus MAbR variants 
with attenuated neurovirulence. Previous studies have isolated MAbR variants of 
JE (Cecilia & Gould, 1991; Hasegawa et a/., 1992) and TBE (Holzmann et a/., 
1990) viruses which displayed reduced neuroinvasiveness compared to their 
parent virus following extraneural inoculation. However, these variants did not 
display reduced neurovirulence following i.e. inoculation. In contrast, five of the
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864r YF virus variants characterised in this study no longer induce a lethal 
encephalitis in mice following inoculation by the i.e. route. These virus variants 
were apparently unable to replicate in mouse brain as no infectious virus or viral 
RNA could be detected by eight days post-inoculation. These findings emphasise 
the critical role of the E protein in the mechanism of viral pathogenesis.
The 864R(-wt)-2 variant virus was found to be significantly more virulent 
than its parent 17D(-wt) virus, despite being antigenically very similar to the 
completely avirulent 864R(-wt)-1 variant (Ledger, 1990). This represents the 
reversion of an attenuated variant to the neurovirulent phenotype of the "wild- 
type" virus, in this case the 17D-204-UK vaccine virus.
Sequence analysis of the M and E protein genes of the 864R variant viruses 
revealed that, in each case, the altered neurovirulence was effected by a single 
amino acid substitution in the E protein. No changes were identified in the M 
protein. These findings have mapped the 17D-204 substrain-specific epitope 
recognised by MAb 864 to the B domain of the two dimensional E protein model 
proposed by Mandl et a/. (1989). Two amino acid positions, E-305 and E-325, 
have been identified at which neutralisation-escape mutations may occur. The 
epitope recognised by MAb 864 has previously been shown to be conformation 
dependent (Deprés et a/., 1990), and therefore it is likely that these residues are 
closely orientated in the correctly folded E protein. Substitutions of serine or 
valine for phenylalanine at E-305 or leucine for serine at E-325 all result in the 
loss of the MAb 864-defined epitope. Furthermore, phenylalanine at E-305 and
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proline at E-325, as found in the 17DD substrain viruses, also results in the 
absence of this epitope. The effects of these various amino acid substitutions on 
the hydrophobicity of the E protein in this region are shown in Figure 7.3.
It is especially interesting to note that at both E-305 and E-325 substitutions 
have occurred during the attenuation process from the wild-type Asibi virus. In 
particular, compared to the Asibi virus, both 17DD and 17D-204 vaccine viruses 
have a serine to phenylalanine amino acid substitution at E-305, suggesting that 
this substitution may also have existed in the original 17D attenuated variant. 
Moreover, reversion of the E-305 amino acid in variant 864R(-wt)-2 to the serine 
observed in the Asibi wild-type virus led to the re-emergence of the neurovirulent 
phenotype. The 17D-204 substrain viruses have a unique proline to serine amino 
acid substitution at E-325 from the wild-type Asibi virus and the 17DD substrain 
viruses. This observation^consistent with the 17D-204 substrain specificity of the 
MAb 864-defined epitope.
Clearly, this epitope is of major importance to the neurovirulence of these 
viruses in the mouse model. Domain B of the E protein has previously been 
implicated in the tissue tropism of flavivi ruses, presumably due to its role in 
binding of the virus to the host-cell receptor. It is proposed, therefore, that the 
altered neurovirulence phenotype displayed by the 864R variant viruses is a direct 
consequence of a conformational change in the E protein which, in turn, may 
have affected binding of the virus to its specific host-cell receptor. Consequently, 
the virus may be unable to enter the cell and/or unable to replicate. The lack of
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Figure 7.3: Hydrophobicity of the 864R variant virus E proteins from E-280 to E-350 
plotted on the "Soap" program on PCGENE.
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infectious virus and viral RNA in the brain is consistent with this proposal.
The increased virulence of the 864R(-wt)-2 variant virus is also proposed 
to be due to alteration in conformation of domain B, but in this instance the 
position of the substituted amino acid is different and leads to more efficient 
replication of the virus in host cells than previously observed for the parent virus. 
This appears to be a second-site mutation, able to reverse effects of the E-240 
mutation described in Chapter 6 which partially attenuated the 17D(-wt) variant 
virus.
The results obtained for the 864R W HO variants differed from those 
described above. It must be remembered that these viruses do not have an amino 
acid substitution at E-240, but have an additional substitution at E-153 which 
leads to N-linked glycosylation of the E protein. In the 864R WHO-1 variant an 
amino acid substitution was identified at E-305, different to that observed in the 
864R(-wt)-2 virus. Although all mice displayed clinical signs of encephalitis, this 
single amino acid change significantly attenuates the 864R WHO-1 variant virus 
for mouse neurovirulence.
The E-325 amino acid substitution identified in the 864R WHO-2 virus E 
protein was identical to that seen in 864R(-wt)-1 and the 864R(+wt) variants. 
However, in this background the substitution did not attenuate the virulence of 
the variant. This suggests that either the E-153 mutation negates the effects of this 
the E-325 mutation, or that the E-240 change in the 17D(+wt) and 17D(-wt)
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variants is essential to the attenuated phenotype. Overall, it appears that amino 
acid substitutions at these positions have a cooperative effect and that the 
molecular basis of virulence is multifactorial. Positions E-305 and E-325 are 
presumably located in close proximity in the three-dimensional structure of the 
E protein forming an epitope which has critical importance in viral pathogenesis. 
Indeed, the presence of amino acid substitutions at E-305 in all 17D vaccine 
viruses and E-325 in the 17D-204 substrain suggests that this epitope may have 
contributed to the attenuation of these viruses.
Finally, it is possible to speculate on the mechanism of altered 
neurovirulence. In radioimmunoprecipitation and western blotting analyses, MAb 
864 recognises the E and prM proteins (Gould et al., 1985; Gould et al., 1989). 
This suggests that the 17D-204 substrain-specific epitope is associated with the 
prM-E interaction. The hypothesis that this interaction contributes to the 
expression of virulence is supported by the observation that MAb 813 
radioimmunoprecipitates E and prM of the 17D-204 vaccine viruses, but only the 
E protein for wild-type Asibi virus.
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CHAPTER 8
Molecular and biological analysis of YF variant viruses with a 
17DD substrain-specific E protein epitope
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8.1 Introduction
17D-204 vaccine viruses produced by different manufacturers have 
previously been demonstrated to consist of variants clearly distinguishable in 
terms of both plaque size on Vero cells and virulence for mice (Liprandi, 1981). 
From the 17D-204-SA vaccine virus two types of variant were isolated, a small 
plaque avirulent type and a large plaque type of intermediate virulence for mice. 
The large plaque type represented the majority of the population. Two large 
plaque variants, plaque-purified three times, were shown to induce a mixed 
response of death or protection in mice. The observed response was, therefore, 
considered to be an intrinsic characteristic of this substrain rather than the product 
of a mixed population.
In a similar study, a large plaque variant of the 17D-204-SA vaccine virus, 
designated 17D(LR), was plaque-purified three times on LLC-MK2 cells (Ledger et 
a/., 1992). This variant virus exhibited mouse neurovirulence properties 
comparable to the non-plaque-purified parent virus (Barrett, personal 
communication). However, the two viruses were distinguishable on the basis of 
antigenicity, measured by IIF, PRNT and HAI assays (Ledger, 1990; Ledger et a/., 
1992). One notable difference was the elicitation of high HAI activity by MAb 
HI 0 with the 17D(LR) variant virus, but not with the parent virus. MAb HI 0 was 
previously characterised as 17DD substrain-specific (Sil, 1990) and accordingly 
the 17D(LP) variant was speculated to possess a 17DD substrain-specific E protein 
epitope. The location of this epitope in the primary amino acid sequence of the
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E protein is investigated in this study.
A subsequent study was conducted by Ledger (1990) with the intention of 
selecting MAb neutralisation escape (MAbR) variants using the 17D-204 substrain- 
specific MAb 864. The 17D(LP) virus was incubated with MAb 864, followed by 
incubation with goat-anti mouse immunoglobulin to form virus-antibody 
complexes. These were then precipitated by high-speed centrifugation and the 
supernatant was examined for residual infectivity compared to appropriate 
controls. In excess of 99.6% of the 17D(LP) variant virus was "precipitated" by 
this technique, leaving a residual 40 pfu of virus in the supernatant. In this study, 
the virus in the supernatant was amplified by propagation in Vero cell culture and 
designated 17D(864). The biological and molecular properties of the 17D(864) 
virus were investigated in this study, as a potential MAb 864R variant.
8.2 Results
8.2.1 Mouse neurovirulence of the 17D(LP) and 17D(864) variant viruses in 
outbred mice
The 17D(LP) variant virus, parent to the 17D(864) variant virus, was found 
to be neurovirulent in adult outbred strain NIH Swiss mice inoculated with 103 
pfu by the i.e. route. All of the mice inoculated with this virus died with an AST 
of 7.3 ± 0.3 days.
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The 17D(864) variant virus was amplified by two passages in Vero cells 
prior to use in the experiments described in this chapter. This virus exhibited 
intermediate neurovirulence for adult outbred strain NIH Swiss mice inoculated 
with 103 pfu by the i.e. route. From a group of 24 mice, 10 (42%) developed 
signs of viral infection approximately nine days post-inoculation. In a subsequent 
experiment, virus at three cell culture passages was used as the inoculum in a 
group of eight mice, four of which (50%) displayed signs of sickness at 10 days 
post-inoculation (Table 8.1).
The symptoms of disease exhibited by these mice differed from the normal 
course of infection with YF virus in mice. Sickness was manifested in the form of 
a stiffening of the hind legs, occasionally resulting in total hind limb paralysis. 
This paralysis was found to be permanent, as seen in a mouse observed for seven 
months post-inoculation and was accompanied by general wasting of the body. 
Only one death was recorded in the second group of mice, 17 days post­
inoculation.
8.2.2 Mouse neurovirulence of the 17D(864) variant virus in inbred mice
The pathogenesis of the 17D(864) variant virus was investigated in three 
strains of inbred mice; C3H (H-2k), C57BL/6 (H-2b) and Balb/c (H-2d). Groups of 
eight to ten mice were inoculated as described for the outbred mice, using virus 
from the second cell culture passage. As illustrated in Table 8.1, the susceptibility 
of these mice to infection with the 170(864) variant virus varied. The course of
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disease observed in the Balb/c mouse strain most closely resembled that seen 
previously in outbred NIH Swiss mice, causing a degree of hind limb paralysis in 
all of the mice inoculated and 20% mortality.
In C57BL/6 strain mice, hind limb paralysis was less evident and a 57% 
mortality rate was recorded. C3H strain mice were found to be markedly more 
susceptible to infection with this virus. All mice died with an AST of 13.3 ± 0.7 
days. The symptoms observed were far more severe, with mice becoming 
completely paralysed, hunchbacked and wasted, approximately eight days post­
inoculation.
8.2.3 Replication of the 17D(864) variant virus in mouse brain
Replicative viral titres in mouse brain samples were measured in a parallel 
experiment to the one described in Section 8.2.1. NIH Swiss outbred mice were 
inoculated by the i.e. route with 103 pfu of the 170(864) variant virus. Brains 
were harvested at 11, 23 and 30 days post-inoculation for virus titration.
At 11 days post-inoculation, virus was detected in mouse brain at an 
infectivity titre of 5.5 x 104 pfu/brain (Table 8.2). However, beyond 11 days post- 
inoculation no infectious virus could be detected by plaque assay, indicating that 
the infectivity titre was less than 15 pfu/brain. In the brain of one paralysed C3H 
strain mouse, sacrificed on day nine post-inoculation, a virus infectivity titre of 9 
x 105 pfu/brain was measured.
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Virus Daypost-inoculation
Infectivity 
titre (pfu/brain)
Viral RNA 
detectable by RT-PCR
11 5.5 x 10 4 +
170(864) 23 <15<15
+
+
30 <15<15
+
Table 8.2: Infectivity titres in infected mouse brain homogenate. PCR results taken 
from Figure 8.1
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8.2 .4  Persistence of the 170(864) variant viral RNA in mouse brain
RT-PCR was performed to determine whether any viral RNA persists in the 
mouse brain at time-points after clearance of infectious virions to a level below 
plaque assay detection. In these preliminary investigations, RT-PCR was performed 
on the mouse brain homogenates assayed in Section 8.2.3 using primers for the 
E protein gene (AJ7UP-YF100). As shown in Figure 8.1, viral RNA could be 
detected in the brains of all mice at 11 days and 23 days post-inoculation. 
Furthermore, in one mouse out of two sacrificed on day 30 post-inoculation, viral 
RhÎA was detected in the brain. Negative and positive controls included in Figure
8.3 are an uninfected NIH Swiss mouse and viral RNA extracted from cell culture 
supernatant, respectively. The cDNA fragment amplified in these experiments 
represented over 1.3 kb of the genome. Consequently, a positive result suggested 
that the viral genome was intact, not degraded, despite the absence of infectious 
material at the later time-points.
8.2.5 Histopathologic and immunocytochemical examination of brain sections
To examine whether long-term persistence of 17D(864) viral RNA in 
outbred strain NIH Swiss mouse brain was associated with any histopathologic 
changes, brain sections from two mice were examined by Dr. G. Campbell. Both 
mice, sacrificed at days 11 and 30 post-inoculation, were observed to have hind 
limb paralysis. Routine haematoxylin and eosin staining revealed scattered foci 
of meningeal and perivascular inflammation. Red neurons associated with hypoxia
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Figure 8.1: Viral RNA amplified by RT-PCR from homogenised mouse 
brain, separated by gel electrophoresis. RT-PCR primers were 
AJ7UP—YF100 (1331 bp).
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were observed in the corpus callosum, cerebellum and brainstem, but may have 
been an artefact. No evidence of demyelination of neurons was observed. In 
addition, no viral antigen could be detected by immunocytochemical staining of 
the sections with polyclonal antiserum to YF virus. Thus, despite the presence of 
low levels of viral RNA and scattered foci of CNS inflammatory cells, other 
histopathologic abnormalities could not be detected in the brain sections.
8.2.6 Biological analysis of the 17D(864) variant virus
In PRNT assays, the 170(864) variant virus was found to be neutralised by 
MAb 864 to a 0.8 log10 reduction titre. This was comparable to the neutralisation 
activity of MAb 864 with the 17D-204-SA vaccine virus and with the 17D(LP) 
variant. Therefore, the 170(864) variant virus was determined not to be a MAb 
864r variant as it was not resistant to neutralisation by the selecting MAb.
In addition, it was observed that, unlike the parental 17O(LP) variant, the 
170(864) variant virus did not have large plaque morphology.
8.2.7 Amplification, cloning and sequencing of the viral RNA
For each of the two variant viruses, 17D(LP) and 170(864), viral RNA was 
extracted from cell culture supernatant and the region of the genome encoding 
the M and E proteins was amplified by RT-PCR in two overlapping fragments. As
described previously, primer pairs CAG-YF7 and AJ7UP-YF100 were used. Gel-.
v . . .
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purified cDNA fragments were cloned and sequenced. For the 17D(LP) variant 
two clones of each cDNA fragment were sequenced and no clonal variation was 
observed. However, in the case of the 17D(864) variant virus, clonal variation 
was observed in the AJ7UR-YF100 defined fragment between three clones 
analysed. Accordingly, clones of the cDNA fragment obtained in Section 8.2.4 
by RT-PCR amplification of RNA extracted from an infected mouse brain were 
also sequenced over this region.
8.2.8 Comparison of the M and E protein genes of the 17D(LP) variant virus
and the parental 17D-204-SA virus
The nucleotide and deduced amino acid sequences of the M and E protein 
genes of the 17D(LP) variant virus and the parental 17D-204-SA vaccine virus 
(Chapter 3) were compared (Table 8.2). Two nucleotide differences were 
identified between the two viruses in the E protein gene at nt-2349 and nt-2408.
T O t 'C'A t- /'
In the deduced amino acid sequence, the latter nucleotide change was found to 
encode the substitution of an alanine residue in the 17D-204-SA virus for a valine 
residue at E-459 in the 17D(LP) variant virus. The other E protein gene nucleotide 
mutation (at nt-2408) was silent and the M protein gene sequence was found to 
be identical in the two viruses.
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Nucleotide Asibi 17D-204-SA 17D(LP) 17D(864) Amino acid Substitution
854 C T - T T M-35 L to F
883 A G G G - -
1127 G A A A E-52 G to R
1140 C T T T E-56 A to V
1482 C T T T E-170 A to V
1491 C T T C E-173 T to I
1572 A C C C E-200 K t o T
F tO S.
1750 C T T T -
1819 C T T T -
1870 G A A A E-299 M to I
1887 C T T T E-305 S to F
1946 C T T T E-325 P to S
1965 A G G G E-331 K to R
2112 C A A A E-380 T to R
2193 C T T T E-407 A to V
2219 c T T T E416 A to T
2349 C c Atq.-v.;-::: ;•
2356 G A A A - -
2408 T T A A -
Table 8.3: Comparison of the M and E protein gene sequences of Asibi, 17D-204-UK 
17D(LP) and 17D(864). fl] Amino acid substitutions; Q  non-coding nucleotide mutations 
Asibi senuence taken from Rice<?/^/n9851
8.2.9 Comparison of the M and E protein genes of the 17D(LP and 17D(864)
variant viruses
Initially, the nucleotide and deduced amino acid sequences of the M and 
E protein genes were determined for virus extracted from tissue culture at the 
third passage from the original virus stock. These sequences were compared with 
sequence data previously accumulated for the 17D(LP) variant virus and the 17D- 
204-SA vaccine virus (Table 8.2). All three cDNA clones examined were 
demonstrated to have a nucleotide mutation at nt-2349 from the sequence of the 
parental 17D(LR) variant virus. However, clonal variation was observed in the 
AJ7UP-YF100 RT-PCR amplified fragment as one clone had a further mutation at 
nt-1674. This mutation was shown to result in a phenylalanine to serine amino 
acid substitution in the E protein at position E-234. The nucleotide change at nt- 
2349 was shown to represent a reversion to the sequence of the 17D-204-SA 
vaccine virus. Therefore, the 17D(864) variant virus is deduced to have an alanine 
residue at position E-459, identical to the 17D-204-SA vaccine virus. However, 
the silent nucleotide mutation previously identified at nt-2408 from 17D-204-SA 
to 17D(LP) was also found in all three clones of this virus. The M protein genes 
of all three viruses were found to be identical.
The nucleotide mutation observed in one clone at nt-1674 may have been 
representive of a variant in the virus population or a mismatch error during RT- 
PCR amplification of the viral RNA. As the 17D(864) virus exhibited an 
intermediate mouse neurovirulence, it was proposed that the virus may consist of
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a population of variants, differing in their lethality for mice. Accordingly, viral 
RNA, extracted from infected mouse brain and amplified by RT-PCR across this 
region (Section 8.2.4), was also sequenced for comparison. Three clones of this 
PCR-amplified fragment were found not to have a nucleotide substitution at nt- 
1674 and, accordingly, this mutation is suspected to have been a PCR mismatch 
error or representative of a small population of variants.
8.3 Discussion
A single amino acid substitution was revealed in the E protein of the 
17D(LP) variant virus at position E-459. Therefore, this mutation is speculated to 
be responsible for the appearance of the 17DD substrain-specific epitope on the 
E protein of this variant. The E-459 amino acid substitution lies in the proposed 
transmembrane region of the E protein at the carboxy-terminus (Mandl et a/., 
1989). The 17DD substrain-specific epitope recognised by MAb H10 is unlikely 
to be in this position, as this region of the primary amino acid sequence would 
not be exposed on the surface of the virus for MAb binding. These data are 
suggestive of a secondary site mutation occuring at a position distant from the 
epitope, but influencing the presentation and conformation of the E protein such 
that the 17DD substrain-specific epitope appears on the surface. A similar 
observation was made by Allison et al. (1994) who reported a mutation at E-455 
in TBE virus which altered the antigenic structure of the E protein. However, as 
the 17D(LR) variant virus is not neutralised by MAb H10 and the process of HAI
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is only poorly understood, these findings are difficult to interpret.
Since loss of the E-459 mutation and reversion to normal plaque 
morphology were coincident in the 17D(864) variant virus, this amino acid 
substitution has been implicated in the plaque size phenotype of the virus. 
However, there may be other changes elsewhere in the genome which contribute 
to the determination of plaque morphology. The substitution of a valine for an 
alanine residue is considered to be a relatively conservative exchange of 
hydrophobic amino acids.
Mice infected with the 170(864) variant virus exhibited clinical signs of 
disease not previously reported for a flavivirus. The mechanism by which the 
disease pathogenesis is altered is currently not understood. However, the 
molecular determinants encoding this change were not identified in the M or E 
protein genes. Consequently, it is proposed that the responsible mutations have 
occurred elsewhere in the genome, perhaps in the non-structural proteins. Such 
a phenomenon has not been reported previously in the flavivirus field and 
deserves to be investigated further in the future.
The data suggest that the susceptibility of mice to this viral infection is 
dependent on host-encoded factors. Inbred strains of mice displayed very different 
responses to the infection, but the level at which susceptibility is encoded cannot 
be elucidated at this time. Also noteworthy was the demonstration of viral RNA 
persisting in the brain more than 19 days after clearance of infectious virus to
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levels below the sensitivity of detection (< 15  pfu/brain). Persistent viral infections
in vivo  have not previously been reported for YF virus, but similar observations
-
have been made for other related RNA viruses including the alphavirus, Sindbis 
(Levine & Griffin, 1992). It is likely that virus is also persisting at low levels, 
possibly in the spinal cord and brain stem. Further investigations are necessary to 
determine the molecular basis of the altered virulence phenotype and viral 
persistence.
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CHAPTER 9
Molecular and biological analyses of YF variant viruses without 
a YF type-specific E protein epitope
243
9.1 Introduction
The preceeding chapters have demonstrated that the YF live-attenuated 
17D vaccine strain represents an invaluable opportunity to investigate the 
molecular basis for attenuation of flavivirus virulence. However, before evaluating 
the biological significance of individual mutations arising in the E protein during 
the attenuation process, the structure-function relationship of E protein epitopes 
must be clarified. MAbs specific for E protein were found to be a powerful tool 
for the characterisation of structural and functional properties of this protein 
(reviewed in Heinz, 1986). Neutralising antibodies can be used to select antigenic 
variants for viruses in vitro  and has been applied to several flaviviruses.
To date, only one YF type-specific E protein epitope has been 
characterised at the molecular level (Lobigs et a/. 1987). Variants were selected 
using two YF type-specific MAbs (2E10 and 2C9) which neutralised the parent 
17D-204-ATCC vaccine virus substrain to a titre greater than 5 log10 units. 
Nucleotide sequence comparison of the M and E protein genes of the variants 
with those of the parent virus (Rice et a i,  1985) revealed a single nucleotide 
change in the E gene of each. The resulting amino acid substitution at position E- 
71 or E-72 mapped the 2C9/2E10-defined, YF type-specific epitope to the A 
domain of the E protein.
Previously, in this laboratory, Ledger (1990) used another YF type-specific 
MAb (B39) to select for neutralisation-resistant antigenic variants of 17D-204 virus
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in vitro  as shown in Figure 9.1. MAb B39 represents one of a panel of E protein- 
reactive MAbs raised against the 17DD-Brazil vaccine virus substrain and has 
beencharacterised previously as a YF type-specific MAb (Barrett et a/., 1989; 
Ledger et a/., 1992). In PRNTs, MAb B39 neutralised the 17D-204-WHO vaccine 
virus substrain to high titre (4 log10 units), but failed to neutralise any of the other 
YF virus strains tested, including 17DD-Brazil (Barrett et al., 1989). Ledger (1990) 
described the plaque-purification of two MAbR variants of the 17D-204-WHO 
virus, resistant to neutralisation with MAb B39. These variants were designated 
B39r WHO-1 and B39R WHO-2. The authenticity of these B39R variants was 
assessed by IIF and PRNT assays, which revealed loss of binding and 
neutralisation by the selecting MAb, and thus confirmed the loss of the B39- 
defined E protein epitope.
In this study, the location of the B39-defined YF type-specific epitope has 
been identified in the primary amino acid sequence of the E protein by sequence 
analysis of the B39R neutralisation escape variants. Significant features of this 
epitope have been compared with those of the 2E10-defined YF type-specific 
epitope previously localised by Lobigs et a/. (1987). In addition, the role of these 
epitopes in virus virulence for mice has been investigated. The 2E10R variant virus 
was kindly provided by Dr. J. Schlesinger.
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17D-204-WHO
Selection for resistance to YF type-specific MAb B39 ^
j
B39r WHO-1 
B39r WHO-2
Figure 9.1: Derivations of the B39R variant viruses.
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9.2 Results
9.2.1 Biological analysis of the B39R and 2E10R variants
A panel of five YF type-specific MAbs (B39, 2E10, G23, H3 and H33) was 
employed in IIF and PRNT assays to compare the E protein antigenic structure of 
the B39R variants with their parent virus, 17D-204-WHO, and also with the 2E10R 
variant and its parent virus, 17D-204-ATCC (Figure 9.2). For the purposes of this 
study, the infectious clone-derived virus (Rice et a/., 1989) was used in place of 
17D-204-ATCC as the original virus stock used by Lobigs et a/. (1987) was not 
available.
9.2.2 Sequence analysis of the B39R variants
Since neutralisation resistance could result from amino acid changes in the 
M or the E protein, both genes were sequenced to determine the molecular basis 
of MAb neutralisation escape and locate the B39-defined, YF type-specific epitope 
in the primary amino acid sequence. For nucleotide sequence analysis, viral RNA 
was amplified by RT-PCR in two overlapping fragments corresponding to nt-625 
to nt-1312 and nt-1223 to nt-2554, thus covering the entire M and E protein- 
encoding genes. Two subclones from each of two separate PCR amplifications 
were sequenced by dideoxynucleotide chain termination sequencing.
Comparative sequence analyses of the B39R variants with the published
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17D-204-WHO
B39R WHO-1
B39R WHO-2
17D-204-ATCC
2E10v2
-4.0
-3.0
• 2.0
- 1.0
- 0.0
-4.0
-3.0
-20
- 1.0
- 0.0
4.0
3.0 
20
1.0 
0.0
-4.0
-3.0
-2 0
^ - 0.0
h-4.0
3.0
-2 0
- 1.0
B39 2E10 G23 H3 H33
YF type-specific MAb
G0
.§1 G<DG
$
Figure 9.2: Comparison of virus neutralization patterns with a panel of YF type-specific MAbs 
(B39, 2E10, G23, H3 and H33). The extent of neutralization is measured in log10 units of 
reduction in virus titer.
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sequence of their parent virus revealed no nucleotide changes in the M protein 
gene, while each variant differed from 17D-204-WHO by a single nucleotide 
change and corresponding amino acid substitution in the E protein (Table 9.1): 
B39r WHO-1 mutated from Thr to lie at 2-158 (C to T at nt-1446); B39R WHO-2 
from Asp to Gly at E-155 (A to G at nt-1437).
Previous comparison of the nucleotide sequence of the E protein genes 
ofl 7D-204-ATCC (Rice et a/., 1985) and 17D-204-WHO viruses has identified a 
single amino acid substitution of Asp to Thr at position E-153 (Post et a/., 1992). 
Both B39r variants were identical to the published 17D-204-WHO sequence at 
this position, thereby confirming this result.
9.2.3 Mouse virulence studies
In order to assess the virulence characteristics of the MAbR variants in vivo, 
groups of seven to nine female mice, 4 weeks old and weighing 20-25 g (outbred 
strain TO or NIH Swiss, Harlan Olac, Indianapolis, IN) were inoculated i.e. with 
103 pfu of virus. Mice were monitored daily for signs of illness and death and AST 
was calculated (Table 9.2). All mice inoculated i.e. with either the parent 17D- 
204-W HO virus strain or the B39R variants died, although when strain TO mice 
were inoculated they were found to be slightly less sensitive than NIH Swiss 
strain mice (data not shown). Similarly, all mice died when inoculated i.e. with 
either variant 2E10R or its parent virus, 17D-204-ATCC. Therefore, none of the 
variants were attenuated for mouse neurovirulence.
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Nucleotide Asibi 17D-204-WHO B39RWHO-l B39RWHO-2 Amino acid Substitution
854 C T T T M-35 L to F
A >
883 A G G G - ■
1127 G A A A E-52 G to R
1140 C T T T E-56 A to V
1431 A C C C E-153 N to T
1437 A A A G E-155 D to G
1446 C C T C E-158 T to I
1482 c T T T E-170 A to V
E
1491 c T T C E-173 T to I
1572 A C C C E-200 K to T
1750 c T T T -
1819 c T T T - -
1870 G A A A E-299 M to I
1887 C T T T E-305 S to F
1946 C T T T E-325 P to S
1965 A G G G E-331 K to R
2112 C A A A E-380 T to R
2193 C T T T E-407 A to V
2219 C T T T E-416 A to T
2356 G A A A - -
Table 9.1: Comparison of the M and E protein gene sequences of Asibi, 17D-204-WHO 
and the B39R variant viruses. I I Amino acid substitutions.
Asibi sequence taken from Rice<?A?/(1985).
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Virus Number dead/ number inoculated % mortality
Average survival 
time (AST) in days
17D-204-WHO 8/8 100% 7.3 + 0.2
B39R WHO-1 9/9 100% 8.7 +0.2
B39r WHO-2 8/8 100% 7.7 ±  0.2
17D-204-ATCC 7/7 100% 8.2 ±  0.2
2E10r ATCC 9/9 100% 7.6 ±  0.3
Table 9.2: Neurovirulence of the B39R and2E10R variant viruses compared with their parent 
viruses, 17D-204-WHO and 17D-204-ATCC. Adult mice were inoculated i.e. with 103 pfu 
of virus
251
To investigate the possibility of increased virulence variant B39R WHO-2 
was inoculated i.p. into one week old mice or i.n. into weanling mice (data not 
shown). This variant was found to be as avirulent as its parent virus, confirming 
that this variant did not have increased neuroinvasive properties.
9.3 Discussion
Loss of binding and neutralisation of the MAbR variant viruses by the 
selecting MAb was initially confirmed. Subsequently, comparative analyses of the 
E protein antigenic structure of parent and variant viruses were performed using 
a panel of five YF type-specific MAbs (Figure 9.2). Although MAb B39 bound to 
17D-204-ATCC, no neutralization of 17D-204-ATCC or its 2E10R derivative was 
observed with this MAb. MAb 2E10, however, was found to neutralize both the 
17D-204-WHO parent virus and its B39R variants to an equal extent. Therefore, 
loss of one MAb-defined epitope had no conformational influence on 
neutralization involving the other epitope, indicating that these two YF type- 
specific epitopes are located on topologically distinct sites on the E protein.
The concomitant loss of neutralization of the 2E10R variant by MAbs 2E10 
and H33 suggests that these MAbs define structurally overlapping epitopes on the 
E protein. A similar phenomenon may operate in the case of the B39R variants 
where loss of neutralization by MAb B39 is coincident with appearance of 
neutralization by MAb G23. Thus, the YF type-specific MAbs investigated here
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bind epitopes clustered in two antigenically discrete regions, suggesting that there 
are at least two discrete YF type-specific epitopes on the surface of the E protein.
Identification of single amino acid substitutions at position E-t 58 in variant 
B39r WHO-1 and E-155 in variant B39R WHO-2 mapped the YF type-specific, 
B39-defined epitope within domain C of the E protein, a disulphide-free loop 
comprising amino acid residues E-130 through E-174 (Mandl et a/., 1989). 
Conversely, substitutions responsible for loss of the YF type-specific epitope 
recognized by MAb 2E10 were previously identified at position E-71 (Lobigs et 
a/., 1987) in domain A, a disulfide rich region including amino acid residues E-50 
through E-125 and E-200 through E-250 (Figure 9.3a). These findings further 
substantiate the conclusion that there are at least two discrete type-specific 
neutralizing epitopes on the surface of the YF virus E protein.
Both of the YF type-specific neutralising epitopes (defined by MAbs 2 El 0 
and B39) are located in predominantly hydrophilic regions of the E protein as 
might be expected given that hydrophilic domains are generally located on the 
surface of a protein where they may interact with antibodies (Figure 9.3b). It is 
speculated that the single amino acid mutations observed allow the B39R variant 
viruses to escape neutralisation by altering the hydrophobicity profile of the E 
protein, and thus changing the conformation of the MAb binding site (Figure 9.4). 
A similar situation has been found for the majority of flavivirus MAbR variants so 
far isolated (Holzmann et a/., 1990; Hasegawa et a/., 1992; Jiang et a/., 1993).
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Figure 9.3a: The positions of the escape mutations on the two-dimensional 
E protein model.
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Figure 9.3b: Hydrophobicity plot of the E protein showing that the B39-defined 
epitope lies in a hydrophilic region of the primary amino acid sequence.
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Figure 9.4: Hydrophobicity of the B39R variant virus E proteins from E-130 to E-175 
plotted on the "Soap" program on PCGENE.
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Figure 9.5: Alignment of currently available flavivirus E protein sequences across the C 
domain. Viruses are grouped according to antigenic complex and are compared to the 
representative virus in their group: panel a:- YF viruses which are serologically distinct from 
other flaviviruses; panel b:- JE serocomplex; panel c:- DEN serocomplex; panel d:- TBE 
serocomplex. The first and last amino acid is numbered from the amino terminus of the E 
protein. Dots ( ) represent conserved amino acids, dashes (-) represent "deleted" amino acids and 
potential N-linked glycosylation sites are underlined. Amino acid substitutions found the the 
B39R variants are shown in bold and their position is indicated by arrows. Amino acid sequences 
for YF, JE, Murray Valley encephalitis (MVE), St. Louis encephalitis (SLE), West Nile (WN), 
Kunjin (KUN), DEN-1, DEN-2, and DEN-4 viruses were adapted from Trent et al (1987); for 
Central European encephalitis (CEE), Kyasanur Forest disease (KFD), Far Eastern TBE 
(FETBE), Langat (LOT), Powassan (POW), LI, Negishi (NEC) and Omsk hemorrhagic fever 
(OHF) from Vengopal et al (1994); and for DEN-3 from Osatomi & Sumiyoshi (1990).
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The number and position of potential N-linked glycosylation sites in 
flavivirus E proteins vary, although similarities are noted among members of the 
same subgroup (Figure 9.5). The 17D-204-WHO and 17DD virus substrains are 
unique among YF virus strains sequenced to date in that they are glycosylated in 
domain C at Asn residue E-151 and E-153, respectively (Post et a/., 1992). It is 
proposed that this structural similarity is significant for the binding and 
neutralising properties of MAb B39, since neutralisation by this MAb appears to 
be glycosylation-dependent (Barrett et a/., 1989). This suggestion is supported by 
the observation that the carbohydrate side-chain moiety has a role in stabilizing 
conformation-independent, sequential epitopes in the C domain (Guirakhoo et a/., 
1989). However, the B39R variants retain the potential N-linked glycosylation site 
at E-153 and therefore, unless a conformational change induced by the amino 
acid substitutions identified abrogates glycosylation, as shown for DEN-2 Jamaica 
(Johnson et a/., 1994), presence of a carbohydrate side-chain is not solely 
responsible for neutralization by this MAb.
The amino acid substitution at E-71 in the 2E10R variant lies at a 
considerable distance in the linear sequence from the only predicted glycosylation 
site in 17D-204-ATCC at E-309. This suggests that the conformation of the 2E10- 
defined epitope is determined, not by asparagine-linked carbohydrate residues, 
but by the three disulphide bonds in domain A.
The B39-defined epitope is the first flavivirus E protein epitope mapped to 
this region of domain C. Previously only one other epitope has been identified
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in domain C at position E-171 in TBE virus (Holzmann et a/.z 1990). Comparison 
of the flavivirus E protein sequences currently available (Trent et al., 1987; 
Osatomi et al., 1990; Venugopal et al., 1994) across this region indicates that, 
although there is a striking degree of homology among members of the same 
serological group, there is a relatively high degree of diversity between different 
subgroups (Figure 9.5). In the YF virus E protein, an eight residue "deletion" is 
observed when amino acid sequence alignment is performed, possibly reflecting 
a difference in the antigenic structure of YF virus E protein in this region. The 
amino acid mutations which faciliated MAb neutralization escape in the B39R 
variants are positioned on either side of this deletion. Thus, it is speculated that 
the B39-defined YF type-specific epitope is created by bringing together a unique 
group of amino acid residues and that this region may also be type-specific in 
other flaviviruses.
Neither YF type-specific epitope contributed to YF virus virulence for mice 
and, although the role of flavivirus E protein glycosylation in viral replication and 
pathogenesis is unknown, these results suggest that it is relatively inconsequential 
to the course of YF virus infection in the mouse model. In contrast, E protein 
glycosylation in domain C of TBE (Rletnev et al., 1992) and DEN-4 (Kawano et 
al., 1993) viruses has been closely linked to virulence of these viruses for mice. 
This does not exclude the possibility that these epitopes are important for some 
other virus property.
In conclusion, selection of MAbR variants has proven to be a useful
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technique for localizing E protein epitopes and also investigating the effects of 
single amino acid mutations on virus pathogenicity. In this study, a YF type- 
specific epitope was mapped to the C domain of the YF virus E protein, thus 
demonstrating that the virus possesses at least two discrete YF type-specific E 
protein epitopes. The region to which the B39-defined epitope maps has 
previously been shown to be important in mouse virulence of other flaviviruses. 
However, in this study this epitope was shown not to be essential for YF virus 
virulence for mice. The possibility of substituting other virus epitopes in this 
position to produce a recombinant vaccine virus is, therefore, promising.
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CHAPTER 10
Studies on the interaction of YF viruses with 
host cell binding sites
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10.1 Introduction
The first steps taken by an enveloped virus during host cell infection are 
attachment and fusion. Binding of the virion to specific cellular receptor/binding 
site molecules is mediated by the viral spike protein(s). It is this mechanism that 
directs the tissue tropism and pathogenesis of many viruses (reviewed in Fields 
& Greene, 1982; Dimmock, 1982; Marsh & Helenius, 1989). For flaviviruses, 
neither the viral nor the host cell determinants involved in cell attachment have 
been clearly defined. The broad host range of the flaviviruses suggests that the 
cell receptor (s) may have conserved structure across the chord ate and arthropod 
phyla.
The YF viruses display both viscerotropic and neurotropic specificity, 
depending on the host and the virus strain (Fitzgeorge & Bradish, 1980; Gibson 
et a/., 1990). In primates inoculated with wild-type YF virus, visceral infection 
results. In animals inoculated intracerebrally, virus replicates in brain tissue, and 
there is histopathological evidence of encephalitis. However, the animals die of 
hepatitis. In comparison, the attenuated YF vaccine viruses 17D and FNV do not 
cause viscerotropic disease in man or monkeys, but do possess varying degrees 
of neurotropic potential. This is in contrast to the mouse model, where all YF 
virus strains examined are neurotropic, without evidence of hepatitis. The 
pathology of these diseases may be accounted for by the focal viral infection and 
direct viral damage to certain cell types that bear a specific binding site.
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Changes in the tissue tropism of YF viruses during the attenuation process 
may arise following changes to the surface epitopes of the virus which are critical 
for the binding of the virus to cell surface receptors. Hahn et al. (1987) 
discovered that a relatively high percentage (38%) of amino acid substitutions 
between the wild-type Asibi and derivative 17D-204 vaccine viruses had occurred 
in the E protein, suggesting a positive selection pressure. It was concluded that 
one or a combination of the amino acid changes could be responsible for the loss 
of viscerotropism displayed by the YF vaccine virus. However, the substitution(s) 
responsible for the alteration of tissue tropism remain uncertain.
In this study, a number of YF variant viruses have been identified which 
exhibit unusual neurovirulence phenotypes in mice, ranging from altered clinical 
signs to complete avirulence. The conformation of the E protein was directly 
implicated in the manifestation of these virulence-altered phenotypes. Alteration 
of virus tropism may be responsible for the attenuation or modification of virus 
disease. It was proposed, therefore, that the tissue tropism of these variant viruses 
may have been altered by affecting the binding of the virus to its specific cellular 
receptor. Consequently, the virus may infect a different cell type or fail to enter 
the cells, resulting in an abortive infection. In order to test this hypothesis, both 
parent and variant viruses were studied for their relative abilities to bind mouse 
or monkey brain membrane receptor preparations (MS-MRR and MK-MRR, 
respectively).
Of the YF vaccine viruses, the FNV strains were shown to display a
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particular predilection for neural tissue, presumably as a result of their adaptation 
to mouse brain passage during derivation (Mathis et al., 1928). The FNV-Yale 
virus strain was found to be highly neurotropic (Chapter 4). In this chapter, 
attempts were made to select for FNV-Yale variant viruses which are able to 
escape binding to MK-MRR and consequently might be expected to exhibit a 
difference in neurotropism in monkeys and perhaps also in mice.
10.2 Results
10.2.1 Viruses tested for MS-MRR and MK-MRR binding activity
In this section, instead of using an in vivo animal model, an in vitro  assay 
was used to investigate the binding of virus to specific animal tissues. The MRPs 
were prepared by homogenisation of mouse or monkey brain tissue as described 
in Chapter 2. The viruses included in this study are listed in Table 10.1, together 
with a summary of their phenotypes. The positive and negative controls for virus 
binding were a highly neurotropic JE virus (strain P3) and a non-neurotopic DEN 
4 virus (strain H241), respectively.
Each virus was incubated separately with MS-MRR and MK-MRR, and 
bound virus was removed by precipitation, as described in Chapter 2. The 
residual virus infectivity (i.e., the unbound virus) in the supernatant was titrated 
by plaque assay on Vero cells, and the percentage of bound virus was calculated.
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Virus strain Pathogenesis in mice
17D-204-ÙK Neurovirulent
ITD(-wt) Attenuated
864R (-wt)-l Attenuated
864R(-wt)-2 Neurovirulent
17D(+wt) Neurovirùlent
864r (+wt)-l Attenuated
864R (+wt)-2 Attenuated
864r (+wt)-3 Attenuated
17D-204-WHO Neurovirulent
864R WHO-1 Attenuated
864R WHO-2 Neurovirulent
17D(LP) Neurovirulent
17D(864) Attenuated
FNV-NT Neurovirulent
FNV-IP Neurovirulent
FNV-FC Neurovirulent
FNV-Yale Neurovirulent
MRPR FNV-1
MRPr FNV-2
MRPr FNV-3
See Table 10.2
MRPr FNV-4
MRPR FNV-5
MRPR FNV-6
DEN 2 (H241) Attenuated
JE (P3) Neurovirulent
Table 10.1: The viruses included in the study of virus/host cell binding
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Each assay was repeated two or more times. Since the data is derived from a 
biological assay, a two-fold discrepancy between duplicate experiments was 
considered relatively insignificant. Consequently, only binding differences of 10- 
fold or more were considered significant.
10.2.2 Binding of the YF vaccine virus strains
The relative binding of the YF vaccine viruses to MS-MRR and MK-MRR is 
compared in Figure 10.1. The FNV viruses were consistently shown to bind to 
both MS-MRR and MK-MRR to a high degree. In all cases, the proportion of 
bound virus reached in excess of 91% and in some instances as high as 99.8%. 
In comparison, the 17D-204 vaccine viruses tested displayed equivocal levels of 
binding, ranging from 55% to 82%. One exception was identified in the 17D- 
204-W HO virus, which was found to bind with high affinity (99.9%) to MS-MRR 
in repeated assays. Binding of this virus to monkey brain was, however, similar 
to that of the 17D-204-UK virus.
The P3 strain of JE virus bound MK-MRR and MS-MRR at levels of 90% 
and 99% respectively as might be expected for a strongly neurotropic virus. On 
the other hand, the non-neurovirulent DEN 4 virus, strain H241, did not bind to 
either MRP, suggesting that nonspecific adherence of virus to membrane 
preparations was not occuring to significant levels.
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Figure 10.1: Comparison of MRP binding by the YF vaccine viruses.
MS: mouse-MRP; MK: monkey-MRP
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10.2.3 Binding of the 17D-204 variant viruses
Binding of the 17D-204 variant viruses was, in general, comparable to the 
binding of the 17D-204 parent viruses described above (Figure 10.2). 
Comparisons between the corresponding parent/variant virus pairs are outlined 
below.
17D(+wt)/17D(-wt) variants: Both of these variant viruses were found to 
bind both MS-MRR and MK-MRR to a lesser extent than the 17D-204-UK parent 
virus (Chapter 5). However, whether or not this difference should be considered 
significant is in question as the reduction was less than the 10-fold cut-off.
864r variants: The 864R variant viruses derived from the 17D(+wt) and 
17D(-wt) viruses (Chapter 7) bound to receptor preparations to varying degrees.
It is interesting to note that, for each virus, the levels of binding to MS-MRR and 
MK-MRR appears to be directly proportional.
Comparison of the binding of the 864R WHO-1 and 864R WHO-2 variant 
viruses revealed an inversely proportional relationship. Binding of the 864R W H O -2  
virus to MS-MRR was found to be similar to that observed for the 17D-204- 
W HO parent virus, whereas binding was reduced for the 864R WHO-1 variant. 
Conversely, the 864R WHO-1 variant virus bound MK-MRR to a significantly 
higher degree than either the parent 17D-204-WHO virus or the other 864R WHO 
variant.
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Figure 10.2: Comparison of MRP binding by the 17D-204 vaccine viruses
and their variants. MS: mouse-MRP; MK: monkey-MRP
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17D(LP) and 170(864) variants: No significant differences were observed 
in the binding of these viruses to either the MK-MRR or the /ytS-MRP. Binding was 
at a level similar to that previously seen for the 170-204 viruses.
10.2.4 Selection of MK-MRR binding escape variants of FNV-Yale virus
Approximately 99% of the FNV-Yale virus bound to the MK-MRR, 
corresponding to a 100-fold reduction in the residual infectivity titre. Six FNV-Yale 
virus variants, which were present in the supernatant and therefore unbound, 
were plaque-purified and amplified in Vero cell culture. The binding of these 
variant viruses, designated MRPR FNV-1 to 6, was tested against both MK-MRR 
and MS-MRR.
All six MRPr FNV virus variants exhibited a reduction in ability to bind 
either receptor preparations (Figure 10.3). MRPR FNV-2 was identified as the most 
promising "binding escape variant" as residual binding activity was found to be 
the lowest for this variant. This variant virus was characterised further, as 
described in the following sections.
10.2.5 Pathogenesis of the MRPr FNV-2 variant virus in adult outbred mice
Groups of 10 adult outbred NIH Swiss mice were inoculated by the i.e. 
route with 103 pfu of either the parental FNV-Yale virus or the MRPR FNV-2
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Figure 10.3: Comparison of MRP binding by the FNV viruses and the "MRP binding
escape" variants. MS: mouse-MRP; MK: monkey-MRP
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variant virus (Table 10.2). This preliminary comparison revealed that both viruses 
were lethal for mice by this route of inoculation and the AST of the mice was not 
statistically different (5.2 ± 0.4 for FNV-Yale versus 5.6 ± 0.2 for the MRPR FNV- 
2 variant virus).
10.2.6 Pathogenesis of the MRPr FNV-2 variant in suckling mice
The parent FNV-Yale and the variant MRPr FNV-2 viruses were each 
inoculated by the i.p. route into one litter of five day old, suckling mice. 
Comparison of the results revealed that both viruses were lethal for mice by this 
route, but that the AST of mice inoculated with the MRPR variant virus was 
reduced to 6.7 ± 0.2 days compared to 7.4 ± 0.2 days for the FNV-Yale parent 
virus.
10.2.7 Nucleotide sequence analysis of the MRPr FNV-2 variant virus
Since virus binding to cellular receptors potentially involves both the M 
and the E proteins, the genes encoding both proteins were amplified by RT-PCR 
using primer pairs CAG-YF7 and AJ7UP-YF100. Gel-purified fragments were 
cloned and two clones of each fragment sequenced.
The nucleotide and deduced amino acid sequence of the M and E protein 
genes of the MRPR FNV-2 variant were compared with the sequence data 
previously determined for the FNV-Yale parent virus (Chapter 4) and the wild-type
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Nucleotide F W  FNV-Yale MRPR FNV-2 Amino acid Substitution
4 854 c T T M-35 L to F
992 A T T E-7 V to A
1006 C T T - -
1036 T C C - -
1134 C T T E-54 A to V
1155 A c C E-61 Y to S
1156 C G G E-61
1306 G A A -
E
1432 T A A E-153 N to K
1653 G A A E-227 G to E
1718 A G G E-249 N to D
1793 T T C E-274 Y to H
1819 C T T - -
2092 C T T - -
2193 T C C E-407 V to A
2239 T C c . . - - •
2344 G A A E-457 M to I
2437 T C C - -
Table 10.3: Comaprison of the M and E protein sequences of FW , FNV-Yale and the
MRP R FNV-2 variant viruses.
| | Amino acid substitution from FNV-Yale to the MRPr FNV-2
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F W  strain (Table 10.3). Only one nucleotide and resulting amino acid difference 
was observed between the two FNV viruses at position E-274 in the E protein. A 
tyrosine residue in the FNV-Yale parent virus and FW  was exchanged for a 
histidine residue in the variant. No changes were identified in the M protein gene.
10.3 Discussion
The predilection of viruses for certain host cell types confers a degree of 
tropism to the virus. Wild-type YF viruses have all previously been demonstrated 
to be predominantly viscerotropic, although they are neurotropic in the mouse 
model. However, coincident with the attenuation of the 17D and FNV vaccine 
virus strains, the tropism for visceral tissues was lost. Both of the YF vaccine virus 
strains exhibit degrees of neurotropism in both mice and monkeys. The FNV virus 
strains are much more strongly neurotropic due to their selection by extensive 
passaging in adult mouse brain; a fact which is largely borne out by the receptor 
binding data presented here, which suggests that the FNV viruses also bind to 
neural tissue to a much greater extent than the 17D viruses. However, the binding 
of the different FNV viruses to the MRPs did not correlate with the reduced 
neurovirulence of FNV-NT in monkeys or FNV-FC in mice (Gibson et a i,  1990).
There are a number of explanations for these results which cannot be 
delineated further at present. Since the FNV viruses also kill mice much more 
quickly than the 17D viruses, it is possible that they recognise a different binding
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site in the brain and perhaps infect cells of a different type. Immunohistochemical 
analyses of mouse brain sections infected with the 17D-204-UK virus revealed 
rare focal lesions in microglial cells. More distinct focal lesions were observed in 
the brain stem for mouse brain infected with the FNV-Yale virus, supporting the 
hypothesis that different cell types are infected. If the binding sites are present on 
only a limited number of cell types, the corresponding tropism can be highly 
specific. An example is the highly specific affinity displayed by polioviruses for 
the anterior horn cell of the CNS (Mimms, 1989).
Although the 17D-204 variant viruses demonstrate very different virulence 
phenotypes for mice, little difference was observed in the binding of these viruses 
to receptor preparations. Consequently, it seems that the avirulence or 
intermediate neurovirulence of some of these strains is not attributable to a 
complete loss of binding activity. As above, these results may be suggestive of a 
change in the tropism of the viruses, especially between the virulent 17D(+wt), 
attenuated 17D(-wt) and revertant 864R(-wt)-2 viruses. Further studies are 
necessary to determine whether the binding kinetics are altered, a factor which 
may also influence the course of infection in vivo. The studies described in 
Chapter 6 suggest that four of the 864R variants, 864R(-wt)-1 and the three 
864R(+wt) variants, cause an abortive infection in mice and the kinetics of the 
binding reaction may also influence this situation. However, the abortive nature 
of this infection need not be a consequence of reduced virus-host cell binding 
alone, as many other virus-encoded and host-encoded factors may come into play 
in vivo.
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Interesting differences in binding levels were observed for the 864R WHO 
variant viruses and their 17D-204-WHO parent virus. Chapters 3 and 9 have 
confirmed published data which states that the 17D-204-WHO virus differs from 
the other 17D-204 viruses by one amino acid substitution that creates an N-linked 
glycosylation site demonstrated to be utilised in vitro  (Post et al., 1992). It now 
appears that the suggested adoption of this vaccine seed lot by all m anufacturées 
should be investigated more thoroughly because the binding of this virus to MS- 
MRR resembles that of the neurotropic FNV viruses and is therefore a cause for 
concern.
The selection of a MRPr variant virus for the FNV-Yale strain, which has 
reduced binding for both MK-MRP and MS-MRP, suggested that it is possible to 
use this technique to alter the tropism of YF virus. This concept has future 
application in the development of live-attenuated vaccine strains for viruses such 
as DEN and TBE, for which effective vaccines are not yet available.
The MRPr FNV-2 variant virus possessed only one amino acid substitution 
from the parent virus in the E protein at position E-274, substituting a histidine for 
a tyrosine residue. This non-conservative exchange of a strongly hydrophilic, basic 
amino acid residue for a slightly hydrophobic aromatic residue was demonstrated 
to alter the hydrophobicity profile of the E protein in this region (Figure 10.4). 
This amino acid substitution occured in a very hydrophilic region of the E protein 
which has been proposed as the contact area for the E and prM proteins 
(Guirakhoo et a i,  1992). Moreover, E-274 occurs within a group of 13 amino
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Figure 10.4: Hydrophobicity of the MRP* FNV-2 virus E protein plotted 
on the "Soap" program on PCGENE.
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acids which are unique in sequence to the YF viruses. This mutation may 
influence the presentation of the E protein or alter the cleavage of the prM protein 
in the maturing virion, presumably affecting the epitopes on the surface of the E 
protein and reducing binding ability. In terms of pathogenesis, the MRPr FNV-2 
variant virus was not attenuated in mice. This result may be representive of 
differences in the virus binding sites in mouse versus monkey brain. Alternatively, 
it may suggest that the data from these in vitro  binding assays cannot be 
extrapolated to the in vivo pathogenesis of YF virus. Investigation of the 
pathogenesis of this variant virus in the monkey model is essential at this stage 
for better characterisation.
These data should only be seen as preliminary, but they are quite 
encouraging. Clearly, binding escape variants can be selected by this technique 
and the loss of binding seems to be attributable to subtle conformational changes 
in the E protein. Further variants need to be characterised to establish the range 
of mutations possible and whether or not they can be mapped to specific regions. 
It is interesting to note the proximity of this amino acid substitution to the E-249 
change conserved among the FNV viruses and the E-299 change conserved 
among the 17D viruses. Furthermore, a substitution at E-270 was identified in a 
JE virus MAbR variant which was found to reduce virulence of the virus by i.p. 
inoculation in mice (Cecilia & Gould, 1991).
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CHAPTER 11
General Discussion
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Membrane-associated proteins comprising the spikes of enveloped viruses 
are required to perform many important functions. Among these are attachment 
of virus to specific host cell receptors, fusion of the viral envelope with host cell 
membranes, virion assembly, budding from infected cells and induction of an 
immune response in vivo. Therefore, it is clear that the potential exists for the 
flavivirus E protein to influence pathogenicity in vivo. In this thesis, variants of YF 
virus with altered virulence phenotypes were characterised at the molecular level, 
with particular emphasis placed on the role of the E protein. In total, 
approximately 75 kilobases of nucleotide sequence data were generated!
Three processes by which attenuated YF viruses have been generated were 
investigated. The first and second attenuated derivatives represent the empirically 
derived YF vaccine viruses, 17D (Theiler & Smith, 1932) and FNV (Mathis et a/., 
1928). The third is a YF virus attenuated by limited passage in HeLa cells, Asibi 
HeLa-p6 (Dunster, 1990). In addition to their attenuated phenotype^a number of 
other similarities in biological properties have previously been identified between 
these three virus strains, including the pattern of epitopes on the E protein. 
Comparison of the E protein amino acid sequence for these viruses, however, was 
unable to identify any common substitutions from their respective wild-type virus 
parents.
A notable occurfënce, coincident with attenuation in all three processes, 
was the appearance of the vaccine-specific epitope(s) recognised by MAb 411 and 
MAb H5 (Gould et a/., 1985; Ledger et a/., 1992; Dunster, 1990) and loss of
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several YF wild-type-specific epitopes. Figure 11.1 provides a comparison of the 
M and E protein amino acid substitutions found to be conserved within each 
vaccine strain. It is speculated that the amino acid residues at positions E-52, E-54 
and E-27 are three-dimensionally folded in close proximity and collectively form 
the vaccine-specific epitope. The appearance of this epitope also appears to be 
coincident with loss of certain wild-type-specific epitopes. This suggests that the 
E protein "switches" to a different conformation, triggered by specific amino acid 
substitutions and that the epitopes recognise the same E protein structure, 
differently presented.
A second interesting observation is conservation of an amino acid 
substitution at M-35 between the 17D and FNV strains compared to their 
respective parent viruses. Moreover, a substitution in the M protein at M-67 was 
also revealed in the Asibi HeLa-p3 virus. These findings implicate the prM/M 
protein in the attenuation process, but further studies are required to determine 
the nature and extent of its involvement.
In addition to the investigations described above, the data presented in 
Chapter 3 confirmed the genetic stability of the 17D-204 vaccine viruses. This is 
an important observation in light of the increasing incidence of YF worldwide. 
The potential demand for preventive YF vaccination, as opposed to emergency 
mass vaccination (Monath & Nasidi, 1993), will require the modernisation of 17D 
vaccine production in the future. In particular, the advisability of universal 
adoption of the WHO seed virus, 17D-204-WHO, with the additional
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Figure 11.1: Comparison of the amino acid sequences of the M andE proteins of the 
YF virus attenuated/wild-type pairs.
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glycosylation site should be investigated further to eliminate potential problems 
associated with the genetic diversity of this strain.
There have been many reports on the heterogeneous nature of 17D-204 
vaccine virus populations. This property has previously been exploited in the 
selection of a number of YF virus variants (Gould et a/., 1989; Ledger, 1990). 
Nucleotide sequence analyses of the genes encoding the M and E proteins of 
these variant viruses were undertaken with the initial aim of mapping specific 
epitopes in the primary amino acid sequence. Furthermore, the effects of these E 
protein conformational changes in terms of virus pathogenesis in the mouse 
model were characterised.
Comparison of the M and E protein sequences of two 17D-204-UK virus 
variants, one with and one without the epitope recognised by wild-type-specific 
MAb 117, mapped this epitope to amino acid E-173 in the C domain of the E 
protein. The 17D(+wt) variant virus was shown to have mouse neurovirulence 
comaparable with the parent virus. In contrast, the 17D(-wt) variant virus was 
significantly attenuated by i.e. inoculation of mice. Determination of the full- 
length genomic sequence of the 17D(-wt) virus revealed only one amino acid 
substitution from the published sequence of 17D-204-France (Dupuy et a/., 1989). 
This difference occurred in the E protein at E-240. Accordingly, it is proposed that 
the substitution of an amino acid at this position is responsible for the attenuated 
phenotype of the 17D(-wt) variant virus. The substitution of residue E-240 was 
also conserved between the two 17D variant viruses, implicating the E-173
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change in the virulence of the 17D(+wt) variant virus.
The 17D(-wt) variant virus displayed an intermediate virulence phenotype, 
killing 17% of inoculated outbred mice. This suggests that the susceptibility of 
mice to infection by this variant is probably determined by host-encoded factors. 
For example, haplotype restriction of murine humoral immune responses has 
previously been reported for JE virus (Wills et a i,  1993). Consequently, the 
possibility of haplotype restriction of immunity to the 17D(-wt) variant virus needs 
to be investigated further in inbred mouse strains.
MAbR variants, selected from the 17D(-wt) and 17D(+wt) variant viruses 
using 17D-204 substrain-specific MAb 864 (Ledger, 1990), also displayed unusual 
virulence phenotypes. Four of the 864R variants were shown to be avirulent 
following i.e. inoculation of adult mice. This is the first report of a flavivirus being 
completely attenuated for mouse neurovirulence. Mouse brain infectivity titrations 
and immunohistochemical analyses revealed that the viral infection was abortive, 
with infectious virus cleared from the CNS by three days post-infection. 
Avirulence was associated with a single E protein amino acid substitution at E- 
325. Similar results have previously been obtained with other viruses, including 
the closely related alphavirus, Sindbis (Lustig et a/., 1988; Tucker & Griffin, 1991; 
Polo & Johston, 1991). Interestingly, an 864R WHO variant virus with an identical 
amino acid substitution at E-325 displayed neurovirulence comparable with the 
17D-204 viruses, indicating that neurovirulence is multifactorial.
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One 864R(-wt) variant virus was found to have reverted to a neurovirulent 
phenotype. A secondsite mutation at E-305 was identified which appears to 
negate the attenuating effects of the E-240 mutation. This substitution represents 
a reversion to the wild-type Asibi sequence at this position. One 864R variant of 
the 17D-204-WHO virus also exhibited an intermediate virulence phenotype, but 
in this instance, surviving mice developed clinical signs of encephalitis followed 
by complete recovery. Virus titres in the brain were not measured, but it is 
speculated that the ability of this variant to replicate in mouse brain tissue is 
reduced. This phenotype was also shown to be associated with an amino acid 
substitution at E-305.
The characterisation of YF viruses which cause encephalitis of varying 
degress in mice provides an excellent animal model for the study of flavivims- 
induced CNS disease. The epitope recognised by the 17D-204 substrain-specific 
MAb 864 was mapped to a conformational region of the E protein B domain, 
encompassing residues E-305 and E-325. In addition, the importance of this 
epitope in the tissue tropism and virulence of the virus was established. It appears 
that substitutions at E-240 or E-153 were also able to influence pathogenicity of 
the virus and different combinations of these mutations have a collective effect. 
Ongoing studies are separating these amino acid substitutions and investigating 
them individually in the 17D infectious clone. The mechanism by which these 
amino acid changes alter mouse virulence of the virus can then be investigated.
For the first time, a YF virus strain, 17D(864), was identified which was
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able to persist in mouse brain. The clinical signs of virus infection were 
manifested as a chronic hind limb paralysis in outbred mice, a disease course not 
previously seen for YF virus. In inbred mouse strains, virus virulence was 
exhibited to differing degrees, ranging from lethal to completely attenuated. This 
was suggestive of host-encoded susceptibility factors, as described previously. 
However, the virulence phenotype of this virus was found not to be encoded in 
the M or E protein genes, implying that a non-structural protein(s) may be 
involved in the expression of virulence.
Preparations of mouse and monkey brain membrane receptors were used 
to study the binding of several virus strains in vitro. The 17D strain viruses 
exhibited equivocal binding results. However, the FNV virus strains bound to a 
high degree, consistent with their adaptation to CNS tissue during derivation. 
Variants of the FNV-Yale virus were selected which were deficient in their ability 
to bind monkey brain tissues. These variants also displayed a reduction in mouse 
brain binding in vitro, suggesting that the properties of mouse and monkey neural 
receptor binding may be linked, in vivo, however, no significant difference was 
observed in neurovirulence of the variant and parent viruses, although they were 
distinguishable on the basis of their neuroinvasiveness in suckling mice. 
Unfortunately it was not possible to test the virulence of this variant virus in 
monkeys. The loss of binding was attributable to a single E protein amino acid 
substitution at E-274, in the predicted contact region of the prM protein.
This system has potential for the selection of variant viruses with altered
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tissue tropism. Since attenuation of both the FNV and 17D vaccine viruses was 
accompanied by a change in their tissue tropism (from viscerotropic to 
neurotropic) it seems that this technique would provide a means to select 
attenuated variants of other flavivi ruses in a more consistent and reproducible 
manner, rather than by empirical passage in animals.
The combined information presented in this thesis has added to the 
understanding of the attenuation process of YF virus. During the attenuation of the 
17D vaccine viruses from the wild-type Asibi virus, a total of ten amino acid 
substitutions were accumulated in the M and E proteins (one in M and nine in E). 
These studies have identified the M protein mutation (M-35) and three of the E 
protein mutations (E-52, E-173 and E-305) as potentially important in the 
attenuation of the 17D virus. These amino acid positions can now be analysed 
further by site-directed mutagenesis of the 17D infectious clone.
The three-dimensional structure of the TBE virus E protein has recently 
been determined and hopefully will be published in the near future. This will 
enable determinants of pathogenesis on the E protein to be interpreted and put 
into perspective. Similarly, by using infectious clone technology (Rice et a/., 
1989) other E protein amino acid substitutions can be analysed to elucidate the 
molecular basis of pathogenesis of YF virus. Finally, this thesis has investigated 
the M and E protein genes. Clearly, the other proteins and the non-coding region 
will also contribute to the phenotype of the virus and these remain to be 
elucidated.
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